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Abstract 
 
 
Human endogenous retroviruses (HERVs) are estimated to form approximately 5% of the 
human genome. While the majority of sequences are defective, containing premature stop 
mutations and frameshift mutations, a number encode fully functional proteins. HERVs have 
been proposed as aetiological agents for a variety of autoimmune diseases, including 
rheumatoid arthritis (RA), systemic lupus erythematosus, and multiple sclerosis (MS), and 
have been detected in a variety of tumours. The study aims to develop tools to detect and 
investigate human endogenous retroviruses in order to establish their roles in MS and 
anaplastic astrocytomas. A method of detecting and quantifying levels of HERV-W env 
messenger ribonucleic acid (mRNA) and MSRV gag by reverse transcriptase polymerase 
chain (RT-PCR) reaction in a variety of cell lines was developed, with PCR products detected 
in all cell lines tested, and in particular, high levels of transcription occurring in the BeWo 
choriocarcinoma cell line. In the astrocytoma cell lines, those with P53 mutation had higher 
levels of HERV-W env. MSRV gag variants were also detected in these cell lines, but 
stimulation with interferon-γ, a proinflammatory cytokine, did not alter expression significantly. 
An antibody against an epitope of MSRV gag has been successfully developed, purified and 
tested to determine the expression of a predicted linear epitope. This epitope was recognised 
in all cell lines tested, but unusually for a HERV showed nuclear expression. Further analysis 
is needed to confirm the identity of the protein detected. Finally a number of retroviral 
peptides with homology to putative antigens were predicted using a novel bioinformatics 
approach, of which two, HERV-W env 412 and MSAV gag 274, were tested in an enzyme-linked 
immunosorbent assay of plasma samples from MS patients, patients with other neurological 
diseases and normal healthy donors. No significant differences in antibody titres were found 
between the sample groups for either peptide. 
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Abbreviation List 
 
 
ALV  avian leucosis virus 
ANN  artificial neural network 
ANOVA analysis of variance 
AP  alkaline phosphatase 
APC  antigen presenting cell 
ATP  adenosine 5'-triphosphate 
BLAST  basic local alignment search tool 
BLOSUM blocks substitution matrix 
BSA  bovine serum albumen 
CASP  critical assessment of techniques for protein structure prediction 
CDK  cyclin-dependent kinase 
cDNA  complementary DNA 
CNS  central nervous system 
DAPI  4’-6’-diamidino-2-phenylindole 
DCM  dichloromethane 
DIPEA  diisopropylethylamine 
DMEM  Dulbecco’s modified Eagle’s medium 
DMF  N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
DNA  deoxyribonucleic acid 
dNTP  deoxyribonucleoside triphosphates 
EAE  experimental autoimmune encephalomyelitis 
ECACC  European Collection of Cell Cultures 
EDSS  Expanded Disability Status Scale 
EDTA  ethylenediaminetetraacetic acid 
EGFR  epidermal growth factor receptor 
ELISA  enzyme-linked immunosorbent assay 
ENV  envelope 
ERV  endogenous retrovirus 
FCA  Freund’s complete adjuvant 
FCS  foetal calf serum 
FIA  Freund’s incomplete adjuvant 
Fmoc  fluorenylmethoxycarbonyl 
GAG  group-specific antigen 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
HBSS  Hanks’ buffered salt solution 
HCTU  2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium- 
hexafluorophosphate 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HERV  human endogenous retrovirus 
HHV  human herpesvirus 
HIV  human immunodeficiency virus 
hnRNP  heterogenous nuclear riboprotein 
HObT  1-hydroxybenzotriazole 
HRES  HTLV-related endogenous retrovirus sequence 
HRP  horse radish peroxidase 
HSRV  human spumaretrovirus 
HSV  herpes simplex virus 
HTLV  human T cell lymphoma virus 
IDDM  insulin-dependent diabetes mellitus 
IFN  interferon 
IL  interleukin 
LTR  long terminal repeat 
LINE  long interspersed element 
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MAG  myelin associated glycoprotein 
MALDI-TOF matrix-assisted laser desorption ionisation time of flight mass 
spectrometry 
MBP  myelin basic protein 
MEM  minimum essential medium 
MHC  major histocompatability complex 
MOG  myelin oligodendrocyte glycoprotein (MOG 
MoMuLV Moloney murine leukaemia virus 
mRNA  messenger RNA 
MS  multiple sclerosis 
MSRV  multiple sclerosis-associated retrovirus 
MTT  3-(4,-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
NEAA  non-essential amino acids 
NHD  normal healthy donor 
OASIS  old astrocyte specifically induced substance 
OPD  O-phenylenediamine 
PBMC  peripheral blood mononuclear cell 
PBS  phosphate buffered saline 
PCNA  proliferating cell nuclear antigen 
PDB  protein database 
PERV  porcine endogenous retrovirus 
PLP  proteolipid protein 
POL  polymerase 
PPD  purified protein derivative 
PROT  protease 
PSI-BLAST position-specitfic iterative basic local alignment search tool 
PTEN  phosphatase and tensin homologue 
RA  rheumatoid arthritis 
RNA  ribonucleic acid 
RPMI  Roswell Park Memorial Institute 
SCID  severe combined immunodeficiency 
SINE  short interspersed element 
SZRV  schizophrenia-associated retrovirus 
Tert-BoC tert-butyloxylcarbonyl 
TGF  transforming growth factor 
TIS  triisopropylsilane 
TM  transmembrane 
TMB  3’3’,5’5’ tetramethylbenzidine 
TMEV  Theiler’s murine encephalitis virus 
TNF  tumour necrosis factor 
tRNA  transfer RNA 
VZV  varicella-zoster virus 
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1 Introduction 
 
 
1.1 Human endogenous retroviruses 
 
Human endogenous retroviruses (HERVs) are estimated to form approximately 5% of the 
human genome. In contrast to exogenous retroviruses such as human immunodeficiency 
virus (HIV) and human T cell lymphoma virus (HTLV), HERVs are not transmitted from 
person to person, but are transmitted vertically (inherited) through the germ line. HERVs 
represent footprints of ancient retroviral infection, and as such have been termed “fossil 
viruses” (Sverdlov, 2000). Phylogenetic analysis has indicated that integration into the 
genome occurred over 60 million years ago, and that a particular family, HERV-W is present 
in humans and old world monkeys (Kim et al., 1999) but not in new world primates indicating 
that HERV-W integrated into primate chromosomes at some point in time between the 
divergence of old world and new world apes and the emergence of man, approximately 33 
million years ago (Figure 1.1). 
 
Structurally HERVs closely resemble their endogenous counterparts, comprising of POL, 
ENV, and GAG genes flanked by long terminal repeats (LTRs) which are important in the 
integration of retroviruses into the host genome (Figure 1.2). Downstream from the 3’ LTR is 
a short 18 nucleotide sequence known as the primer binding site, where host transfer RNA 
(tRNA) hydbridises to the genome and initiates reverse strand DNA synthesis. The open 
reading frame consists of a number of genes important in the retroviral life cycle. The GAG 
gene encodes the group-associated antigen, a capsid protein, which in the deltaretroviruses 
is in the same reading frame as the PROT (protease) and POL (RNA polymerase gene), and 
translated as a single precursor protein before being processed and cleaved in the 
cytoplasm. In other retroviral families PROT and POL may be present in different reading 
frames. ENV encodes an envelope protein which is always expressed as a single entity, and 
has two distinct regions, a transmembrane (TM) and a receptor-binding surface (SU) domain. 
A number of retroviruses also encode accessory proteins through alternative splicing, such 
as REC and NP9 in the HERV-K (HML-2) family. 
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Figure 1.1 Phylogenetic tree of integration of HERV proviruses into the 
primate germline (from Kim et al., 1999) 
 
 
 
HERV-W proviruses integrated into the primate genome ≥33 million years ago, before the 
divergence of old and new world primates. HERV-W LTRs are present in both old and new 
world monkeys. By comparison ERV-9 integrated more recently (~12 million years ago), and 
is only found in hominids. 
 
 
Figure 1.2 Structure of HERVs 
  (adapted from Goff, 1996) 
 
 
 
The HERV open reading from consists of GAG, PROT, POL and ENV genes surrounded by 
long terminal repeats at the 3’ and 5’ end. Some HERVs encode accessory proteins using 
alternative splicing, such as the REC and NP9 gene products. 
gag 
prot env 
pol 
  
Accessory protein, 
e.g. rec, np9 (HERV-K 
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Previously retroviruses were classified according to morphological and biological criteria, 
particularly with regard to particle formation observed under electron microscopy. Type A 
retroviruses produce unenveloped particles, which accumulate in the cytoplasm of cells, while 
retroviruses of types B, C, and D produce enveloped particles which display different 
morphology, for example type C retroviruses assemble at the plasma membrane and have a 
spherical inner core, whilst type D retroviruses assemble in the cytoplasm, and upon budding 
exhibit a cylindrical core. After formalisation of the genera by the International Committee on 
Taxonomy of Viruses (Goff, 1996), retroviruses are classified according to a number of 
criteria, including the morphology, genome structure, receptor utilisation, and the tRNA used 
as a primer. 
 
HERVs are currently classified according to their degree of sequence similarity to their 
exogenous counterparts (Table 1.1). Class I HERVs, which include HERV-H, HERV-W, 
ERV-3, and ERV-9, show similarities to the exogenous gammaretroviruses, such as Moloney 
Murine Leukaemia Virus (MoMuLV). The class II HERVs are all related to exogenous alpha-, 
beta-, and gammaretroviruses, which use tRNAlys as a primer binding site. The final class of 
HERVs, class III, are related to the foamy viruses (spumaretroviruses). 
 
Table 1.1 Classification of endogenous retroviruses 
  (adapted from Nelson et al., 2003) 
 
 
Class I related to gammaretroviruses  
(e.g. MoMuLV) 
    
 Group 1 HERV-HF HERV-H, HERV-F 
 Group 2 HERV-RW HERV-W, MSRV, HERV-R (ERV 9), HERV-P 
 Group 3 HERV-ERI HERV-E, HERV-R (ERV 3), RRHERV-I 
 Group 4 HERV-T  
 Group 5 HERV-IP HERV-I, HERV-IP-T47D 
 Group 6 HERV-FRD  
    
Class II related to alpha-, beta-  and deltaretroviruses  
(e.g. Mouse Mammary Tumour Virus, Avian Leucosis Virus) 
    
 Group 1 HERV-K (HML-1)  
 Group 2 HERV-K (HML-2) HERV-K10, HERV-K18, HERV-K-HTDV 
 Group 3 HERV-K (HML-3)  
 Group 4 HERV-K (HML-4) HERV-K-T47D 
 Group 5 HERV-K (HML-5)  
 Group 6 HERV-K (HML-6)  
 Group 7 HERV-K (HML-7)  
 Group 8 HERV-K (HML-8)  
 Group 9 HERV-K (HML-9)  
 Group 10 HERV-K (HML-10)  
    
Class III related to spumaretroviruses (foamy viruses) 
    
 HERV-L   
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Multiple copies of HERVs are found in the human haploid genome, with at least 70 GAG, 
100 PRO and 30 ENV sequences present in the case of HERV-W (Voisset et al., 2000). The 
vast majority of these sequences are defective, containing frameshift mutations and 
premature stop codons (Kim and Lee, 2001). Few HERVs encode full-length proteins 
(De Parseval et al., 2003), though a number do. HERV-W ENV encodes syncytin, an 
envelope protein which mediates cell fusion in the placenta (Mi et al., 2000), and may have a 
role in embryogenesis. HERV-W env can also induce syncytia formation in primate and pig 
cells (Blond et al., 2000). 
 
While it is clear that endogenous retroviruses play a beneficial role, co-evolving with their 
hosts, HERVs have been linked with pathogenic roles. HERVs have been linked with breast 
and germ-line cancers (Weiss, 2001), psychiatric conditions such as schizophrenia 
(Deb-Rinker et al., 1999; Karlsson et al., 2001), and a variety of autoimmune disorders such 
as RA, systemic lupus erythematosus (SLE), insulin-dependent diabetes mellitus (IDDM), 
Sjögren’s syndrome, and multiple sclerosis (MS) (Obermayer-Straub and Manns, 2001). With 
pathogenic roles for HERVs yet to be clearly established, concern has been expressed with 
xenotransplation and the possibility of porcine endogenous retroviruses (PERVs) causing 
human disease (Michie, 2001). 
 
 
1.2 Multiple sclerosis 
 
1.2.1 Symptoms 
 
Multiple sclerosis (MS) is a chronic disease that tends to begin in late childhood or early in 
adult life, involving demyelination of axons of neuronal cells of the central nervous system 
(CNS). It is the most common of the demyelinating diseases, with a lifetime risk of diagnosis 
of 5.5 per 1,000 women in the United Kingdom population, and 3.1 per 1,000 for men (Alonso 
et al., 2007). 
  
The symptoms of MS manifest in a number of ways, including disturbances in visual acuity 
occasionally resulting in double vision, affected motor control of the limbs, lack of 
coordination, bowel and bladder incontinence, spasticity, sensory impairment (e.g. loss of 
pain, touch, and temperature) (Charil et al., 2003). MS manifests differently in different 
people, and there are four main forms – benign MS (where symptoms are mild and recovery 
occurs after a few attacks); relapsing-remitting MS (the majority of cases, where symptoms 
flare up and relapse for a while); secondary progressive MS (where the disease progressively 
worsens after attacks); and primary progressive MS (where there is no distinct relapse or 
remission period and symptoms steadily worsen) (Lublin and Reingold, 1996). 
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1.2.2 Immunopathology 
 
Pathologically, MS manifests as demyelinated plaques known as lesions, with large numbers 
of infiltrating lymphocytes and macrophages present. These lesions can occur at any location 
in the CNS white matter, but are commonly found in optic nerves, periventricular white 
matter, brain stem, cerebellum and the white matter in the spinal cord (Charil et al., 2003). 
 
The events that initiate MS are unclear (possibly due to viral or bacterial infection causing 
upregulation of endothelial adhesion molecules and proteases), but immune cells cross the 
blood-brain barrier and cause damage (Figure 1.3). The brain is an immunologically 
privileged site, and while T cells are present in the brains of healthy individuals no 
autoimmune response occurs, although T cells reactive to myelin components are found in 
the blood of healthy individuals (Steinman, 1996). Initial activation of these cells is likely to 
occur outside the central nervous system, e.g. as a result of molecular mimicry with other 
antigens.  
 
Disruption of the blood-brain barrier is caused by matrix metalloproteases (MMPs) enabling 
an increase in lymphocyte infiltration into the CNS. A number of these show increased 
expression in MS, including MMP-7, MMP-9 (Cossins et al., 1997; Lindberg et al., 2001), and 
a disintegrin and metalloproteinase domain 17 (ADAM-17) (Plumb et al., 2006). Additonally, 
ADAM-17 cleaves membrane-bound pro TNF-alpha (TNF-α) into soluble TNF-α (Black et al., 
1997), a potent pro-inflammatory cytokine. 
 
Activated T cells then encounter antigens in the CNS, and encounter antigen presenting 
cells, such as microglia, in the brain triggering clonal expansion of T cells, cytokine 
production and the further recruitment of infiltrating lymphocytes, including B cells and 
cytotoxic T cells. Activated Th2 cells produce interleukins (including IL-4, IL-5, IL-6, IL-10 and 
IL-13), inducing B cells to secrete immunoglobulins which bind to components of the myelin 
sheath. In some lesions, oligodendrocyte loss is also seen (Kornek & Lassman, 2003), 
possibly as a result of attack by invading cytotoxic T cells recognising MHC-I (major 
histocompatability complex) bound antigens. Table 1.2 details the role of different types of T 
cell involved in MS pathogenesis, as well as other cell types such as B cells, 
macrophages/microglia and endothelial cells. 
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Figure 1.3:  Immunopathology of MS 
 
Following migration through the blood-brain barrier, autoreactive T cells encounter antigen 
presenting cells in the CNS, leading to T cell activation, and recruitment of B cells, 
macrophages, and cytotoxic T cells resulting in tissue damage via a number of routes 
. 
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Table 1.2 Cell types involved in MS 
 
 
Cell type Subtype Role Stimulus Products 
T cell CD4+ Th1 Macrophage activation 
Cytotoxic activity 
MHC-II TNF-α  
IFN-γ 
 CD4+ Th2 B cell activation MHC-II IL-4 
IL-6 
IL-13 
 CD8+ 
cytotoxic 
MHC-I mediated cytotoxicity MHC-I ROS 
 γδ MHC independent cytotoxicity heat shock 
proteins 
 
B cell  Antibody secretion 
Clonal expansion 
 
IL-4 
IL-6 
IL-13 
IL-4 
Microglia  Antigen presentation IL-1 
IFN-γ 
IL-1 
TNF-α 
Macrophage  Antigen presentation 
Inflammation 
Effector cell in demyelination 
IL-1 
IFN-γ 
IL-1 
IFN-γ 
TNF-α 
Endothelial cell  Disruption of BBB (by MMPs) 
enables lymphocyte infiltration 
  
 
 
While MS is considered to be a T cell-mediated disease, largely due to the presence of T 
cells present in MS lesions, it is clear that B cells have an important role in the pathology of 
the disease. Firstly, B cells produce antibodies which bind to components of the myelin 
sheath (such as myelin basic protein (MBP), myelin associated glycoprotein (MAG), myelin 
oligodendrocyte glycoprotein (MOG), and proteolipid protein (PLP) or other potential 
autoantigens in the CNS (e.g. heat shock proteins and arrestins (see Table 2.1 for a more 
extensive list). The presence of oligoclonal bands are found in approximately 95% of MS 
patients (Link & Huang, 2006), and is an important diagnostic marker of the disease. IgM in 
the CSF, produced by CD5+ B cells is of a low affinity and targets lipid rich epitopes (Boes, 
2000) such as components of the myelin sheath. These immunoglobulins opsonise myelin, 
leading indirectly via chemokine induction, resulting in destruction by macrophages, which 
themselves are recruited by pro-inflammatory cytokines such as tumour necrosis factor alpha 
(TNF-α) and interferon gamma (IFN-γ). Antibody binding to myelin components may also bind 
to complement, triggering a cascade resulting in further tissue damage. 
 
Only a small proportion (approximately 7%) of antibodies are of the IgM subclass (Esiri, 
1977), suggesting a role for memory B cells (which appear to be the main effector cells) and 
secreted IgG. There is evidence of clonal expansion of B cells within MS lesions (Baranzini et 
al., 1999), and in the CSF (Colombo et al., 2000). Antibodies present may be produced within 
the CNS by B cells, or penetrate the blood-brain barrier. 
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The second role of B cells in MS are as antigen presenting cells (APCs). A number of cell 
types are capable of acting as APCs in the CNS, including infiltrating B cells, microglia 
(Hayes et al., 1987), and astrocytes (Zeinstra et al., 2000). Upregulation of MHC-II in these 
cells leads to Th1 and Th2 cell activation.  
 
 
1.2.3 Epidemiology 
 
MS is geographically distributed worldwide, but temperate areas, predominantly populated by 
those of European descent, have a higher incidence of the disease than elsewhere in the 
world. In North America the disease has a North-South gradient with between 150-200 cases 
per 100,000 population in the Northern United States and Canada, compared with a risk of 30 
per 100,000 in the southern states (Cook, 1996). 
 
Migration studies have shown that those who emigrate from a high risk country to a lower risk 
country after the age of 15 retain the prevalence of their country of origin (Kurtzke, 1997), 
suggesting that MS is a disease of geography rather than genetics, and that an event 
(infection or other environmental factors are a possibility) that happens during mid teenage 
years influences the development of MS. Certainly MS tends to be diagnosed most frequently 
during young adulthood. Hawkes (2002) suggested that MS may, at least in some cases, be 
a sexually transmitted disease, largely on epidemiological data where the incidence of MS 
increased in the Faroe Islands, the Orkneys and Shetland, and Iceland during and after 
World War II, where significant Allied troops were stationed. These clusters may indicate that 
MS (or a trigger for the disease) may be an infectious agent. Other arguments for a sexually 
transmitted agent include the similar ages of onset, high incidences where there is a liberal 
sexual attitude (and conversely, low rates in stricter countries), though others have argued 
that Hawkes’ paper is speculative and that genetic susceptibility may explain much of the 
epidemiology, and that there is no evidence for vertical transmission of MS, in contrast to 
exogenous retroviral infection, such as HIV and HTLV (Stewart, 2002). 
 
 
1.3 The retroviral link to MS 
 
A number of pathogens have been implicated as potential causes of MS, but no link has been 
definitively established (Table 1.3). A number of retroviruses have been considered as 
candidates as a number have links with similar neurodegenerative disorders, such as HTLV-
1, which causes tropical spastic paraparesis, and the Visna-Maedi virus which causes an 
MS-like disease in sheep. Other exogenous retroviruses such as human spumaretrovirus 
(HSRV) (Lycke et al., 1994) have been investigated as potential causes of MS, but no 
association has been found. 
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Table 1.3:  Viruses associated with MS 
  (adapted from Cermelli & Jacobsen, 2000) 
 
Group Family Viruses 
RNA Viruses Coronaviridae Coronavirus 
 Flaviviridae Tick borne encephalitis viruses 
 Retroviridae HTLV-I 
  HERVs / retrovirus-like particles 
 Paramyxoviridae Measles virus 
  Mumps virus 
  Parainfluenza virus 1 
  Simian virus 5 
 Rhabdoviridae Rabies virus 
 Togaviridae Togavirus 
DNA Viruses Herpesviridae Herpes Simplex type 1 & 2  
  Varicella zoster virus 
  Epstein-Barr virus 
  Cytomegalovirus 
  Human herpesvirus 6 
Unconventional agents  Scrapie agent 
  Bone marrow agent 
 
 
 
Retroviral activity was discovered in a leptomeningeal cell line derived from an MS patient by 
Perron et al. (1989), leading to the possibility that an unknown retrovirus could be responsible 
for the disease. Phylogenetic analysis showed that MS associated retrovirus (MSRV) is 
“related to, but distinct” (Perron et al., 1997) from ERV-9, an endogenous retrovirus. ERV-9 
appears to be widely distributed in various tissues in healthy individuals, and it has been 
argued that MSRV and ERV-9 are virtually indistinguishable, and therefore MSRV is present 
in various tissues of the whole population, and not just MS patients. MSRV, along with other 
similar sequences isolated from MS patients have been classified as part of the HERV-W 
family of endogenous retroviruses (Blond et al., 1999), using a primer binding site with 
similarities to that of avian retroviruses which use tRNAtrp.  
 
MSRV pol transcripts have been detected in the CSF of nearly 50% (13 of 27) of MS patients 
tested, but not in controls with other neurological disorders. In the same study, transcripts 
were also detected in the plasma and B cell cultures derived from MS patients, but not in 
controls (Perron et al., 1997). Similarly HERV-W mRNA has been detected in the serum of 
MS patients (Garson et al., 1998). MSRV pol sequences are found in the serum and CSF of 
healthy individuals, though at a much lower frequency than that of MS patients (Nowak et al., 
2003). In a study of Sardinian MS patients, MSRV was detected in the serum in 80% of 
cases, compared to a rate of 13% in healthy blood donors (Dolei et al., 2002). In a 6 year 
follow-up study (Sotgiu et al., 2006), patients who were positive for MSRV pol sequences had 
a poorer prognosis than those who were negative, with a higher relapse rate, disability 
accumulation and a higher chance of progression (with 2 of 10 MSRV pol positive cases 
entering the progressive phase, compared to none in the MSRV pol negative group).  
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HERV-W env transcripts have been determined, using a real-time PCR system, to be more 
highly expressed in pathological sections of MS patient brain tissue (Antony et al. 2007). 
HERV-W env transcripts appear to have particularly high expression in some areas of the 
brain, particularly in the cerebellum and pons (Kim et al., 2008). 
 
Another study used random phage peptides, some of which had amino acid similarity to 
MSRV/HERV-W envelope protein, and detected increased antibody titres in MS patients 
(Jolivet-Reynaud et al., 1999). Fluorescent in situ hybridisation (FISH) also shows an 
increased copy number of pol sequences on chromatin fibres of MS patients compared with 
healthy controls (Zawada et al., 2003). Antony et al. (2006) indicated that HERV-W env 
expression is significantly higher in MS brain tissue than that of controls but this finding is not 
reflected in patient serum. Another study by Mameli et al. (2007a) confirmed that HERV-W 
env expression is upregulated in MS patients when compared with normal and pathological 
controls, though translation into protein is limited to active MS lesions. Unlike the Antony 
study, expression of RNA was found to be increased in peripheral blood mononuclear cells 
(PBMCs) (Mameli et al., 2007), though a number of sequences (approximately 30%) isolated 
from PBMCs show evidence of recombinations from proviruses located at a number of loci - 
5q11.2, 6q21, 7q21.2 (ERVWE1), 14q21.3, 15q21.3, 17q12 and Xq22.3 in both MS patients 
and controls (Laufer et al., 2009). 
 
Immunohistochemistry has indicated that HERV-W products are expressed in the brain of 
both normal and MS patients, though the expression pattern differs (Perron et al., 2005). In 
MS patients, env antigen was overexpressed only in recent demyelinating regions, where gag 
accumulation was higher in demyelinated white matter. In controls env was expressed widely 
within white matter, whilst gag was expressed widely in neurons.  
 
Other human retroviral sequences have been linked to MS, including HERV-H/RGH-2, a type 
C-related endogenous retrovirus (Christensen et al., 1997). HERV-H/RGH-2 has been 
detected in the plasma of 24 out of 33 MS patients (Christensen et al., 2000), and over 50% 
of MS patients had antibodies directed against RGH-2 synthetic peptides (Christensen et al., 
2003). In the latter study a variant pro-env splice variant was expressed in 40% of MS 
PBMCs, compared to 10% in controls. The HTLV-related endogenous retrovirus sequence 
(HRES-1) has been found to be widely expressed in peripheral blood mononuclear cells of 
both MS patients and healthy controls (Rasmussen et al., 1995).  
 
HERV-W has been linked to other neurological diseases such as schizophrenia, a psychiatric 
disorder that affects approximately 1% of the population. The sequence of schizophrenia 
associated retrovirus (SZRV) shows a high degree of homology to that of MSRV (Deb-Rinker 
et al., 1999). SZRV RNA has been found in 29% of individuals with recent-onset 
schizophrenia/schizoaffective disorder (Karlsson et al., 2001). HERV-W LTRs have also been 
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localised at the chromosomal location Xq21.3, which has been linked to psychosis (Kim & 
Crow, 2002). Raised levels of HERV-W gag from the putative gene PTD015, located at 
11q13.5 has been described in mononuclear cells of patients with schizophrenia (Yao et al., 
2008), but expression in astrocytes appears to be reduced (Weis et al., 2006) in the condition 
(as well as in subjects with major depression and bipolar disorder). 
 
 
1.4 Detection of HERVs in other autoimmune diseases 
 
HERVs, including sequences related to ERV-9, HERV-K and HERV-H have been detected in 
synovial fluid cells of patients with RA compared with those of controls (Nakagawa wt al., 
1997). Using a multiplex PCR approach, Ejtehadi et al., (2006) found a higher expression of 
HERV-K10 gag transcripts in PBMCs of RA patients, when compared to patients with non-
inflammatory osteoarthritis and normal healthy donors (NHDs). Similarly, quantitative PCR 
investigating levels of HERV-K18 superantigen transcripts is increased in juvenile RA 
patients when compared to controls, but is not higher in SLE patients (Sicat et al., 2005). 
Other HERV-K transcripts have been described in RA, such as rec9 of HERV-K (HML-2) 
(Ehlhardt et al., 2006), though rather than being upregulated in the disease state, it was 
found that expression was decreased in cultured synovial tissue from RA patients when 
compared to osteoarthritis controls. Studies looking for MSRV pol transcripts in RA serum, by 
contrast have found no significant differences in expression between patients and controls 
(Gaudin et al., 2000). 
 
There is also evidence that HERV-E (clone 4-1) is detectable in SLE patients, and gag 
sequences have been detected in PBMCs of lupus patients but not controls, with inactivated 
stop codons present in part of the gag region (Ogasawara et al., 2000). In addition to mRNA, 
antibodies reactive against a recombinant gag protein are found in 48.3% of SLE patients 
and 35.0% of Sjögren’s syndrome patients, but not in healthy controls (Hishikawa et al., 
1997). 
 
By way of contrast, although Conrad et al., 1997 identified an autoreactive T cell 
superantigen, reportedly encoded by HERV-K18 in IDDM patients, other studies have failed 
to detect significant differences in HERV-K18 mRNA expression, with env transcripts 
detected in 100% of patients and controls, in PBMCs (Jaeckel et al., 1999) and plasma 
samples (Badenhoop et al., 1999). Additionally, Badenhoop et al. (1999) found that there was 
no significant difference in antibody reactivity in the plasma samples between IDDM patients 
and healthy controls. 
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1.5 Astrocytic neoplasms 
 
Intracranial neoplasms can occur in all areas within the cranial vault, such as the brain, 
meninges and pituitary gland, and can affect all types of cell present in the CNS. Cell types 
affected include glial cells (astrocytes, oligodendrocytes, microglia, ependymal cells, and 
radial glia), meninges, blood vessels, lymphatic cells, endocrine glands, as well as the skull. 
Tumours of the glial cells are referred to as gliomas. The incidence of primary brain tumours 
is roughly 4,300 cases per annum in the United Kingdom (McKinney, 2004), equating to 7 
cases per 100,000 in the population. Typically, the symptoms of gliomas can manifest in a 
variety of ways, including headaches (sometimes with nausea and vomiting), movement or 
sensation changes affecting specific areas of the body, seizures, confusion. memory loss and 
personality changes (Wen and Kasari, 2008). 
 
The World Health Organisation currently classifies astrocytic neoplasms into four malignancy 
grades based on histological/cytological and immunocytochemical characteristics. Lower 
grade tumours closely resemble normal astrocytes while higher grade tumours show 
evidence of nuclear pleomorphism, mitotic activity, and widespread necrosis and 
angiogenesis at the tumour site. Grade I tumours, or pilotic astrocytomas most commonly 
occur in children, and tend to be non-aggressive with progression rarely occurring. The 
higher grade tumours (grades II, III and IV) tend to occur in adults, with the incidence peaking 
between 25-50 years in grade II astrocytomas, and between the ages of 45 and 70 years in 
grade IV (glioblastoma multiforme, GBM) . The prognosis differs according to grade with 
glioblastoma patients having a mean survival time of 9-11 months compared to about 7 years 
in patients with grade II astrocytomas (Collins, 2004). 
 
The molecular genetic basic of glioblastomas falls into two groups (for a detailed review see 
Rasheed et al., 1999). De novo glioblastomas show a high frequency of loss of 10q 
chromosomal heterozygosity, amplification and rearrangement of epidermal growth factor 
receptor (EGFR), alterations in phosphatase and tensin homologue (PTEN gene), deletions 
of cyclin-dependent kinase (CDK) inhibitor 2a, but a low frequency of P53 mutation. In 
progressive glioblastomas P53 mutation is frequent with amplification of platelet derived-
growth factor receptor alpha polypeptide. Amplification of epidermal growth factor receptor, 
alterations in phosphatase and tensin homologue, and deletions of CDK inhibitor 2a 
(CDKN2A) occur with lower frequency in progressive tumours. Other changes present in 
gliomas include loss of heterozygosity for 9p, 13q, 17p, 19q and 22q, with a gain of 7q, but 
have also lost 10q (Inda et al., 2003). 
 
p53 mutations are infrequent in de novo cases of glioblastoma, but commonplace in 
secondary cases which have progressed from lower grade tumours (Nozaki et al., 1999). 
Loss of p53 function results in breakdown of the regulation of cell growth, leading to genomic 
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instability and malignant transformation. The vast majority of mutations that deactivate p53, 
tend to occur in the DNA binding domain (Walker et al., 1999), affecting its role as a 
transcriptional regulator.  
 
p53 plays an important role in cell cycle arrest via the upregulation of the P21 gene (WAF-21, 
Cip-1), which encodes for a protein which binds to and inhibits a number of cyclin dependent 
kinases, including CDK 4 as well as binding to the C-terminal domain of proliferating cell 
nuclear antigen (PCNA), inhibiting DNA synthesis at S phase (although not DNA repair) (for 
review see Levine, 1997). The second role that p53 plays is in triggering apoptosis of cells 
that are damaged beyond repair. p53 induces the transcription of Bax, a pro-apoptotic protein 
while also simultaneously downregulating Bcl2, which encodes a negative regulator of 
apoptosis which competes with Bax (Basu & Haldar, 1998). Finally, p53 has 3’→5’ 
exonuclease activity, indicating a possible role in DNA repair (Albrechtsen et al., 1999).  
 
Loss of heterozygosity results in allelic loss of tumour suppressor genes, unmasking 
defective copies of tumour suppressor genes which function abnormally. One such tumour 
suppressor gene is PTEN, located at 10q23, and is a common loss in glioblastomas (a loss of 
heterozygosity is seen in approximately 74% of cases, of which PTEN is defective in 60% of 
those cases) (Wang et al., 1997). PTEN is a lipid phosphatase, activating phosphokinase 
B/Akt which signals cells to stop dividing and undergo apoptosis (Knobbe et al., 2002). 
Mutation of this gene causes an escape from these processes, and cellular proliferation. 
Cyclin dependant kinases are involved in progression of cell cycle. CDKN2A is one such 
inhibitor, and is associated with a loss of heterozygosity at 9p (Ueki et al., 1996). It inhibits 
CDK 4, which is almost exclusively expressed in higher grade tumours (Lam et al., 2000), 
and acts by phosphorylating the retinoblastoma (Rb) oncogene product, expressed at G1 
phase of cell cycle (Harbor et al., 1999). Dephosphorylation of Rb inhibits the cell cycle, 
allowing the cell cycle to progress beyond the G1 phase, preventing cell cycle arrest. 
 
Conversely, gains result in an increase in expression of oncogenes. A commonly seen gain in 
glioblastoma multiforme patients is at 7p (Misra et al., 2004), usually in tandem with 10q loss 
(Inda et al., 2003). Of note, EGFR is located at 7p12 (Wang et al., 1993), and is 
overexpressed in up to 50% of glioblastomas (Ekstrand et al., 1991).  EGFR is a 
transmembrane protein that binds a number of ligands, including epidermal growth factor and 
transforming growth factor β. Binding of these ligands results in activation of a number of 
signal transduction pathways and cellular proliferation. Interestingly a number of 
glioblastomas also express EGFRvIII, a characteristic mutant of EGFR with a 267 base pair 
deletion coding for amino acids in the extracellular domain (Wong et al., 1992), resulting in an 
autocrine loop (Ramnarain et al., 2006), without the need for an external stimulus.  
Regardless of whether wild-type EGFR is overexpressed due to chromosome gains, or the 
presence of mutant EGFRvIII, cellular proliferation is markedly increased as a result. 
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1.6 How can HERVs contribute towards the disease process? 
 
A number of factors can influence HERV expression, including exogenous factors, such as 
exogenous viral infection and ultraviolet (UV) light, and endogenous factors such as 
cytokines and chemokines (Figure 1.4). Normally most HERVs are transcriptionally silent and 
are heavily methylated. The use of demethylating agents such as 5-aza-deoxycytidine 
increases the transcription of a number of silent genes, such as HERV-E4.1 (Ogasawara et 
al., 2003). UV light can induce expression of a number of retroviruses, e.g. HIV (Stanley et 
al., 1989), HERV-K-T47D, and ERV9 (Hohenadl et al., 1999). Patients with SLE are often 
photosensitive, and exposure to UV light can exacerbate systemic symptoms (Kind et al., 
1993). As MS incidence is a disease associated with latitude, it may be possible that UV light 
may be an aetiological factor. 
 
HERV expression can also be transactivated by external viruses, notably members of the 
herpesvirus family, including herpes simplex type 1 (HSV-1), varicella-zoster virus (VZV), 
Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6) (Brudek et al. 2004). A 
synergistic inflammatory response occurs in peripheral blood taken from both MS patients 
and controls when HERV antigens and HSV-1 and HHV-6 antigens. Immediate early protein 
1 has been shown to transactivate HERV-W LTRs in vitro (Lee et al., 2003). HERV-W env, 
though not gag transcripts are upregulated in vitro in the CCF-STTG1 astrocytoma cell line 
following HSV-1 infection. HERV-W env and gag transcripts are also upregulated in CCF-
STTG1, as well as in the histiocytic cell lymphoma cell line, U937 and a human kidney cell 
line, 293F. The results for influenza A transactivation showed a similar pattern to that of 
serum deprivation (with the exception of 293F), indicating that cellular stress may partly be 
responsible for the effects seen (Nellåker et al., 2006). Other HERV families can also be 
transactivated by herpesviruses, such as HERV-K by HSV-1 (Kwun et al., 2002) and EBV 
(Sutkowski et al., 2001). Cytokine expression also can affect HERV expression. IL-4, IL-6, 
IFN-α, and TNF-α increase the expression of MSRV pol, whilst IFN-β (which is used in MS 
therapy) has the converse effect (Serra et al., 2003). Similarly the promoter for ERVWE1 
(HERV-W env) is activated in vivo upon stimulation of the U87-MG glioblastoma cell lines 
with the proinflammatory cytokines IFN-γ, TNF-α, IL-1 and IL-6, and inhibited by IFN-β, which 
dampens the immune response in the CNS (Mameli et al., 2007b). 
 
It is possible that alterations in HERV expression mediated by such factors could trigger MS, 
either by directly targeting the central nervous system, or by altering the immune response 
towards it. A number of mechanisms have been proposed for retroviral involvement in MS, 
such as free radical induction, modulation of the immune response (molecular mimicry, 
superantigen activity, production of immunosuppressive peptides), and insertion into cellular 
genes, such as T cell receptors and the MHC complex (Adelman & Marchonis, 2002). 
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Figure 1.4  How HERVs may contribute towards MS  
Adapted from Adelman & Marchalonis (2002) 
 
 
A number of factors can influence the expression of HERVs, such as viral infection and 
cytokines. Altered expression of HERV products could lead to MS through a variety of routes. 
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The aberrant expression of HERV-W gene products may directly damage the brain, causing 
plaque formation. A 17kDa glycosylated protein secreted by macrophages/monocytes, has 
been detected in the cerebrospinal fluid of relapsing-remitting MS patients containing reverse 
transcriptase activity (Ménard et al., 1997b). The presence of MSRV RNA was also 
detectable in the supernatants of these macrophages/monocytes in cell culture (Ménard et 
al., 1997a). It is likely that macrophages secrete a number of similar neurotoxins during the 
course of severe neurological disease associated with HIV infection. Syncytin may induce 
reactive oxygen species (such as nitric oxide), as well as IFN 1β which damages 
oligodendrocytes, preventing demyelination (Antony et al., 2004). Such syncytin-mediated 
direct damage may be via the induction of old astrocyte specifically induced substance 
(OASIS), an endoplasmic reticulum stress sensor and the subsequent production of nitric 
oxide synthase (Antony et al., 2007). Overexpression of OASIS results in the suppression of 
ER stress-induced cell death where there is an accumulation of unfolded proteins in the ER 
lumen (Kondo et al., 2005).  
 
Molecular mimicry occurs when the immune system fails to discriminate self from non-self, 
and antibody responses are directed against self antigens with similar epitopes to foreign 
antigens encountered, such as proteins present in bacteria, viruses, fungi, and protozoa. The 
best characterised example is rheumatic fever where antibodies directed against cell 
membrane antigens present on certain strains of group A streptococci which are cross-
reactive with human heart tissue antigens, resulting in damage to heart muscle and valves 
(Kaplan, 1963).  
 
Myelin components, such as myelin basic protein (MBP) and myelin proteolipid protein (PLP) 
show similarities in (small parts) of the structure to proteins produced by a number of bacteria 
and viruses (Shaw et al., 1986; Wuchterpfennig & Stromiger, 1995). Animal models have 
provided a useful tool in trying to understanding the pathology of the disease. Experimental 
autoimmune encephalomyelitis (EAE) can be induced in mice by injecting them with myelin 
proteins, such as MBP and PLP in complete Freund’s adjuvant (Martin and McFarland, 
1997). Another common animal model used to model is Theiler’s Murine Encephalitis Virus 
(TMEV), with pathologic and immunological similarities to MS. In TMEV-infected mice it 
appears that myelin antigens are presented to naïve T cells by antigen presenting cells in the 
CNS, known as microglia. It has also been shown that an amino acid substitution at the T cell 
receptor primary contact site prevents the pathology of the disease (Miller et al., 2000). Non-
pathogenic variants of TMEV can be engineered to cause early onset disease by inserting 
mimic peptides as well as myelin components such as PLP (Olson et al., 2001).  
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It has been reported that a member of the HERV-K family encodes a superantigen that may 
contribute to IDDM by stimulating a particular subset of T cells (vβ7) (Conrad et al., 1994; 
Conrad et al., 1997). It may be possible that another HERV may act in a similar way by 
stimulating T cells which are responsible for the destruction of MBP. The MSRV envelope 
protein induces a superantigen-type response in T lymphocytes encoding Vβ16 chain as a 
surface receptor (Perron et al., 2001). In addition, immunising MSRV particles into a 
humanised severe combined immunodeficiency (SCID) mouse resulted in a T cell mediated 
pathogenesis, leading to brain damage, death and the overexpression of the proinflammatory 
cytokines IFN-γ and TNF-α (Firouzi et al., 2003).  
 
In addition to influencing T cell responses directly, MSRV may promote an inflammatory 
response by activating monocytes to produce such cytokines, driving the immune system 
towards a Th1 response. The SU subunit of MSRV has been shown in vitro to directly 
stimulate monocytes to produce IFN-γ and TNF-α  in a CD14 and TLR4-dependant manner 
(Rolland et al., 2006). 
 
Both HERV-H (De Parseval et al., 2001; Manengey et al., 2001) and HERV-W encode 
immunosuppressive peptides in their envelope genes. These proteins have a high degree of 
homology to a peptide, CKS-17 derived from MoMuLV (Figure 1.5), which has been shown to 
downregulate immune effector functions (Cianciolo et al., 1985), causing an imbalance 
between the Th1 and Th2 response. CKS-17 has been shown to downregulate Th1 cytokines 
in vitro, including IL-2, IL-12 and IFN-γ while increasing IL-10 production (Haraguchi et al., 
1995). In the placenta the immunosuppressive domain may protect the developing foetus 
from immune response (in addition to its role in placental differentiation), but if expressed 
elsewhere at abnormal levels, the delicate balance of the immune response may alter. It is 
worth noting that Th1 cytokines drive the inflammatory response, whilst the Th2 cytokines 
dampen the Th1 response. 
 
 
Figure 1.5  Comparison of immunosuppressive domains of HERVs 
 
Moloney MuLV (CKS-17) LQNRRGLDLLFLKEGCL 
HERV-H (RGH-1)  CRGLDLLFLKEGGP 
HERV-H (p62)  LQNRRGLDLLTAEKGCL 
HERV-W (7q)   LQNRRALDLLTAERGGT 
 
The CKS-17 p15E immunosuppressive domain is highly conserved amongst human 
endogenous retroviruses and retroviral elements. Differences from the CKS-17 sequence, 
such as insertions and substitutions are highlighted in red. 
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HERVs may contribute towards pathogenesis of tumours in a number of ways, by 
retrotransposition (causing chromosomal instability), promoter insertion, immunomodulation, 
disruption of normal HERV-related functions, recombination, or by the production of fusion 
proteins (for review see Larsson & Andersson, 1998).  Retroviruses and retrotransposons are 
mobile elements which can integrate into the genome and disrupt gene function. Integration 
of retroelements into the coding region of tumour suppressor genes may act in a similar 
manner to a point mutation, disrupting protein function. Small interspersed elements (SINEs) 
related to HERV-K have also been found integrated into the DNA repair gene, XRCC1 (Misra 
et al., 2001). Similarly, the insertion of Long interspersed element 1 (LINE-1) into the tumour 
suppressor gene, APC which is mutated in familial polyposis coli and sporadic colorectal 
tumours (Miki et al., 1992).  
 
Insertion of retroelements adjacent to proto-oncogenes, may place the gene under the control 
of a viral promoter, altering the level of expression. In B cell lymphomas of chickens, the 
avian leucosis virus (ALV) integrates adjacent to the proto-oncogene, C-MYC, and removes it 
from cellular control, placing the gene under the influence of a viral promoter (Hayward et al., 
1981). In rats, the c-Ha-Ras oncogene is overexpressed tenfold due to the insertion of a 
defective retrovirus in N-methyl-N-nitrosourea induced rat mammary cancer adjacent to the 
promoter (Bera et al., 1998). Hypomethylation of the MMTV promoter induces the expression 
of c-neu, in transgenic c-neu transgenic mice, indicating that the promoter is usually heavily 
methylated (Zhou et al., 2001).  Another example is that of HERV-E (PTN) which inserts 
adjacent to the growth factor pleiotrophin, acting as an additional promoter in 
choriocarcinoma (Schulte et al., 1998). HERVs may also be attributable as a consequence of 
cell transformation, where disruption in normal cell function results in hypomethylation of 
HERV LTRs and retrotransposons, e.g. HERV-W retrotransposons in malignant ovarian 
cancers (Menendez et al., 2004). 
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1.7  Aims and objectives of the project 
 
The research project aims to identify potential HERV epitopes, and to develop primers and 
antibodies against HERVs in order to provide a set of tools to enable detection of HERVs at 
serological, RNA and protein level, and to investigate potential mechanisms of how HERVs 
may play a role in the pathogenesis of multiple sclerosis and cancer. The overall approach, 
summarised in Figure 1.6, involved the following:  
 
• Antibody titre determination 
A novel bioinformatic approach was utilised to identify HERV epitopes in silico, as 
potential molecular mimics, with sequence homology with autoantigens implicated in 
the pathogenesis of multiple sclerosis, (Chapter 2). Peptides of predicted epitopes 
were synthesised, and used in an enzyme-linked immunosorbent assay to analyse 
antibody titres in multiple sclerosis patients (Chapter 3). 
 
• Analysis of mRNA expression 
A reverse transcriptase polymerase chain reaction was developed and used to detect 
and quantify levels of HERV-W env and MSRV gag expression in vitro in cancer cell 
lines, with a particular focus on astrocytomas/glioblastomas as HERV-W transcripts 
are known to be widely expressed in the brain, including cancer cell lines derived 
from astrocytomas (Yi et al., 2002; Nakamura et al., 2003; Stauffer et al., 2004), In 
order to investigate whether HERV expression is upregulated in the presence of 
proinflammatory cytokines involved in MS pathology, the reverse transcriptase PCR 
(RT-PCR) system was used to investigate MSRV gag expression in a microglial cell 
line exposed to interferon-γ (Chapter 4). 
 
• Analysis of protein expression 
Rabbit serum containing polyclonal antibodies against a peptide previously predicted 
by a colleague (who used a similar approach to that taken in Chapter 2) were raised 
commercially. These antibodies were evaluated and purified in order to apply in an 
indirect immunofluorescence-based protocol to determine the subcellular localisation 
of MSRV gag protein, or more precisely, the epitope, is detectable in astrocytoma cell 
lines and whether mRNA expression can correlate with protein expression.  
(Chapter 5) 
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Figure 1.6 Overview of research project methodology 
 
The research project utilised a number of techniques in order to detect and evaluate HERV 
expression at serological (green), mRNA (turquoise), and protein (lavender level). A novel 
bioinformatics approach (yellow) was utilised to predict epitopes to construct as peptides for 
serological detection and to and raise antibodies for protein detection. 
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2 Analysis of B cell epitopes 
 
 
2.1 Introduction 
 
While MS is thought to be a T-cell mediated disease, largely due to the presence of infiltrating 
T cells at MS lesions and through studies of autoimmune encephalitis there is increasing 
evidence that B cells and antibodies have an important role in the disease. Over 90% of MS 
patients show the presence of oligoclonal antibodies in cerebrospinal fluid, which is a 
diagnostic marker of the disease (Bernard et al., 1981). IgG antibodies and complement, 
associated with macrophages, are found in actively demyelinating lesions with patients with 
multiple sclerosis (Breij et al., 2008). It is interesting to note that antibody-producing plasma 
cells appear to be more prevalent in late lesions with oligodendrocyte loss and extensive 
destruction of the myelin sheath (Ozawa et al. 1994). 
 
A number of putative autoantigens have been proposed for MS, and those which epitope 
mapping was carried out on are summarised in Table 2.1. These include components of 
myelin, as well as a number of other proteins ranging from heat shock proteins to proteins 
involved in signal transduction. A large number of potential autoantigens have been 
investigated, including a variety of other molecules such as neurofascin (Mathey et al., 2007), 
a cell adhesion molecule found on axons; transketolase (Lovato et al., 2008), an enzyme 
involved the pentose phosphate pathway; and neuron-specific enolase (enolase 2) 
(Forooghian et al., 2007), a metalloenzyme involved in glycolysis. 
 
The shape (or tertiary structure) that a protein adopts is largely dictated by its amino acid 
sequence (primary structure). Amino acids in the polypeptide chain interact with each other, 
and it is these interactions which hold a protein in shape, and thus influence its biochemical 
properties. Antibodies bind to the native conformation of the protein, and these regions which 
are recognised by antibodies are known as epitopes (or antigenic determinants). 
 
Using bioinformatics, or in silico analysis, the aim was to identify continuous (linear) epitopes 
present in retroviruses implicated in the aetiology of MS, and to investigate the possibility of 
molecular mimicry with a number of putative autoantigens. Continuous epitopes are 
comprised of single segments of polypeptide chain, where discontinous (conformational) 
epitopes are formed by different segments which have been brought together due to protein 
folding. Identification of linear epitopes enables us to produce short peptides for use in ELISA 
screening, and allows the production of polyclonal antibody for use in screening tissues by 
immunohistochemistry and western blotting. 
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Table 2.1 Putative autoantigens in MS 
 
 
Autoantigen Function B cell T cell References 
     
Myelin-associated    
Myelin Basic Protein Component of myelin 
sheath 
? ? Wajgt & Gorny, 1991 
Burns et al., 1983 
Myelin Associated 
Glycoprotein 
Component of myelin 
sheath 
? ? Wajgt & Gorny, 1991 
Johnson et al., 1986 
Myelin 
Oligodendrocyte 
Glycoprotein 
Component of myelin 
sheath 
? ? Sun et al., 1991b 
Proteolipid Protein Component of myelin 
sheath 
? ? Sun et al., 1991a 
NoGo A Neurite outgrowth inhibitor ?  Reindl et al., 2003 
Oligodendrocyte 
specific protein 
(Claudin 11) 
Component of myelin 
sheath 
? ? Bronstein et al., 1999 
Vu et al., 2001 
     
Other proteins     
Alpha B Crystallin Heat shock protein ? ? Agius et al. (1999) 
Chou et al. (2004) 
Arrestin Retinal protein. Signal 
transduction. 
?  Ohguro et al., 1993 
Beta Arrestin CNS protein. Signal 
transduction. 
?  Ohguro et al., 1993 
2’3’-cyclic nucleotide 3' 
phosphodiesterase 
Signal transduction. 
Synaptic transmission. 
?  Walsh & Murray, 1998 
Heterogeneous 
ribonucleoprotein 
(hnRNP) 
Involved in mRNA 
expression and transport. 
?  Sueoka et al., 2004 
HSP 60 Heat shock protein ? ? Prabhakar et al., 1994 
Ruiz-Vazqez & De Castro, 2003 
HSC 70 Heat shock protein. Co-
localises with MBP? 
 ? Mycko et al., 2004 
HSP 70 Heat shock protein. Co-
localises with MBP? 
 ? Mycko et al., 2004 
Transaldolase Involved in pentose 
phosphate pathway 
(generation of NADPH) 
? ? Colombo et al., 1997 
 
 
A number of different proteins have been proposed as candidate autoantigens in MS (for B 
and T cells). These include a number associated with the myelin sheath, and a wide array of 
other proteins such as signalling molecules and heat shock proteins. 
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A number of criteria were considered to be important in identifying epitopes, including primary 
structure analysis (hydrophilicity, polarity, flexibility and accessibility), and secondary 
structure prediction (identification of alpha helices and beta turns). The protocol followed is 
summarised in Figure 2.1. 
 
 
2.2 Methods and theory 
 
2.2.1 Primary structure prediction 
 
One of the major factors in determining protein structure is hydrophilicity. In a solvent 
environment, hydrophobic residues remain in the core of the protein, while the hydrophilic 
residues (which are largely polar or charged), such as arginine, aspartic acid, and glutamic 
acid are exposed on the protein surface and accessible to antibody. Mutations of 
hydrophilic/polar residues can affect protein folding and thus structure, such as the R1137P 
mutation of fibrillin in Marfan Syndrome (Thomas et al., 1995).  
 
Another important consideration is that antibody-antigen interactions are dependant on non-
covalent forces. These include electrostatic forces, hydrogen bonds, Van der Waals forces, 
and hydrophobic interactions (where molecules pack together to exclude water).  
 
Hopp and Wood (1981) devised a method based on hydrophilicity to determine antigenic 
determinants in a number of proteins. Amino acids were assigned a value adapted from 
those previously assigned by Levitt (1976). The authors used a computer program to work 
along the polypeptide chain to produce a plot of values averaged over a 6 amino acid stretch. 
Known epitopes were found to be located at the peaks of these plots.  
 
Amino acid sequences obtained from GenBank (http://www.ncbi.nlm.nih.gov/Entrez/) were 
inputted into the ProtScale tools found on the ExPaSy server (http://ca.expasy.org). Values 
greater than 1.2 and 10 for hydrophilicity and polarity respectively were taken to be 
significant. The ProtScale tools work in a similar way to the Hopp and Wood study, utilising a 
sliding window technique where the mean value over a given window size (9 is the size used) 
is assigned to the central amino acid (Figure 2.2). The tools provide both graphical (Figure 
2.3) and numerical output.  The default window size of 9 amino acids was selected, as this is 
considered to be an optimal value for detecting structural features of globular proteins, in 
contrast to a 19 amino acid window more suitable for the analysis of transmembrane domains 
(Claverlie and Notredame, 2003). 
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Figure 2.1 Overview of methodology 
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Figure 2.2 Overview of the ‘sliding window technique’ 
 
In the sliding window technique, parameter values (listed in Appendix A) (e.g. for 
hydrophilicity) are obtained for each individual amino acid. The mean is taken over a 9 amino 
acid stretch and assigned to the central amino acid. This gives an indication of how 
hydrophilic the region is, rather than just the individual amino acid. For hydrophilicity, values 
of 1.2 or greater are taken to be significant.  
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Hphob. (421)  = 9/Hphob.
425
417
∑  
  = (3.0 - 1.5 + 3.0 + 3.0 - 1.8 + 3.0 + 3.0 + 3.0 - 1.8) / 9 
  = 1.433 
 
   
Hphob. (422)  = 9/Hphob.
426
418
∑  
  = (-1.5 + 3.0 + 3.0 - 1.8 + 3.0 + 3.0 + 3.0 - 1.8 + 3.0)/9 
 
  = 1.122 
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Figure 2.3 Protscale output for HERV-W env (syncytin) hydrophilicity 
 
An example of a graphical Protscale output for syncytin using the Hopp and Woods scale for 
hydrophilicity. Note that there is a strong hydrophilic peak at approx. 420 aa, and a number of 
smaller peaks. Such peaks often correspond to exposed regions on a protein’s surface. 
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While the peptide bonds in a polypeptide chain are rigid, planar structures as the C-N bond 
which has partial double-bond characteristics, flexibility in the chain is present in the bonds 
surrounding the α-carbon atoms (Figure 2.4). Amino acids with larger side chains, such as 
methionine collide with each other and hinder flexibility. The distribution of amino acids with 
more flexible side-chains are important in the function of the protein (Vihinen et al., 1987), 
and therefore would be more likely to be present near the surface of the protein. The flexibility 
scores were based on values calculated by Bhaskaran & Ponnuswamy (1988). Amino acids 
were scored on a scale from 0 (minimum flexibility) to 1 (maximum), and values of greater 
than 0.5 were taken to be significant. The authors showed that flexibility correlated with both 
hydrophilicity and polarity. 
 
The final criterion used was that of accessibility. For obvious reasons, residues that are 
inaccessible are unlikely to be interacting with other proteins, such as antibody, if they are 
buried away. The scale of surface accessibility to solvents was obtained from Janin (1979). 
 
 
Figure 2.4 Illustration of protein flexibility 
 
In proteins the peptide bond is a rigid planar unit. Flexibility in a protein occurs around the 
α-carbon atom. Larger side chains tend to have less rotational flexibility as these are more 
likely to collide with other residues. 
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 2.2.2 Secondary structure prediction 
 
Polypeptide chains can also fold into regular structures, such as alpha helices and beta turns. 
The arrangement of these structures is called the secondary structure. Alpha helices are 
rod-like structures, formed by a coiled polypeptide chain where the each CO group is 
hydrogen-bonded to the NH2 group of the residue 4 further up in the chain. Alpha helices can 
coil round each other, forming ‘coiled coils’ giving rise to strength and rigidity in a protein, 
particularly in the case of structural proteins, such as keratin in hair. The ends of alpha 
helices are often polar, and as such are likely to be found on the surface of proteins. 
 
Beta turns are hairpin structures where the direction of the polypeptide chain reverses on 
itself, and the CO group is hydrogen-bonded to the NH2 group 3 further up in the chain. In 
contrast to alpha helices, the structures are stabilised by hydrogen bonding between residues 
in different strands. 
 
Earlier methods of secondary structure prediction involved looking at the properties of amino 
acids within the protein sequence. The method of Chou and Fasman (1974) analysed the 
amino acid of 15 proteins with known three-dimensional structures, and calculated the 
probability that each particular amino acid would be found within an alpha helix or beta 
strand. Each amino acid was then classified into their propensity to form or break secondary 
structures. By summing up these propensities along segments of the sequence, it is possible 
to determine whether the segment as a whole is part of an alpha helix, a beta strand or a coil 
region. A similar method, the GOR method developed by Garnier et al. (1978) involved the 
use of a sliding window technique averaging across a 17 amino acid window size to increase 
the accuracy. Such methods have been shown to be 56-60% accurate, in comparison to the 
70-80% accuracies claimed (Jones, 2003). 
 
As such methods are only moderately accurate and quite cumbersome, modern methods of 
secondary structure prediction rely on studying multiple aligments carried out by Artificial 
Neural Networks (ANNs). Such neural networks are collections of mathematical models 
which aim to mimic adaptive biological learning. These networks are comprised of a number 
of highly interconnected processing elements (analogous to synapses) linked to weighted 
connections (analogous to neurons). Such networks are “trained” by identifying particular 
output patterns (e.g. secondary structure) and relating them to the input pattern (e.g. amino 
acid sequence), enabling the neural network to learn relationships between the patterns. In 
addition, neural networks have the advantage of being reproducible, rapid by carrying out 
large numbers of tasks in parallel, and capable of dealing with complex data. 
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PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred) was used to predict alpha helices in protein 
sequences.  PSIPRED was selected as it is ranked as the most accurate prediction program 
in the Critical Assessment of Techniques for Protein Structure Prediction (CASP) 4 meeting 
(http://predictioncenter.org/casp4/Casp4.html). A neural network utilises PSI-BLAST 
(position-specitfic iterative basic local alignment search tool) position scoring matrices rather 
than sequence alignments used in a number of methods. PSI-BLAST operates by carrying 
out multiple BLAST searches and creating a multiple alignment, producing a profile which can 
predict homologies between distantly related sequences (Altschul et al., 1997). PSI-PRED 
acts by utilising these intermediates, producing a large amount of data which is filtered by the 
2 neural network layers, giving a prediction of secondary structure (helix, strand or coil, with a 
confidence level of 0 (poor) to 9 (high)). Helix predictions with a confidence level of 5 or 
greater, i.e. those with a greater chance of adopting a structure based on the PSI-PRED 
prediction algorithm, were taken as a threshold value. 
 
PSIPRED does not predict beta-turns, so another web-based server, BetaTPred2 
(http://www.imtech.res.in/raghava/betatpred2/) was used. This program takes a similar 
approach to PSIPRED as it utilises a neural network trained on PSI-BLAST position scoring 
matrices, but to recognise beta-turns (Kaur & Raghava, 2004). In addition to PSI-BLAST 
position scoring matrices, PSIPRED prediction results are also used as an input. The authors 
claim an overall accuracy of 75.5% (Kaur & Raghava, 2003). 
 
 
2.2.3 Alignment of epitopes 
 
Once the epitopes for both retroviruses and the putatitive autoantigens were identified 
(Appendix B), they were aligned to identify sequence homology, and potential molecular 
mimicry. Lalign (http://www.ch.embnet.org/software/LALIGN_form.html) was used in 
preference to BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) as BLAST is capable of only 
identifying the “best” match, this is not necessarily the one that is of the most interest. LAlign 
passes the query through a substitution matrix (e.g. blocks substitution matrix - BLOSUM 50, 
the default used), which aligns the peptide sequences in a manner which the conservation 
score is the highest. Each residue is given a score based on how well it is conserved, and 
these are summed.  
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Mutations of the gene affect protein sequence differently. Certain residues are less likely to 
be conserved (Valdar and Jones, 2004), such as tryptophan (which is coded for by only one 
RNA triplet, UGG), and the scores given for conservation are higher. Conversely, if gene 
mutation is less likely to alter the residue, as is the case with leucine (coded for by 9 different 
RNA triplets), scores assigned are lower. If the mutation changes the residue to a residue 
with different physicochemical properties, the substitution matrix applies a penalty. 
 
 
2.2.4 Three-dimensional structure prediction using homology modelling 
 
In order to obtain an accurate three-dimenstional model where there is no known structure, it 
is important to carry out fold recognition in order to obtain an accurate model (Shortle, 1997). 
In order to evaluate where the predicted epitopes of selected proteins were in three 
dimensions, the sequences were inputted into an online fold recognition program, 
GenTHREADER (http://bioinf.cs.ucl.ac.uk/psipred). GenTHREADER works by carrying out 
multiple sequence alignments and comparing these to fold library sequences in the 
Brookhaven Protein Data Bank (Jones, 1999b). Like the PSIPRED protein structure 
prediction server, GenThreader utilises a neural network to give a measure of confidence in 
the evaluation. Three-dimensional structures of homologous proteins are highly conserved, 
with proteins sharing 50% identity of residues over a domain exhibiting almost identical 
structures (Claverlie & Notredame, 2003), and even down to 20% identity a good model can 
be predicted. 
 
Where a homologous protein was identified, with a p-value assigned by GenThreader of 
<0.001 (or ‘high’), the PDB sequence was retrieved from the European Bioinformatics 
Institute’s PDBsum database (http://www.ebi.ac.uk/pdbsum/). Downloaded PDB sequences 
were then visualised using Cn3D version 4.1 (National Center for Biotechnology Information), 
available (http://www.ncbi.nlm.nih.gov/structure/CN3D/cn3d.shtml). 
 
 
2.3 Results 
 
Comparison of the retroviral epitopes identified with those of putatative autoantigens yielded 
a number of interesting results (Table 2.2 – see Appendix B for a list of epitopes).  With the 
exception of alpha beta crystallin and claudin 11 (oligodendrocyte specific protein), all of the 
autoantigens showed potential for molecular mimicry with the retroviruses identified, in 
particular the Visna virus (largely due to the large number of epitopes idenfied, as Visna 
encodes large, polar proteins). 
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Of particular interest is the number of retroviral sequences with similarity to NoGo A, a myelin 
protein produced by oligodendrocytes which is involved in the inhibition of neurite growth 
(Chen et al., 2001). Serum IgG and CSF IgM antibodies against NoGo A are detectable in 
MS patients (Reindl et al., 2003). It may be more likely that these antibodies indicate levels of 
tissue damage, rather than acting as an autoantibody, though this is likely to be true for the 
vast majority of autoantigens. 
 
 A large number of epitopes were identified for NoGo A, as it is a large, highly hydrophilic 
(and polar) protein. Epitopes from both HERV-H and HERV-W (including the MSRV variant) 
env proteins show a high level of similarity to NoGo A epitopes (Table 2.3a). HERV-H env 
shares an identical 8 amino acid stretch with NoGoA, and the probability of this arising by 
chance is extremely low (E(10,000): 0.0023). The similarity between HRES-1 and NoGo A is 
due to a stretch of glutamic acid residues.  
 
An identified MSRV pol epitope shows similarity to both isoforms of myelin associated 
glycoprotein precursor (Table 2.3b). The glycosylated form of MAG is a lectin-binding protein, 
which has N-linked oligosaccharide sidechains attached, is responsible for mediating myelin-
neuron cell-cell interactions, MAG is located in the periaxonal space of the myelin sheath, 
and although less abundant, it is more accessible than MBP which lines the interior of the 
myelin sheath where it interacts with acidic lipids (Quarles, 2007). 
 
MS patients commonly suffer from visual disturbances, and consequently there is frequently 
damage of the optic nerve. A number of retinal antigens, such as the arrestins have been 
investigated as putative autoantigens. Ohguro et al. (1993) carried out a small scale study 
finding 8 out of 14 MS patients were seropositive for antibodies to S-arrestin/beta arrestin, but 
not in any of the 50 controls tested. The authors showed that the antibodies recognised the 
major epitope of S-arrestin, located between residues 290-320. While bioinformatics analysis 
identified an epitope between 296-311, no cross-reactivity with any of the viral epitopes was 
found by alignment. However, potential mimicry between HERV-W/MSRV envelope and gag  
proteins was identified at another predicted S arrestin epitope located between residues 229-
243. 
 
Epitope mapping has previously been used within our research group to identify potential 
molecular mimics, and homology between MSRV gag protein and MBP has been found 
(Table 2.3).  
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 Table 2.2 Overview of alignments of retroviral epitopes against  
autoantigen epitopes 
 
Potential molecular mimicry was found with a number of retroviruses with all of the 
autoantigens with the exception of alpha beta crystallin and claudin 11. A large number of 
matches were found with NoGo A, compared with the other proteins investigated. 
 
 
  HERV-H HERV-W HRES-1 HTLV-1 MSRV Visna 
  env gag env gag p15 p25 gpp gp46 tax env gag pol env gag pol 
 # 2 1 2 2 2 3 9 1 2 3 2 4 12 7 12 
α B Crystallin 1                
β Arrestin 1A 5                
β Arrestin 1B 7                
Claudin 11 1                
CNP 10                
hRNP 8                
HSP 60 12                
HSP 70 1A 14                
HSP 70 1B 14                
HSP 70 8-1 14                
HSP 70 8-2 9                
MAG A 4                
MAG B 3                
MBP 3                
NoGo A 18                
PLP 1                
S Arrestin 10                
T’aldolase 1 4                
 
Key 
        – 4 aa alignment ;         – 5 aa alignment ;         – 6 or greater aa alignment 
 
Abbreviations:  
CNP = 2', 3'-Cyclic Nucleotide 3' Phosphodiesterase; HERV = HERV; HRES = HTLV-related endogenous sequence; hnRNP = Heterogenous 
nuclear riboprotein; HSP = Heat shock protein; HTLV – Human T cell lymphoma virus; MAG = Myelin associated glycoprotein; MBP = Myelin 
basic protein; PLP = Proteolipid protein 
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 Table 2.3 Comparison of human endogenous retroviral epitopes identified 
with autoantigens. 
 
(a) NoGo A 
HERV-H env (230)  SPCSSDSPPRPSSRLL 
       ::::::::    
NoGo A (8)  PLVSSSDSPPRPQPA 
HERV-H gag (190) QFTLKKVAGAKGIVK 
        .::::.: :  .: 
NoGo A (665)  VSLKKVSGIKEEIKEPENIN 
HERV-W env (117) GGVQDQAREKHVKEVIS 
            : ::: 
NoGo A (352)          KLVKEDEVVSSEKAKDSFNEKRVAV 
HERV-W env (412) GIVTEKVKEIRDRIQRRAEELRNTGP 
   .::::: 
NoGo A (503) QIVTEKNTSTKTSNPFL 
HRES-1 p15 (68)    RALHPPSGRDREEEEEMGY 
           :  ...::::: 
NoGo A (23)  FKYQFVREPEDEEEEEEEEEEDEDEDLEELEVLER 
MSRV env (120) IQGQAREKQVKEAISQ 
          : ::: 
NoGo A (352)        KLVKEDEVVSSEKAKDSFNEKRVAV 
MSRV env (412) RIVTEKVKEIRDRIQC 
   .::::: 
NoGo A (503) QIVTEKNTSTKTSNPFL 
MSRV pol (580)     TFLPDNEEKIEHNCQQV 
           :.:::.  : 
NoGo A (321) EEIIVKNKDEEEKLVSNNIL 
 
 
(b) Myelin Associated Glycoprotein 
MSRV pol (731) LHCQGHQEEEEREIEGNRQADIEAKKAARQDSPLEML 
              :: :: 
MAG A/B (184)      AVLGRLREDEGTWVQ 
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 Table 2.3 Comparison of human endogenous retroviral epitopes identified 
with autoantigens (continued). 
 
(c) S Arrestin 
HERV-W env (134) GGVQDQAREKHVKEVIS 
           :: ::.. 
S Arrestin (229)   TVTNNTEKTVKKIKA 
MSRV env (120) IQGQAREKQVKEAISQ 
         :: ::. 
S Arrestin (229) TVTNNTEKTVKKIKA 
MSRV gag (274) TCVLEGLRKTRKKPMN 
     : .. .:: :: 
S Arrestin (229)  TVTNNTEKTVKKIKA 
 
 
 
Table 2.4 Comparison of human endogenous retroviral epitopes 
(previously predicted in the research group by Denise Roden) 
with myelin basic protein. 
 
MSRV gag (311) LREALRKHTSLSP 
             ::: 
MBP (41)             LSP 
 
 
 
 
 
 
 
 
 
 
These tables show LAlign outputs comparing predicted retroviral epitopes against those of 
putatative autoantigens. (:) represents identical amino acids, whilst (.) represents chemical 
similarity (where the Point Accepted Matrix (PAM) (Dayhoff et al., 1978) substitution score is 
less than or equal to 0). 
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HERV-W env and MSRV gag were entered into the GENthreader program in order determine 
where HERV-W env 412 and MSAV gag 274 for homology modelling, in order to determine 
where are likely to be located in three dimonsions. 
 
GENthreader identified a number of alignments to protein data bank structures, with HERV-W 
env and MSRV env showing at least a high degree of homology to three alignments and one 
alignment respectively (Figures 2.5 and 2.6). Proteins predicted to have domains with similar 
structures to HERV-W env included domains envelope proteins of HERV-FRD_6rp24.1, 
MoMuLV and a strain of Zaire ebolavirus, whilst MSRV gag had a high homology to the gag 
polyprotein of AKV murine leukaemia virus (Table 2.5). The HERV-W env412 epitope was not 
present in the homologous domains of the envelope protein structures, but the MSAV gag 274 
epitope was present towards the C-terminus of the AKV murine leukaemia virus gag 
polyprotein (Figure 2.7). One further point of note is that the alignment inducates that the 
complete sequence of the AKV murine leukaemia virus shows homology to MSAV gag 274, 
 
 
Table 2.5 Details of proteins identified by GENThreader as having high 
homology matches, or better, with HERV-W env and MSAV gag 
 
 
Query 
protein 
PDB ID UniProt 
ID 
Protein name Homologous 
amino acids on 
retrovirus 
HERV-W env 412 / 
MSAVgag 274 
epitope present? 
HERV-
W env 
1y4m P60508 HERV-FRD_6p24.1 
provirus ancestral 
envelope 
polyprotein 
357-410 
 
No 
 1mof P03385 MoMuLV envelope 
glycoprotein p15 
296-309 
 
No 
 2ebo Q05320 Zaire ebolavirus 
(strain Mayinga-76) 
(ZEBOV) envelope 
glycoprotein 
353-406 No 
MSAV 
gag 
1u7k P03336 
 
AKV murine 
leukemia virus (AKR 
(endogenous) 
murine leukemia 
virus) gag 
polyprotein 
143-285 MSAV gag 274 
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Figure 2.5 GENthreader alignment summary for HERV-W env 
 
 
 
 
 
One homologous PDB structure alignment, with a ‘certain’ homology match (p<0.0001) and 2 
with a ‘high’ match (p<0.001) to HERV-W env were identified by GENthreader. 82 alignments 
with a ‘low’ (p<0.1) match were also identified (data not shown). 
 
 
Key       Confidence levels 
 
Conf description of confidence level    CERT p-value < 0.0001 
Score raw score from support vector machine   HIGH p-value < 0.001 
p-val probability of false positive    MEDIUM p-value < 0.01 
Epair pairwise energy for model    LOW p-value < 0.1 
Esolv solvation energy for model    GUESS p-value >= 0.1 
AlnSc sequence alignment score 
Alen Length of alignment 
Dlen Length of PDB entry 
Tlen Length of target sequence 
PDB_ID PDB identifier (+ chain code + domain code in CATH format) 
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Figure 2.6 GENthreader alignment summary for MSAVgag 
 
 
 
 
One homologous PDB structure alignment, with a ‘certain’ homology match (p<0.0001) was 
identified by GENthreader. 9 alignments with a ‘low’ (p<0.1) match were also identified (data 
not shown). 
 
 
Key       Confidence levels 
 
Conf description of confidence level    CERT p-value < 0.0001 
Score raw score from support vector machine   HIGH p-value < 0.001 
p-val probability of false positive    MEDIUM p-value < 0.01 
Epair pairwise energy for model    LOW p-value < 0.1 
Esolv solvation energy for model    GUESS p-value >= 0.1 
AlnSc sequence alignment score 
Alen Length of alignment 
Dlen Length of PDB entry 
Tlen Length of target sequence 
PDB_ID PDB identifier (+ chain code + domain code in CATH format) 
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 Figure 2.7 GENthreader alignment of AKV murine leukemia virus (AKR 
(endogenous) murine leukemia virus) gag polyprotein against 
MSAVgag 
 
 
The PDB structure alignment of AKV murine leukemia virus (AKR (endogenous) murine 
leukemia virus) gag polyprotein (PDB ID: 1u7k) (residues 1-131) shows homology with amino 
acids 143-285 of MSAV gag (the query sequence). Amino acids highlighted in green are 
identical, whilst those highlighted in red are physicochemically different. The MSRV gag 274 
epitope is homologous to the C-terminal of the query. 
         ------------------------------------------------------------ 
1u7kA0   ------------------------------------------------------------ 
Query    LERILENWDQCDTQTLRKKRFIFFCSTAWPQYPLQGRETWLPEGSINYNIILQLDLFCRK 
 
                 10        20        30        40        50        60 
 
                                                                    
         ------------------------------------------------------------ 
1u7kA0   ------------------------------------------------------------ 
Query    EGKWSEVPYVQTFFSLRDNSQLCKKCGLCPTGSPQSPPPYPSVPSPTPSSTNKDPPLTQT 
 
                 70        80        90       100       110       120 
 
                                           10        20        30   
         ----------------------CCCC--CC--CCCCCCCCCCHHHHHHHHHCCCCCCCCH 
1u7kA0   ----------------------PLRM--GG--NGQLQYWPFSSSDLYNWKNNNPSFSEDP 
Query    VQKEIDKGVNNEPKSANIPRLCPLQAVRGGEFGPARVPVPFSLSDLKQIKIDLGKFSDNP 
 
                130       140       150       160       170       180 
 
             40        50        60        70        80        90   
         HHHHHHHHHHHHHCCCCHHHHHHHHHHHCCHHHHHHHHHHHHHCCCCCCCCCCCCHHHHH 
1u7kA0   GKLTALIESVLTTHQPTWDDCQQLLGTLLTGEEKQRVLLEARKAVRGNDGRPTQLPNEVD 
Query    DGYIDVLQGLGQSFDLTWRDIMLLLNQTLTPNERSAAVTAAREF--GDLWYLSQANNRMT 
 
                190       200       210       220         230       
 
                      100       110       120       130             
         H----------HCCCCCCCCCCCCHHHHHHHHHHHHHHHHCCCCCCC------------- 
1u7kA0   A----------AFPLERPDWDYTTQRGRNHLVLYRQLLLAGMQNAGR------------- 
Query    TEERTTPTGQQAVPSVDPHWDTESEHGDWCHKHLLTCVLEGLRKTRKKPMNYSMMSTITQ 
 
                  250       260       270       280       290       
 
                                                              
         ------------------------------------------------------ 
1u7kA0   ------------------------------------------------------ 
Query    GKEENLTAFLDRLREALRKHTSLSPDSIEGQLILKDKFITQSAADIRKNFKSLP 
 
                  310       320       330       340       350 
 
Percentage Identity = 26.7% 
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Figure 2.8 Three dimensional structure of AKV murine leukemia virus (AKR 
(endogenous) murine leukemia virus) gag polyprotein 
highlighting area homologous to the predicted MSAV gag 274 
epitope 
 
 
 
The figure illustrates the three dimensional structure of AKV murine leukaemia virus gag 
polyprotein as visualised using Cn3d 4.1 (National Institute of Biotechnology Information). 
The PDB sequence, 1u7k, was obtained by X-ray crystallography by Mortuza et al., 2004. 
 
Areas highlighted in green represent residues forming alpha helices, and those in gold, beta 
pleated sheets. The area of the chain highlighted in yellow indicates the position amino acids 
120-131 of AKV murine leukaemia virus, which is homologous to the MSRV gag274 epitope, 
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Imaging of the AKV murine leukaemia virus (Figure 2.8) in three dimensions illustrates an 
area homologous to the MSRV gag 274 epitope is located at the C-terminus towards the end of 
an alpha helix. It is quite likely, therefore that the MSRV gag 274 is exposed on the outside of 
the protein, but this is not conclusive as the structure of the MSRV gag protein has only been 
estimated for part of the protein, between amino acids 143-285. 
 
 
2.4 Discussion 
 
The method applied in this study uses a number of different criteria to predict epitopes, 
including physicochemical properties in the case of the primary structure prediction; as well 
as structural predictions based on homology modelling to determine whether the epitopes are 
likely to be presented on the surface of the protein, i.e. between alpha-helices and beta turns, 
in the case of secondary structure prediction. The primary prediction methods on their own 
have a low accuracy, approximately 50% in the case of using hydrophilicity profiles (Hopp 
and Woods, 1981), but taken together with secondary structure analysis, which has a higher 
level of accuracy, between 76.5%-78.3% in the case of PSIPRED (Jones, 1999b), the system 
as a whole can be made more robust. 
 
One problem with this method is that only linear epitopes can be identified. Another is that the 
thresholds for the primary structure prediction rely on artifical thresholds, albeit ones that 
have been used within the research group for a period of time. This has yielded problems in 
that certain hydrophobic proteins, such as PLP had no epitopes predicted for it, even though 
antibodies to this protein have been detected time after time in MS patients. Conversely, with 
large, polar proteins many epitopes have been predicted, and a large number of these may 
be irrelevant. An alternative approach may have been to look for the most hydrophilic areas 
of the proteins, for example by setting the threshold for each protein individually, basing each 
threshold on the maximum and minimum values as a percentage. Some epitopes may be 
missed, but the amount of irrelevant data would be minimised, and epitopes for hydrophobic 
proteins can be determined. 
 
The use of bioinformatics or in silico analysis does not prove that molecular mimicry is taking 
place, but rather a powerful tool to provide a large amount of data that can be used alongside 
experimental work. In order to test for potential molecular mimicry, two of the predicted 
epitopes, HERV-W env 412 and MSRV gag 274 were selected to be synthesised as short 
peptides, and tested in a pilot study to test for seropositivity in MS patients and controls in an 
ELISA based protocol.  
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Figure 2.9 Comparison of HERV-H env 230, HERV-W env 412 and MSAV 
gag 274 epitope properties 
 
 
HERV-H env 230 
 
 
HERV-W env 412 
 
 
MSAV gag 274 
 
 
 
 
 
Legend 
Primary structure 
    hydrophilicity >1.2     polarity >10      accessibility >7      flexibility >0.5  
Secondary structure 
    alpha helix (conf >5)     beta turn 
 
    >3 thresholds on amino acid       >3 thresholds within 3 residues 
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In order to further evaluate whether the epitopes of the peptides for production were likely to 
be located on the outside of the protein, homology modelling on the basis of known structural 
data was performed using a protein threading method. The results indicated that the MSRV 
gag 274 epitope is likely to be exposed on the protein surface. Ab initio analysis may yield 
further data, particularly on the HERV-W env sequence, where no suitable model was 
determined. 
 
Ab initio prediction methods, such as Robetta (Kim et al., 2004) and Folding@home 
(Marianayagam et al., 2005) can be used to determine the three dimensional structure where 
homology modelling cannot. These methods rely on a large amount of computing power, and 
in the case of Folding@home, a distributed computing network utilising unused central 
processing unit power on computers that have the client installed is used (Shirts and Pande, 
2000). Ab initio methods still have limitations, and are currently more suited for shorter 
proteins, with Robetta optimised for short, single domain proteins of less than 120 amino 
acids (Kim et al., 2004). 
 
There were a number of reasons for selecting HERV-W env 412 and MRSV gag 274 for further 
investigation. Both HERV-W env 412 and MSRV gag 274 are highly hydrophilic regions (Figure 
2.9), and are predicted to lie between structural features (alpha helices and beta-pleated 
sheets), and therefore are more likely to be on the outside of the protein. By contrast, the 
epitope predicted for HERV-H env 190 is not hydrophilic and is predicted to sit in the middle of 
a beta sheet. Even though this epitope shows an extremely high homology (8 amino acids) to 
a predicted epitope of NoGo A (Table 2.3a), the sequence has few characteristics of a good 
epitope. A further consideration in the choice of peptides was that both HERV-W env and 
MSRV gag proteins have been detected in demyelinating region of MS lesions, with a high 
accumulation of gag in demyelinated white matter (Perron et al., 2005) whilst random phage 
peptides with amino acid similarity to HERV-W env were found to be present in raised titres in 
MS patients (Jolivet-Reynaud et al., 1999).   
 
Ultimately, the peptides predicted can be used to produce rabbit polyclonal antibodies in 
order to provide a standard curve in order to accurately estimate titres, and to detect the 
epitopes by immunocytochemistry in cancer cell lines (in the manner of the antibodies used in 
Chapter 5, as HERVs are known to be aberrantly expressed in tumours and are 
transcriptionally active in the brain (see Chapter 4 for a review of the literature), as a 
precursor to investigating pathological sections of MS tissues and controls.  
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3 Determination of antibody reactivity against retroviral 
epitopes in MS patient plasma by ELISA 
 
 
3.1 Introduction 
 
A number of potential epitopes were identified in silico using bioinformatic analysis, as 
outlined in Chapter 2. Short (~15aa) sequences from two of these predicted epitopes, 
HERV-W env 412 and MSRV gag 274 (highlighted in Table 3.1) were selected to be 
synthesised as peptides, and screened in small pilot study involving an ELISA-based assay 
to test for potential reactivity of antibodies present in plasma samples of a number of well-
defined MS patients and controls (including patients in remission, people with other 
neurological disorders and healthy volunteers). Assaying the peptides was necessary to 
determine immune responses in patients to particular predicted molecular mimics as a 
precursor to production of polyclonal antibodies. The production of polyclonal antibodies 
would provide a positive control for the ELISA, enabling titres to be estimated (by comparing 
to a calibration curve) and also a tool to investigate protein expression (e.g. 
immunohistochemistry in pathological sections, western blotting of protein extracts from 
peripheral blood, cerebrospinal fluid or pathological tissue). 
 
 
Table 3.1 HERV-W env and MSRV gag peptides used in the ELISA 
system and their homology to MS autoantigens 
 
 
 
HERV-W env (412) GIVTEKVKEIRDRIQRRAEELRNTGP 
   .::::: 
NoGo A (503) QIVTEKNTSTKTSNPFL 
 
 
MSRV gag (274) TCVLEGLRKTRKKPMN 
     : .. .:: :: 
S Arrestin (229)  TVTNNTEKTVKKIKA 
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HERV-W env 412 showed homology to a predicted epitope of NoGoA, with a stretch of 5 
identical amino acids. NoGoA is a myelin protein produced by oligodendrocytes which is 
involved in the inhibition of neurite growth in undamaged CNS tissues (Chen et al., 2000). 
Serum IgG and CSF IgM antibodies against the terminal domain of NoGo A are detectable in 
relapsing-remitting MS patients, but the levels did not differ significantly from patients with 
other inflammatory neurological diseases (Reindl et al., 2003). There was no response in 
SLE patients, suggesting that anti-Nogo A antibodies are detectable in serum as a response 
to CNS injury, though not specific to MS.  
 
MSRV gag 274 was identified as an immunodominant region of MSRV gag, showing a short 
stretch of amino acids homologous to S arrestin. S arrestin has been long been identified as 
an important autoantigen in uveitis, with a strong T cell response to the protein in uvetis 
patients. Immunisation of a particular epitope of bovine S arrestin (also known as S antigen), 
peptide M (DTNLASSTIIKEGIDKTV) causes experimental autoimmune uveitis in Lewis Rats 
(Donoso et al., 1987). Peptides with homology to peptide M, including a gag-pol polyprotein 
from a baboon endogenous retrovirus and hepatitis B virus DNA polymerase, act as 
molecular mimics in vitro (Singh et al., 1990). 
 
Autoantibodies to S-arrestin or similar antigen (such as β-arrestin) were present in 8 out of 14 
MS patients, with higher titres of antibody during active disease than in remission in 2 of 
these patients (Ohguro et al., 1993). The authors of this study showed that the major 
recognition site of the autoantibodies was at the immunogenic site identified in uveitis 
patients. As neurological symptoms, such as optic neuritis are a common complaint in MS 
patients, retinal proteins may be considered potential candidate autoantigens in the disease. 
 
Samples of each of the two peptides were coated onto 96 well plates and ELISAs were 
carried out on these in order to screen for reactivity of antibodies present in plasma samples 
of well-defined relapsing-remitting MS patients during remission, patients with other 
neurological diseases, and normal healthy donors. 
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3.2 Methods 
 
3.2.1 Peptide synthesis 
 
Solid phase peptide synthesis is a method of constructing peptides which are anchored to a 
resin (the solid phase) by an acid-cleavable linker group. This enables peptides to be 
produced with each synthesis step occurring in the same reaction vessel, where the reagents 
can be removed by filtration while the beads remain. An overview of the method is detailed in 
Figure 3.1. 
 
The growing polypeptide chain is made by adding a series of amino acids to the C-terminal, 
in contrast to in vivo protein synthesis where ribosomes add amino acids from the N-terminal. 
To prevent polymerisation of the amino acids, a protective group such as 
Fluorenylmethoxycarbonyl (Fmoc) is employed. In order to remove the protective group and 
facilitate further rounds of peptide synthesis, a deprotection step is necessary. Incubation in 
basic conditions, e.g. in 20% piperidine removes Fmoc protection, whilst side chains with 
acid-cleavable protection (e.g. tert-Butyloxylcarbonyl (tert-Boc)) remain. 
 
The amino acids are added in excess (typically a 2-fold amount is used) in order to keep 
yields high. If each coupling step of a 15 aa peptide was 99% efficient, the final yield would 
be 86.0% (0.9915), whereas if the coupling efficiency decreased to 95%, the final yield would 
be much lower at 46.3% (0.9515). It is therefore vital to check whether coupling and 
deprotection steps have been successful by carrying out a Kaiser test. The Kaiser test relies 
on the detection of free amine groups, where nihydrin reacts with unprotected amino acids, 
giving rise to blue beads. Where the amino acid has coupled, the Fmoc from the coupled 
amino acid prevents the reaction taking place, and no colour change occurs. 
 
For an amino acid to couple, it is necessary to activate the terminal carboxyl acid group on 
the growing polypeptide chain. This is done with the addition of Diisopropylethylamine 
(DIPEA) and aromatic oximes (e.g. 1-hydroxybenzotriazole (HObt)) or uronium salts (e.g. 
2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminiumhexafluorophosphate (HCTU)). 
Aromatic oximes and uronium salts also act to protect against racemisation, where amino 
acids spontaneously switch between D- and L-forms. 
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Figure 3.1 Basic overview of solid phase peptide synthesis methodology. 
 
 
 
Peptide synthesis involves repeated steps of addition of amino acids to a peptide chain 
coupled to a resin. Once the desired residues have been added, the peptide is cleaved from 
the resin and protective side chains. 
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When the chain is complete, the polypeptide is cleaved from the resin in acidic conditions 
(e.g. trifluoroacetic acid).This process also removes the acid-cleavable side chain protection 
groups. Triisopropylsilane (TIS) is added to act as a scavenger, preventing reactions with the 
newly exposed side chains present on the polypeptide chain. The peptide is then precipitated 
from solution in diethyl ether, washed and vacuum-dried. As a final check, the mass is 
confirmed with matrix-assisted laser desorption ionisation time of flight mass spectrometry 
(MALDI-TOF).  
 
Laboratory protocol 
 
100 μmole rink amide labelled MBHA resin (Novabiochem) was added to a glass reaction 
vessel and allowed to swell in 4 ml dichloromethane (DCM) for 1 hour. Following the 
incubation the DCM was removed under vacuum. 
 
To remove the Fmoc protective group, the resin was treated by the addition of 4 ml 20% (v/v) 
piperidine in N,N-dimethylformamide (DMF) for 5 minutes, drained under vacuum and 
reincubated in 4 ml 20% (v/v) piperidine for an additional 15 minutes. Following removal of 
20% (v/v) piperidine, the resin was washed 3 times for one minute in DMF. 
 
In order to establish whether the Fmoc was successfully removed, a Kaiser test was 
conducted to establish whether free amines were present on the resin. A small sample of 
resin was removed, washed in ethanol, and centrifuged briefly in order to be able to remove 
the ethanol. One drop of each of solution A (5% (w/v) ninhydrin in ethanol), solution B (80% 
(w/v) phenol in ethanol) was added to the beads, and solution C (20 μM potassium cyanide in 
pyridine), and heated at 120 ºC for 5 minutes. The presence of blue beads indicates that 
there are free amines present, and that the Fmoc removal was successful. If the beads were 
clear (i.e. Fmoc groups still attached), the resin was treated with piperidine and reincubated 
with.20% (v/v) piperidine as before. 
 
200 μmole (2 eq) of the relevant Fmoc-protected amino acid (Novabiochem) were added to 2 
eq HCTU/HOBt in DMF, and activated with 4 eq of DIPEA. This was then added to the beads 
in the reaction vessel, and incubated for 1 hour on an orbital rocker. The resin was then 
washed 3 times for one minute in DMF. 
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To establish whether coupling was successful, a Kaiser test was performed on a small 
sample of beads. The presence of clear beads indicates that there are no free amines 
present, and that coupling of the amino acid was successful. If the beads were not clear, the 
amino acid was recoupled as before. If the coupling was successful, further rounds of peptide 
synthesis (removal of the Fmoc protective group and coupling of the next amino acid) were 
carried out until the peptide chain was complete. 
 
Once the polypeptide chain is completed, the Fmoc protective group was removed by treating 
the resin with the addition of 4 ml 20% (v/v) piperidine in N.N-dimethylformamide (DMF) for 5 
minutes, drained under vacuum and reincubated in 4 ml 20% (v/v) piperidine for an additional 
15 minutes. The resin was washed 3 times with DMF for 1 minute, 3 times with DCM for 1 
minute, and finally 3 times with methanol for 1 minute. The resin was then freeze dried 
overnight. 
 
The polypeptide chain was cleaved from the resin by the addition of 95% TFA : 2.5% TIS : 
2.5 % H2O, followed by filtration through glass wool. Excess TFA was removed in nitrogen 
gas, and the peptide was then precipitated in a 10 fold volume of diethyl ether at 4 ºC, and 
centrifuged at 2,500 g for 2 minutes. The supernatant was discarded, and the pellet re-
centrifuged as above a further 3 times. The predicted mass of the peptide was confirmed with 
matrix-assisted laser desorption ionisation time of flight mass spectrometry (MALDI-TOF) 
(Kratos Kompact Probe). 
 
 
3.2.2 Patient information 
 
Peripheral blood of MS patients and ONDs were taken by venepuncture at St. Thomas's 
Hospital outpatient Neurology Clinic by Dr M. K. Sharief (consultant Neurologist) and those of 
NHDs at the University of Greenwich. Patient plasma samples used, provided by Dr. 
Laurence Harbige, University of Greenwich, were from relapsing-remitting MS patients, aged 
between 27 and 55 years (n=24); patients with other neurological diseases (mean age=49 
years), (including stroke (n=2), epilepsy (n=2) and Parkinson’s disease (n=1)) (n=5); and 
normal healthy donors (n=10, mean age=39 years).  Ethical approval for the project was 
granted by the University of Wolverhampton School of Applied Sciences Ethics Committee on 
26th January 2005 (Appendix C). 
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3.2.3 ELISA of MS patient plasma 
Performed at the Medway School of Sciences, University of Greenwich, Chatham Maritime, Kent 
 
ELISA provides a way of determining the levels of specific antibody (direct ELISA) or antigen 
(sandwich ELISA) in a particular sample. In a direct ELISA, a multiwell plate is coated with 
the antigen of interest, and a sample is applied. Specific antibody binds to the antigen on the 
plate, and this can be detected using an enzyme-labelled anti-species antibody. The enzyme, 
usually Horse Radish Peroxidase (HRP) or Alkaline Phosphatase (AP), catalyses a reaction 
in a substrate that is then added to the wells, producing a colour change that can be 
measured spectrophotometrically. 
 
Laboratory protocol 
 
50 μl of 400 ng HERV-W env 412 or MSRV gag 274 peptide in phosphate buffered saline 
(PBS), pH 7.2 stock was added to the wells of a Nunclon Δ 96 well plate (Nunc), and was left 
to coat overnight at 37 ºC. The plates were washed thoroughly four times in PBS (Sigma) 
with 0.05% Tween-20 using an automated plate washer (WellWash Mk4), and blotted dry. 
 
The plates were then blocked with 150 μl of blocking buffer (PBS with 1% bovine serum 
albumen (BSA); 0.05% Tween-20) and incubated at room temperature for 2½ hours, before 
being washed four times in PBS (Sigma) with 0.05% Tween-20 and blotted by hand. This 
was done to reduce potential unwanted interactions of antibody with the plasticware. Plasma 
samples and controls were diluted 1:50 in blocking buffer. 50 μl of sample dilution was added 
in triplicate to the wells of the plate, alongside appropriate blocking buffer alone to act as a 
negative control. This was then incubated at room temperature for 2½ hours before further 
washing and blotting by hand, as before. 
 
Secondary antibody, F(ab’)2 goat anti-human IgG:HRP (Serotec), was diluted to 1:2000, 
according to the manufacturer’s instructions, and 50 μl of diluted secondary antibody was 
added to each well of the plate, and incubated at room temperature for 1½ hours. The plate 
was then washed and blotted by hand as before. 
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OPD (Sigma) tablets were diluted to 0.4 mg/ml in phosphate citrate buffer with sodium 
perborate (Sigma) to give active substrate buffer. 50 μl of substrate was added to each well 
of the plate, which was incubated for 40 minutes at 37 ºC in the dark. The plate was read at 
450 nm (OPD) in a Multiskan MS (Labsystems) microplate reader. Following colour 
development, the reaction was stopped by the addition of 50 μl 2N hydrochloric acid. The 
stopped product was also read at 492 nm (OPD). 
 
 
3.3 Results 
 
Peptdes for HERV-W env 412 and MSAV gag 274 were successfully manufactured, and the 
molecular weights were determined to be accurate by MALDI-TOF mass spectroscopy 
(Figure 3.2). IgG responses to the HERV-W env 412 peptide was low (virtually 
indistinguishable from peptide negative controls, a measure of non-specific binding to the 
plate by primary antibodies in the serum, which were subtracted from the signal) in all of the 
types of plasma sample (NHD, OND and MS) tested, with no significant differences between 
the groups (Figure 3.3) (One way analysis of variance (ANOVA); F=0.02; p=0.976), indicating 
that antibody levels recognising the epitope present were non-existent. 
 
A stronger IgG response against the MSRV gag 274 peptide was present amongst NHD and 
MS patients (One way T-test, P=0.004 and P<0.0005 respectively), but not OND patients 
(One way T-test, P=0.137). As with the HERV-W env 412 peptide, no significant differences 
were found between each group (Figure 3.4) (One way ANOVA; F=0.30; p=0.740) with 
marginally lower antibody reactivity present in OND controls. 
 
The sensitivity of the assay was poor for both peptides (and thus a high signal to noise ratio), 
with levels of antibody response uncorrected for background having mean absorbances of  
0.160 (Std Dev=0.029) and 0.174 (Std Dev=0.039) for HERV-W env 412 and MSRV gag 274 
respectively. This compared to background levels for peptide negative controls of 0.130 (Std 
Dev=0.024) and 0.142 (Std Dev=0.026), serum-free controls of 0.094 (Std Dev=0.018) and 
0.098 (Std Dev=0.020) and secondary antibody negative controls of 0.095 (Std Dev=0.026) 
and 0.091 (Std Dev=0.019) for the same peptides. 
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Figure 3.2 MALDI-TOF analysis of HERV-W 412 and MSAV gag 274 
peptides 
 
(a) HERV-W 412 
 H-GIVTEKVKEIRDRIQR-NH2 (predicted MW=1940.31) 
 
 
 
(b) MSAV gag 274 
 H-CVLEGLRKTRKKPMN-NH2 (predicted MW=1773.23) 
 
 
 
In Figure 3.2 (a), a peak at approximately 1941 Da is present, indicating the presence of 
HERV-W 412 in the sample (predicted MW=1940.31). As the peptide is not purified (e.g. by 
high performance liquid chromatography), a number of smaller peaks are present. This is 
illustrated in Figure 3.2 (b), where in addition to MSAV gag 274 (peak at 1775.25, predicted 
MW=1773.23), there is a peak at approximately 1671.73 Da corresponding to MSAV gag 274 
without the cysteine residue at the C-terminal due to incomplete coupling (MW=1670.08). 
 
MALDI-TOF performed by Dr. Sarah Jones 
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Figure 3.3 Boxplot comparison of reactivity against HERV-W env 412 
peptide (absorbance at OD450 adjusted for peptide negative 
background) between normal healthy donors (n=10), patients 
with other neurological diseases (n=5) and active MS patients 
(n=24). 
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NHDs (median=0.02058, μ= 0.01803, StdDev=0.01717) have a higher level of antibody 
reactivity (though not significant) against HERV-W env 274 than patients with OND 
(median=0.01600, μ=0.01663, StdDev=0.00843) and MS (median=0.01692, μ=0.01790, 
StdDev=0.01090) (One way ANOVA; F=0.02; p=0.976). 
 
* represents an outlier 
 
 
 
 
 
 
 
Number of replicates = 6; 3 plates run with duplicate wells on each plate 
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Figure 3.4 Boxplot comparison of reactivity against MSRV gag 274 peptide 
(absorbance at OD450 adjusted for peptide negative 
background) between normal healthy donors (n=10), patients 
with other neurological diseases (n=5) and active MS patients 
(n=24).  
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NHDs (median=0.05542, μ=0.04792, StdDev=0.0221) and MS patients (median=0.04658, 
μ=0.04580, StdDev=0.02387) have a higher level of antibody reactivity (though not 
significant) against MSRV gag 274 than patients with OND (median=0.0302, μ=0.0381, 
StdDev=0.0244) (One way ANOVA; F=0.30; p=0.740). 
 
* represents an outlier 
 
 
 
 
 
 
 
 
 
 
 
 
Number of replicates = 6; 3 plates run with duplicate wells on each plate 
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3.4 Discussion 
 
There was no difference in the level of response to either the HERV-W env 412 or 
MSRV gag 274 amongst patients or controls. The HERV-W env 412 peptide showed homology 
to a predicted immunodominant domain of NoGo A, and as with the study by Reindl et al., 
2003, no statistical significance of IgG reactivity was found between MS patients, patients 
with OND, and NHD controls. That particular study looked at both IgM and IgG responses to 
the large N-inhibitory domain located between residues 1-979 of the sequence, which 
includes the epitope predicted and tested in this study. In contrast to IgG, Reindl (2003) 
showed that IgM responses were significantly raised in MS patients and OND controls, 
suggesting a response to brain injury.  A more recent study by Ruprecht et al. (2008) has 
indicated extremely low levels of immune response to recombinant HERV env and MSAV 
gag proteins. This study used a larger sample group, with 50 multiple MS patient and 59 
controls, with only one MS patient having detectable antibody reactivity against HERV-W env, 
and none for MSAV gag. No response was found in controls. 
 
HERV-W gag 412 was found to have homology to an epitope of NoGoA predicted by the 
bioinformatics analysis (NoGoA 502), The functional domain of NoGoA (NoGo-66) is not 
located within this particular epitope, but towards the C-terminus of the molecule (GrandPre 
et al., 2000). The functional sequence is located extracellularly on oligodendrocytes (Oertle et 
al., 2003) and on the inner and outer sequences of the myelin sheath (Huber et al., 2002). As 
NoGoA is thought to play a role in regeneration of the myelin sheath as a result of CNS 
injury, it might be expected that it is upregulated in conditions such as MS. 
Immunohistochemical analysis has recently shown that NoGoA expression in upregulated in 
the oligodendrocytes surrounding active MS lesions (Satoh et al., 2005) but not in other cell 
types, such as astrocytes. Consequently it is surprising that no significant titres were found 
either in MS patients or OND controls. As has been discussed in Chapter 2, a large number 
of epitopes (18) were predicted for NoGo A, and it is more than likely that the responses seen 
in other studies were reactive to a different epitope. 
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The MSRV gag 274 was homologous to S-arrestin, a retinal antigen known to be important in 
the pathogenesis of autoimmune uveitis (Banga et al., 1987). As many MS patients suffer 
from ophthalmic conditions, research into possible retinal antigens has been carried out by a 
number of research groups (Ohguro et al., 1993; Gorczyca et al., 2004). In the Ohguro study, 
IgG antibody levels against arrestins were present in 8 out of 14 MS patients, of which 2 of 
these had a higher titre during active disease than during remission. Gorczyca found a 
number of different retinal antigens were involved in MS including 46 kDa and 41 kDa forms 
of arrestin and S-arrestin, as well as a number of others. The 46 kDa and 41 kDa forms were 
present in patients with reduced visual acuity. No significant evidence was found to support a 
role of molecular mimicry between MSRV gag 274 and S-arrestin, though it may be worth 
testing in a small subset of patients. 
 
It is worth noting that antibody levels were measured in plasma samples rather than patient 
serum. Plasma is considered a more accurate representation of levels in the blood in vivo 
(Sakon et al., 1999), but the presence of clotting factors, such as platelets may potentially 
activate pathways, for example in assays where platelets scavenge vascular endothelial 
growth factor (VEGF) (George et al., 2000).  As the sensitivity of the assay was poor, it was 
difficult to effectively discriminate the samples. This could be for a variety of different reasons. 
The peptide might not have bound efficiently to the plate, resulting in a low signal. To remedy 
this, higher peptide concentrations could be increased until saturation, or higher affinity plates 
such as Nunc Immuno- Plates or Corning Co-Star 3590 . High affinity plates are designed to 
bind proteins via hydrogen-bonding rather than weaker, short-range Van der Waals forces, 
e.g. Nunc Polysorp plates have a large number of hydrophobic binding sites available for 
binding hydrophilic molecules. Other studies have utilised biotinylated peptides and bound 
them to streptavidin coated plates as a method of high-affinity binding (Jayasena et al., 
2001). 
 
Antibody binding sites can also be disrupted or obscured when binding to polystyrene ELISA 
plates, and short peptides may not adopt the same structure independently of the protein as 
other amino acids elsewhere may influence the structure, holding the epitope in place. Such 
factors are difficult to investigate without an established positive control. Altering other factors 
such as blocking buffer components, incubation times and temperatures, concentrations of 
primary and secondary antibodies used, and choice of substrate can also change the 
sensitivity of the assay. Another consideration is that antibodies present may have only been 
weakly cross-reactive to the peptide. Non-specific binding is unlikely, as the controls without 
peptide have considerably lower activity than the samples. 
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In summary, no suitable candidate for producing an antibody was found in this study. It is 
important to note that the two peptides produced were amongst a number identified for 
possible production. Reactivity was found against the peptides, but at low levels, and without 
significant differences between patient groups.  
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4 Detection of HERV-W env and MSRV gag transcripts in 
glioma cell lines and modulation of MSRV gag 
expression levels in a microglial cell line with IFN-γ 
 
 
4.1 Introduction 
 
A number of primers were developed in order to detect and investigate levels of HERV-W 
expression in astrocytoma cell lines.  HERVs are known to be expressed in a number of 
cancer cell lines, including brain tumours (Yi et al., 2002). As astrocytes (and microglia) are 
cell types where HERV-W expression is increased, astrocytoma cell lines were investigated 
to assess the transcription of HERV-W gene products. A multiplex RT-PCR system was 
optimised to give semi-quantitation of HERV-W env transcripts in a number of cell lines, while 
another system was developed to detect and evaluate MSRV gag transcripts. BeWo, a cell 
line derived from a placental choriocarcinoma was selected as a control cell line, as it is 
commonly used as a model of syncytin (HERV-W env) modulated syncytialisation (Kudo & 
Boyd, 2002). Glioma cell lines investigated comprised of astrocytoma short term cultures 
(IN859, IN1472, IN1528, and IN1612) and established glioblastoma cell lines (U251-MG and 
U373-MG). Other cell lines investigated in the HERV-W env system included 2 cell lines 
where other HERVs, notably HERV-K10 and HERV-K (HDTV) are known to be expressed, 
namely MCF-7 (a breast cancer cell line) and Tera 1 (a teratocarcinoma cell line). 
 
After design of the primers it is necessary to optimise the RT-PCR system in order to get an 
efficient reaction resulting in strong, clean bands. A number of factors are important such as 
the annealing temperature, the number of cycles, and concentrations of reagents (notably 
that of primers, template, Taq DNA polymerase, and magnesium chloride concentration). 
Sequencing of the products is also necessary to indicate whether the desired amplicon has 
been targeted successfully. Development of a RT-PCR allows the expression of transcription 
to be determined (either between different cell types or treatment conditions, e.g. by 
cytokines, hormones, or transactivation by exogenous agents), and in conjunction with a 
known housekeeping gene, semi-quantification of their level. 
 
HERV-W gene products have been detected in a variety of different tumours, though in 
particular ovarian cancers.  LTRs are hypomethylated in malignant ovarian tissue in 
comparison to non-malignant tissues (Menendez et al., 2004), which would be expected to 
result in an increase in expression of HERV-W gene products. However a more recent report 
by Hu et al. (2006) indicated that HERV-W RNA sequences are downregulated in ovarian 
cancer. In endometrial carcinomas, syncytin is increased at both mRNA and protein levels in 
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endometrial carcinomas compared with control tissues (Strick et al., 2007). By silencing 
syncytin expression with siRNAs, fusion of the EnCa cell lines was disrupted, whilst treatment 
of the cells with transforming growth factor β (TGF-β) increases syncytin expression and cell 
fusion.  
 
In contrast to this, studies looking at HERV-W gene products have indicated that expression 
takes place in a wide variety of healthy tissues (including the brain, placenta, testis, uterus, 
kidney and liver) and a number of diverse cancer cell lines. HERV-W env and pol transcripts 
were expressed in every sample tested, malignant or otherwise, while HERV-W gag was 
expressed in normal brain, placenta, testes and spleen, but not in any of the cancer cell lines 
tested). Sequence analysis indicated that env and gag displayed a high degree of sequence 
homology (>90%) to the HERV-W sequence at 7q21-22, pol transcripts had a large number 
of point and frameshift mutations (Yi et al., 2002). While HERV-W env sequences are often 
intact, pol sequences show little potential for translation (Yi et al., 2004).  
 
It has been shown that a number of HERVs retain transcriptional activity in the brain by 
expressed sequence tag (EST) analysis (Nakamura et al., 2003), and by digital expression 
profiling (Stauffer et al., 2004), including HERV-W and members of the HERV-K family. It has 
also been shown that HERV-K short interspersed elements are altered in a primary human 
glioma. These elements have homology with a number of genes including the tumour 
suppressor gene BRCA2 and the DNA repair gene XRCC1 (Misra et al., 2001). HERVs may 
contribute towards tumorigenesis in a number of ways, by retrotransposition (causing 
chromosomal instability), promoter insertion, immunomodulation, disruption of normal 
HERV-related functions, recombination, or by the production of fusion proteins (for review 
see Larsson & Andersson, 1998).  
 
HERV-W was initially identified in MS patients, and at a molecular level MSRV pol transcripts 
have been detected in the CSF, plasma, B cell cultures of affected individuals at a higher 
level than healthy donors and patients with other neurological diseases (Perron et al., 1997; 
Nowak et al., 1993). Additionally, there is an increased copy number of pol sequences on 
chromatin fibres of MS patients (Zawada et al., 2003). For a more detailed discussion of 
HERV-W and its link to MS, please see Sections 1.3 and 1.6. 
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A number of cytokines are important in the pathogenesis of MS, including IL-4, IL-5, IL-6, IL-
10, IL-13, TNF-α, and IFN-γ. MSRV pol has been shown to be upregulated by IL-4, IL-6, 
IFN-γ and TNF-α, while IFN-β (which is used in MS therapy) has the converse effect (Serra et 
al., 2003). In order to investigate the effects of IFN-γ treatment on MSAV gag transcription, 
the RT-PCR system was applied to a microglial cell line, CHME3. IFN-γ was used at a 
concentration of 5 u/ml and 50 u/ml used by Serra. MSAV gag was investigated for three 
reasons – firstly, as expression of Gag protein was found to be increased within demyelinated 
white matter in active MS cases (Perron et al., 2005); secondly, that MSAV gag is not 
expressed in normal brain tissue (Yi et al., 2004); and finally, that the effects of cytokine 
stimulation of MSRV gag have not been shown in vitro. As LTRs of retroviruses have 
IFN-γ responsive elements, such as ERV-9 (Andersson et al, 1998), it may be possible that 
upregulation of MSRV gag occurs if the MSAV gag sequence is present in the MHC region. A 
microglial cell line was selected as microglia are key cells in mediating inflammatory 
responses in the CNS, and IFN-γ strongly induces the upregulation of MHC-II in microglia 
(Panek and Benveniste, 1995). 
 
 
4.2  Methods 
 
 
4.2.1 Culture of cells grown as monolayers 
 
Cells were grown to ≥70% confluency in T75 tissue culture flasks (Sarstedt) under the 
appropriate conditions shown in Table 4.1 at 37 ºC. To passage the cells further, the 
supplemented media was aspirated, and cells were washed twice with 2ml Hanks’ Buffered 
Salt Solution (HBSS) (Sigma) in order to remove serum from the cells, which contains trypsin 
inhibitors (Chen et al. 1992). These were then detached by the addition of 2 ml of Trypsin-
ethylenediaminetetraacetic acid (EDTA) solution (Sigma), followed by incubation for 2 
minutes at 37 ºC (for complete detachment of cells). Trypsinisation of the cells was ended by 
the addition of 8 ml of supplemented media, and an appropriate dilution of cells (between 1:2 
and 1:10) was set up in fresh flasks containing 25 ml of fresh supplemented media. 
 
4.2.2 Reverse transcriptase PCR 
 
Reverse transcriptase PCR (RT-PCR) is a method of analysing levels of gene expression. 
This involves a number of steps, including extraction of RNA from the sample (i.e. cultured 
cells, clinical samples), reverse-strand synthesis of complementary DNA (cDNA), PCR 
amplification of the gene of interest, and quantification of the products by densitometry. 
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The first step of RT-PCR involves RNA isolation. The method used here is a variation of the 
Chomcznyski and Sacchi (1987) method, yielding total RNA. The method is cheap and rapid, 
giving a typical yield of 8-15 μg of RNA from cultured epithelial cells. In order to minimise the 
possibility of DNA contamination, all isolated RNA was DNase treated, and analysed 
spectrophotometrically and on a denaturing gel. 
 
Using reverse transcriptase (RT), derived from avian myeloblastosis virus (AMV) or Moloney 
murine leukaemia virus (MOMULV), cDNA copies of the isolated RNA are generated. 
MOMULV RTs considered to be more suitable for longer cDNAs (e.g. >5kb), while AMV RT is 
more rapid, and stable at higher temperatures (Sambrook et al., 1989).  cDNA synthesis 
requires a number of co-factors for the enzyme, such as magnesium chloride, as well as 
nucleotides and primers. Three different types of primers for cDNA synthesis are commonly 
used – oligo(dT) primers (which recognise the poly-A tail present on mRNA transcripts), 
random hexamers (which prime total RNA), and gene-specific primers (typically those used in 
the PCR reaction). 
 
PCR amplifies a specific DNA sequence between 2 oligonucleotide primers which are 
complementary to each DNA strand flanking the region of interest. The DNA strand is pulled 
apart by heating the PCR mixture to 94 ºC, which are then annealed to the primers at a lower 
temperature when the mixture cools (Figure 4.1). The primers act as a starting point for 
thermostable DNA polymerases to synthesise complementary DNA in the presence of each 
of the four deoxyribonucleoside triphosphates (dNTPs) in the appropriate buffer conditions. 
The newly synthesised strands act as further templates for DNA synthesis, with each cycle 
doubling the amount of DNA, and largely consisting of the fragment spanned by the primers. 
 
This product can be visualised by separating the DNA fragments by gel electrophoresis, and 
staining with a DNA intercalating dye, such as ethidium bromide and SYBR green, which can 
be visualised under UV light. The size of the fragments can be determined by comparing with 
fragments of a known size (e.g. in a DNA ladder). The product can be verified by sequencing, 
or by Southern blotting (blotting the DNA onto a membrane and hybridising to a probe 
complementary to a region of the target), 
 
The level of RNA expression can be determined relative to that of a housekeeping gene, 
such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), histidyl tRNA synthetase, or 
18s ribosomal RNA. Using densitometric analysis to get an expression ratio, it is possible to 
obtain relative expression of the gene of interest. It is possible to absolutely quantify by 
comparing expression against known copy numbers of cloned DNA. Real time PCR, where 
the levels of DNA are reported during amplification has made this process quicker and more 
accurate.
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Figure 4.1 Overview of PCR amplification 
 
 
 
PCR amplification relies on repeated cycles of denaturation (strand separation) of a DNA 
template, followed by annealing (binding of the primers) and elongation (DNA synthesis) 
stages to give further DNA template. At every cycle the amount of DNA is doubled, and 
exponential amplification occurs until the reaction efficiency drops as reagents are consumed 
and the DNA polymerase loses activity. 
2nd round
Strand separation and primer 
annealing 
Synthesis of cDNA (extension) 
First round 
of PCR 
3rd round
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Table 4.1 Cell lines used and culture conditions 
 
A list of the cell lines used for RNA extraction, and the culture conditions used. All the cell 
lines, except the IN series and CHME3 are established cell lines. The former are short term 
cell cultures derived from patient biopsies, and the latter is a foetal cell line with limited 
passage. 
 
Cell Line Description Conditions Source 
BeWo Choriocarcinoma F12 Ham’s (Sigma) w/ 
10% foetal calf serum (FCS) (PAA) 
    [5% CO2] 
European 
Collection of 
Cell Cultures 
(ECACC) 
CHME 3 Foetal microglia Dulbecco’s modified Eagle’s 
medium (DMEM) (PAA) w/ 
10% FCS (PAA) [5% CO2] 
Prof. Nicola 
Woodroofe, 
Sheffield-
Hallam 
University* 
IN859 Grade IV astrocytoma F10 Ham’s w/ 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
(HEPES) (Sigma) w/ 
10% FCS (PAA) 
Institute of 
Neurology 
IN1472 Grade IV astrocytoma F10 Ham’s w/ HEPES (Sigma) w/ 
10% FCS (PAA) 
Institute of 
Neurology 
IN1528 Grade IV astrocytoma F10 Ham’s w/ HEPES (Sigma) w/  
10% FCS (PAA) 
Institute of 
Neurology 
MCF-7 Breast cancer Minimum essential medium (MEM) 
(Sigma) w/ 
10% FCS (PAA) 
1% non-essential amino acids 
   (NEAA) (Sigma) 
1% L-Glutamine (Sigma)[5% CO2] 
ECACC 
Tera 1 Teratocarcinoma RPMI (Roswell Park Memorial  
Institute)-1640 (Sigma) w/ 
10% FCS (PAA) 
1% L-Glutamine (Sigma) [5% CO2] 
ECACC 
SW480 Colon adenocarcinoma L-15 Leibovitz (Sigma) w/ 
10% FCS (PAA) 
1% L-Glutamine (Sigma) 
ECACC 
U251-MG Grade IV : Glioblastoma 
Multiforme 
F10 Ham’s w/ HEPES (Sigma) w/  
10% FCS (PAA) 
Institute of 
Neurology 
U373 Grade III Glioblastoma DMEM (PAA) w/ 
10% FCS [5% CO2] 
ECACC 
 
 
* With the kind permission of Prof. Marc Tardieu, University of Paris South 
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4.2.3 RNA extraction and integrity checks 
 
Cell pellets from cultured cells were lysed in 1 ml TRI reagent (Sigma) per 5 x 106 cells, and 
left to stand for 5 minutes at room temperature to allow disassociation of nucleoprotein 
complexes. TRI reagent contains a mixture of phenol and guanidine thiocyanate, a chaotropic 
agent which disrupts protein structure on the cell surface. 200 μl of chloroform was added to 
each 1 ml of cell lysate, and vigorously shaken for 15 seconds before centrifugation at 
12,000g for 15 minutes at 4 ºC.  The mixture separates into 3 separate phases: a red organic 
phase, containing protein; a white interphase, consisting of DNA; and an aqueous phase, 
containing RNA. 
 
Using a pipette, without disturbing the interphase (in order to minimise DNA contamination) 
the aqueous phase was removed, and placed in a fresh eppendorf with 500 μl isopropanol. 
The eppendorfs were then centrifuged at 12,000g for 10 minutes at 4 ºC. The supernatant 
was decanted, and the pellet resuspended in 1 ml 75% (v/v) ethanol in nuclease-free water. 
After briefly vortexing, the resuspended pellets were centrifuged at 7,500 g for 5 minutes at 4 
ºC. The ethanol was then removed and the pellet air-dried for 5 minutes before being 
dissolved in 100 μl of (v/v) 85% nuclease free water; 10% RNase-free DNase (Promega); 5% 
RNasin ribonuclease inhibitor (Promega). In order to remove any trace of contaminating 
DNA, the dissolved RNA was incubated at 37 ºC for 60 minutes, followed by inactivation of 
the enzymes at 65 ºC for 10 minutes. 10 μl aliquots were removed for RNA quantification and 
integrity testing. 
 
RNA was quantified spectrophotometrically using a Genova Mk3 analyser (Jenway). 4 μl 
samples were diluted 1:20 in nuclease free water in a quartz cuvette, and RNA was 
quantified and the A260 : A280 ratio was measured. Samples with A260 : A280 ratios of between 
1.7 and 1.9 were considered suitable for use in RT-PCR. 
 
RNA samples were separated by 1% agarose in Loening Buffer (35.9 mM TRIS, 34 mM 
sodium phosphate (monobasic), 1mM EDTA, stained with ethidium bromide) gel 
electrophoresis and visualised under UV light. When visualised under UV light, a mRNA band 
should be visible, together with bands for 28s and 18s rRNA, with the 28s band of roughly 
double the intensity of that of the 18s band (Figure 4.2). Samples showing evidence of DNA 
contamination (a band near the top of the gel) or significant RNA degradation (a smear near 
the bottom) were considered unsuitable for use in RT- PCR. Samples for RT-PCR were 
snap-frozen on dry ice and stored at -80 ºC until needed. 
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Figure 4.2 RNA integrity gel 
 
RNA integrity gels are run in order to establish that RNA is of an adequate quality for use in 
RT-PCR. DNA contamination would mean that PCR products would be obtained from 
genomic DNA in addition to RNA, affecting reliability of results. 
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4.2.4 Primer Design 
 
HERV-W env and MSRV gag primers (Figures 4.3a & b respectively) were designed using 
DNAStar (Lasergene) computer software. 5 different primers for HERV-W env and a single 
primer pair for MSRV gag were selected on the basis of predicted annealing temperature 
(ideally 59 ºC), similar melting temperatures (within 2 ºC), GC % content (ideally 40-60 %), 
and in order to reduce the possibility of hairpin structures (where the primer can fold on itself) 
and primer-dimers (where the primers bind to each other). Such structures can be minimised 
by choosing primers where the sequences are not complementary to each other, e.g. 
avoiding palindromic sequences AGTCTTGACT) and long repeats (e.g. CCCCC and 
GGGGG). To check that sequences were unique to HERV-W env and MSRV gag, and not to 
other sequences (such as other retroviruses) were entered into BLAST.  
 
Previously published histidyl tRNA synthetase primers (Figure 4.3c) (Ejtehadi et al., 2005) 
were used as a housekeeping gene. This housekeeping gene was selected as it had been 
successfully multiplexed with other HERV primers, such as for HERV-K10, and had 
previously been shown to be stable (Ejtehadi et al., 2005; Ejtehadi et al., 2006). In the 
genomic DNA, the forward primer is located in exon 1, and the reverse primer is located in 
exon 4, giving a genomic product length of 11,440 base pairs. A 319 bp product can only be 
derived from mRNA, whilst conventional PCR is unlikely to produce an amplicon of 11.4 kbp. 
Housekeeping genes should be stably expressed amongst different cell types tested, and be 
unaffected by cell treatments used. This is particularly important where real-time PCR is 
used. 
 
 
4.2.5 cDNA synthesis 
 
1 μg of total extracted RNA, as well as a nuclease free water (Promega) control were 
denatured at 70 °C prior to cDNA synthesis. Reverse transcription was carried out in 20 μl 
reaction mixtures containing 1 x RT buffer (Promega), 5 mM magnesium chloride (Promega), 
1 mM dNTP mixture (Promega), 20 units/ml RNasin® Plus ribonuclease inhibitor (Promega), 
15 units/ml AMV reverse transcriptase (Promega) and 0.5 μg random hexamer primers 
(Promega) per μg RNA. Reverse transcriptase negative controls were also included. 
Incubation at 42 °C for 1 hour in a PTC-100 thermocycler (MJ Research Inc.) was followed by 
heating the cDNA to 99 °C to inactivate the reverse transciptase 
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Figure 4.3 Primers used to detect HERV-W env, MSRV gag and histidyl-
tRNA synthetase 
 
 
(a) NM_014590 Homo sapiens endogenous retroviral family W, env (C7), 
   member 1 (syncytin) (ERVWE1), mRNA 
 
HERV-W env 2-1 GTATGTCTAATGGGGGTGGAGTTC 
  %GC = 50.0, Tm = 60.62 
      pL = 419  
HERV-W env 2-2 GATGCATTGGGAGTTGGTTGTGTA 
  %GC = 45.8, Tm = 63.78 
 
1321 atcctagttg tcctggagga cttggagtca ctgtctgttg gacttacttc acccaaactg 
1381 gtatgtctga tgggggtgga gttcaagatc aggcaagaga aaaacatgta aaagaagtaa 
1441 tctcccaact cacccgggta catggcacct ctagccccta caaaggacta gatctctcaa 
1501 aactacatga aaccctccgt acccatactc gcctggtaag cctatttaat accaccctca 
1561 ctgggctcca tgaggtctcg gcccaaaacc ctactaactg ttggatatgc ctccccctga 
1621 acttcaggcc atatgtttca atccctgtac ctgaacaatg gaacaacttc agcacagaaa 
1681 taaacaccac ttccgtttta gtaggacctc ttgtttccaa tctggaaata acccatacct 
1741 caaacctcac ctgtgtaaaa tttagcaata ctacatacac aaccaactcc caatgcatca 
1801 ggtgggtaac tcctcccaca caaatagtct gcctaccctc aggaatattt tttgtctgtg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primers were designed (against reference sequences where possible, accession numbers 
shown) using DNAStar software (Lasergene), and checked against the NCBI GenBank 
database using BLAST analysis to check that the sequences were unique to the sequence of 
interest. Shaded areas of the sequences indicate where the primers bind.  
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(b) AF123881 MS associated retrovirus element gag 
   polyprotein (gag) mRNA, partial cds 
 
MSRV gag 1-1 AAGGAGGGCAAATGGAGTGAAGTG 
  %GC = 50.0, Tm = 65.39 
      pL = 571 
MSRV gag 1-2 CCTGCTGGCCTGTGGGAGTTGTT 
  %GC = 60.9, Tm = 69.32 
 
  61 atttatattc ttctgcagta ccgcctggcc acaatatcct cttcaaggga gagaaacctg 
 121 gcttcctgag ggaagtataa attataacat catcttacag ctagacctct tctgtagaaa 
 181 ggagggcaaa tggagtgaag tgccatatgt gcaaactttc ttttcattaa gagacaactc 
 241 acaattatgt aaaaagtgtg gtttatgccc tacaggaagc cctcagagtc cacctcccta 
 301 ccccagcgtc ccctccccga ctccttcctc aactaataag gacccccctt taacccaaac 
 361 ggtccaaaag gagatagaca aaggggtaaa caatgaacca aagagtgcca atattccccg 
 421 attatgcccc ctccaagcag tgagaggagg agaattcggc ccagccagag tgcctgtacc 
 481 tttttctctc tcagacttaa agcaaattaa aatagaccta ggtaaattct cagataaccc 
 541 tgacggctat attgatgttt tacaagggtt aggacaatcc tttgatctga catggagaga 
 601 tataatgtta ctactaaatc agacactaac cccaaatgag agaagtgccg ctgtaactgc 
 661 agcccgagag tttggcgatc tttggtatct cagtcaggcc aacaatagga tgacaacaga 
 721 ggaaagaaca actcccacag gccagcaggc agttcccagt gtagaccctc attgggacac 
 781 agaatcagaa catggagatt ggtgccacaa acatttgcta acttgcgtgc tagaaggact 
 
 
 
(c) NM_002109 Homo sapiens histidyl-tRNA synthetase (HARS), mRNA 
 
Histidyl s CTTCAGGGAGAGCGCGTGCG 
  %GC = 65.0, Tm = 69.48 
      pL = 319 
Histidyl as CCTTCAGGACCCAGCTGTGC 
  %GC = 60.0, Tm = 63.20 
 
   1 tcgatagccg gaagtcatcc ttgctgaggc tggggcaacc accgcaggtc gagacagcag 
  61 gcggctcaag tggacagccg ggatggcaga gcgtgcggcg ctggaggagc tggtgaaact 
 121 tcagggagag cgcgtgcgag gcctcaagca gcagaaggcc agcgccgagc tgatcgagga 
 181 ggaggtggcg aaactcctga aactgaaggc acagctgggt cctgatgaaa gcaaacagaa 
 241 atttgtgctc aaaaccccca agggcacaag agactatagt ccccggcaga tggcagttcg 
 301 cgagaaggtg tttgacgtaa tcatccgttg cttcaagcgc cacggtgcag aagtcattga 
 361 tacacctgta tttgaactaa aggaaacact gatgggaaag tatggggaag actccaagct 
 421 tatctatgac ctgaaggacc agggcgggga gctcctgtcc cttcgctatg acctcactgt 
 481 tccttttgct cggtatttgg caatgaataa actgaccaac attaaacgct accacatagc 
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4.2.6 Polymerase chain reaction 
 
In the optimised PCR reaction, 50 μl reaction vessels containing 1 x RT buffer (Promega), 1.5 
mM magnesium chloride (Promega), 200 mM dNTP mixture (Promega), 1.25 units Taq DNA 
polymerase (Promega), and appropriate combinations of magnesium chloride (Promega) and 
primers (Invitrogen), as outlined in Table 4.2, for the reaction and 10 μl cDNA product were 
prepared. During the process of magnesium chloride optimization, a range of between 1.5 
mM and 3.0 mM (in 0.5 mM increments) was used. 
 
 
Table 4.2 Quantities of magnesium chloride and primers used in the 
optimised PCR reaction for HERV-W env and MSRV gag 
 
 HERV-W env  MSRV gag 
 HERV-W env 
(sequencing) 
Multiplex 
(quantification) 
MSRV gag Histidyl tRNA 
synthetase 
     
MgCl2 /mM 1.5 mM 1.5 mM 2.5 mM 2.5 mM 
HERV-W env 
2.1 primer 
2.5 pmol 2.5 pmol) - - 
HERV-W env 
2.2 primer  
2.5 pmol 2.5 pmol - - 
MSRV gag 1.1 
primer 
- - 2.5 pmol - 
MSRV gag 1.2 
primer 
- - 2.5 pmol - 
Histidyl tRNA 
synthetase 
sense primer 
- 5 pmol - 5 pmol 
Histidyl tRNA 
synthetase 
antisense primer 
- 5 pmol - 5 pmol 
     
 
 
Following initial denaturation at 94 °C for 3 minutes, 30 cycles of PCR were carried out with 
denaturation for 1 minute at 94 °C, annealing for 1 minute at 59 °C and extension for 2 
minutes at 72 °C, followed by a final extension step at 72 °C for 10 minutes. Products were 
separated by 2% agarose in Tris-buffered EDTA (Invitrogen) (stained with ethidum bromide) 
gel electrophoresis and visualised under UV light. Gels were imaged using Grabber software 
(BioGene), and PCR products were quantified using Scion Imager software (Scion Corp.) by 
analysing the ratio of HERV-W env product to histidyl tRNA synthetase. 
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4.2.7 Processing of PCR products for sequencing 
 
In order to sequence PCR products, it is necessary to remove excess primers and dNTPs as 
these can interfere with the sequencing reaction. This can be done using chromatographic 
methods (e.g. Miniprep columns) or by enzymatic methods (such as shrimp alkaline 
phosphatase – exonuclease digests). 
 
Laboratory protocol 
 
PCR products were purified by the addition of 2μl of ExoSAP-IT (0.5u shrimp alkaline 
phosphatase; 5u exonuclease I) (Amersham) per 5μl PCR product. The samples were heated 
to 37 °C for 30 minutes followed by enzyme inactivation for at 80 °C for 15 minutes. This 
method enzymatically digests single stranded RNA and excess dNTPs that can interfere with 
sequencing reactions (Werle et al., 1994). The advantage of using this method is that it is 
quick, and avoids sample handling and DNA loss associated with chromatography-based 
techniques. Samples were diluted to 1-2 μl into 10 μl of nuclease free water, and sent to the 
Sequencing Service at the University of Dundee for sequencing. 
 
 
4.2.8 Treatment of CHME3 cells with IFN-γ 
 
CHME3 cells were seeded at 1.15 x 106 cells per T75 flask in DMEM containing 10% FCS 
and incubated at 37 ºC overnight. The media was removed and replaced with 23 ml of fresh 
media containing 5 or 50 ng/ml recombinant IFN-γ (Sigma), or a cytokine-free control . Flasks 
were incubated at 37 ºC for 48 hours prior to RNA extraction. 
 
 
4.2.9 MTT assay for cell viability of CHME3 cell lines treated with IFN-γ 
 
In order to investigate the effects of a particular treatment on a cell line, it is necessary to 
carry out a cell viability assay. The assay is dependant on 3-(4,-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT), a yellow substance in solution, being converted to MTT 
formazan by mitochondrial dehydrogenases which cleave the tetrazolium ring. The reaction 
yields a purple product, insoluble in water, which can be measured spectrophotmetrically 
after being dissolved in solvents, e.g. dimethylsulfoxide (DMSO). Alternate cell viability 
assays include those which report adenosine 5'-triphosphate (ATP) activity, such as CellTiter 
Glo (Promega). 
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Laboratory protocol 
 
CHME3 cells were cultured in the wells of a 96 well plate (Sarstedt), at a seeding density of 1 
x 105 cells per well (e.g. 200 μl of 5 x 105 cells/ml per well), with the exception of well A1 
which acts as a control. The plate was then incubated at 37 ºC for 24 hours. After incubation, 
the medium was then removed by aspiration and replaced with 200 μl fresh medium per well 
containing the 5 or 50 ng/ml recombinant IFN-γ (Sigma) and cytokine-free controls at the 
relevant concentrations (in replicates of 6). Following a further incubation of the plate at 37 ºC 
for 48 hours, the medium was aspirated and replaced with 300 μl media containing 0.5 mg/ml 
MTT stain (Sigma), including well A1 (acting as a background control). The plate was then 
incubated at 37 ºC for 3 hours, the media was then aspirated and 200 μl DMSO (Sigma) was 
added to solubilise the product for 10 minutes. Absorbances were then read at 540 nm on a 
Multiskan MS (Labsystems) microplate reader. The effect of the particular cytokine treatment 
on % cell viability can be calculated by dividing the absorbance of treated cells (adjusted for 
background, A1) with those of untreated cells and multiplying by 100. 
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4.3 Results 
 
4.3.1 Magnesium chloride optimisation 
 
A magnesium chloride concentration gives a higher yield of PCR products at 2.0 mM and 
1.5 mM respectively for histidyl tRNA synthetase and HERV-W env respectively (Figures 4.4a 
and 4.4b). At higher magnesium chloride concentrations with HERV-W env, the fidelity of the 
reaction is reduced, and mispriming seems to occur, and the band becomes smeared (Figure 
4.4b). Conversely, the band intensity of MSRV gag (Figure 4.4c) decreases with increasing 
MgCl2 concentration, but produces a clear PCR product in all cases. 
 
 
4.3.2  Sensitivity testing of HERV-W env multiplex system in the BeWo cell 
line 
 
With a higher RNA input for cDNA synthesis, the yield of HERV-W env PCR product is higher 
(Figure 4.5). Products are detectable at a low RNA input (below 5.0 ng/μl). A true idea of the 
sensitivity of the reaction can be achieved by cloning the sequence into a plasmid, and 
determining the lowest copy number which gives a signal. 
 
 
4.3.3 Comparison of HERV-W env transcripts in cancer cell lines 
 
HERV-W env is expressed at high levels in the BeWo cell line (over 11 times greater than 
that of U251-MG cell line, F=18.94, p<0.0005, One-way ANOVA). HERV-W expression is 
moderate in the established P53 mutant cell lines U251-MG and U373 glioblastoma cell lines, 
the IN1528 P53 mutant short term culture MCF-7 breast adenocarcinoma cell line, and 
teratocarcinoma cell line (Tera-1), and low in the short term P53 wild type astrocytoma 
cultures IN859 and IN1472, and the SW480 colon adenocarcinoma cell line (Figures 4.6 and 
4.7).  
 
Expression of HERV-W env is significantly higher in P53 mutant astrocytoma cell lines 
(μ=0.468, sd=0.198) compared to those with wild type P53 (μ=0.1806, sd=0.013) (2 sample T 
test, T=5.93. p<0.0005) (Figure 4.8). In all runs used for quantification, RT negative controls 
(to rule out genomic contamination of the RNA sample) and dH2O controls (to rule out 
contamination of the reagents) were blank. 
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Figure 4.4 Magnesium optimisation gels for histidyl tRNA-synthetase, 
HERV-W env, and MSRV gag in BeWo cells 
 
 
(a) Histidyl tRNA synthetase 
 
 
 (b) HERV-W env 
 
 
(c) MSRV gag 
 
 
 
PCR products for all PCR products are detectable between 1.5-3.0 mM, but not in the 
negative controls. At higher concentrations of MgCl2 for HERV-W env the band becomes less 
discrete, indicating mispriming. The histidyl tRNA synthetase and MSRVgag primers yield 
less product at lower magnesium chloride concentrations, and do not misprime at the higher 
concentrations.  
 
Number of replicates = 3; 1 RNA batch used for cDNA synthesis, PCR runs performed in triplicate 
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Figure 4.5 Band intensities for histidyl tRNA synthetase and HERV-W env 
  at different RNA input concentrations. 
 
 
 
While the intensity of the bands weakens with decreased RNA input, PCR products are 
readily detectable, even at 5ng per μl cDNA synthesis reaction. No PCR products are present 
in the reverse transcriptase negative and water controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of replicates = 3; 1 RNA batch used for cDNA synthesis, PCR runs performed in triplicate 
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Figure 4.6 Gels illustrating HERV-W env RNA levels in different human cell  
lines in a multiplex PCR reaction. 
 
The ratio of HERV-W env (pL=419) to histidyl tRNA synthetase (pL=319) band intensity is 
stronger in the BeWo cell line compared to the other cell lines tested. The PCR products 
come from cDNA, and not genomic DNA or contaminant RNA as the RT negative controls 
and water controls respectively are blank. 
 
 
 
Number of replicates = 6; 3 RNA batches used for cDNA synthesis, PCR runs performed in duplicate 
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Figure 4.7 Comparison of HERV-W env RNA levels in human cancer cell  
lines 
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HERV-W env RNA is highly expressed in BeWo (μ=4.571, sd=2.365) placental 
choriocarcinoma cell lines (F=18.94, p<0.0005, One-way ANOVA) compared with the other 
cell lines tested: U251-MG (μ=0.522, sd=0.235); U373 (μ=0.417, sd=0.198); IN859 (μ=0.184, 
sd=0.041); IN1472 (μ=0.177, sd=0.055); IN1528 (μ=0.464, sd=0.177); MCF-7 (μ=0.336, 
sd=0.162); SW480 (μ=0.169, sd=0.049); Tera 1 (μ=0.312, sd=0.117). Moderate expression is 
found in the P53 mutant cell lines, U251-MG, U373 and IN1528, compared with IN859 and 
IN1528, which are P53 wild type (F=5.98, p=0.002, One-way ANOVA). 
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Figure 4.8 Boxplot illustration comparing HERV-W env expression in P53 
wild type and P53 mutant astrocytoma cell lines 
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HERV-W env transcripts are expressed at higher levels in P53 mutant astrocytoma cell lines, 
U251-MG, U373 and IN1528 (pooled μ=0.468, sd=0.198, median=0.4040) compared to those 
with wild type P53, IN859 and IN1472 (pooled μ=0.468, sd=0.198, median=0.1787). 
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4.3.4 Detection of MSRV gag transcripts in cancer cell lines 
 
MSRV gag, which putatatively encodes structural elements of the retrovirus, such as the 
capsid and nucleocapsid (Komurian-Pradel et al., 1999) was detected in all cell lines tested, 
including BeWo (a placental choricarcinoma), the astrocytoma short-term cell cultures IN859, 
IN1472, IN1582 and IN1528, the Grade IV glioblastoma multforme cell line U251-MG, the 
Grade III glioblastoma cell line U373-MG (Figure 4.9), and the foetal microglia cell line 
(Figure 4.15). No detection of MSRV gag or histidyl tRNA synthetase was observed in RT 
negative and water controls, or expression of genomic histidyl tRNA synthetase was 
detected. 
 
In contrast to HERV-W env, MSRV gag PCR products were less homologous to the 
sequences that the primers were designed against, namely the reference sequence for 
syncytin/HERV-W env (GenBank accession number NM_014590) and MS associated 
retrovirus element gag polyprotein (gag) (GenBank accession number AF123881) 
respectively. ClustalW alignment of the transcripts against  MSRV gag (AF123881) using 
Megalign (DNAStar) with a number of gaps and mutations present in U251-MG and BeWo 
transcripts, as well as the CHME 3 transcript (Figure 4.11). No significant similarity was found 
to any sequences present in the GenBank database, with similaries to MSAV gag of 68% and 
71% for BeWo and U251-MG isolates respectively, and 76% for CHME-3. Consequently, it is 
likely that a variant of MSRV gag has been detected in these cell lines rather than the MSRV 
gag isolates described previously. Phylogenic analysis using MegAlign and ClustalW 
alignment indicated that CHME3 resembles MSRV gag more closely than either the U251-
MG or BeWo sequences, which are more closely related to each other than the CHME3 or 
MSRV gag sequence (Figure 4.12). 
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Figure 4.9 Alignment of sequence of PCR products with HERV-W 
env (C7)/ syncytin 
 
 
1411 AGGCAAGAGA-AAAACATGTAAAAGAAGTAATCTCCCAACTCACCCGGGT HERV-W env (C7) (#NM_014590) 
   1 -----AGCGTGATCGCTTGTTATAGAATTA-TCTCTCA-CTCACTCGGGT BeWo isolate 
   1 -------CGT-TCAACATGTAAAG--AGTA-TCTCCCAACTCACCCGGGT U251-MG isolate 
 
1460 ACATGGCACCT-CTAGCCCCTACAAAGGACTAGATCTCTCAAAACTACAT HERV-W env (C7) (#NM_014590) 
  44 AC-TGGCACCTTCTAGCTTCTACAAAGGACTAGATTCTCTAAAACTACAT BeWo isolate 
  40 ACATGGCACCT-CTAGCCCCTACAAAGGACTAGATCTCTCAAAACTACAT U251-MG isolate 
 
1510 GAAACCCTCCGTACCCATACTCGCCTGGTAAGCCTATTTAATACCACCCT HERV-W env (C7) (#NM_014590) 
  93 GAAACTTTCCGTATT-ATACTCGCCTGGTAAGCCTATTTAATACCACCCT BeWo isolate 
  89 GAAACCCTCCGTACCCATACTCGCCTGGTAAGCCTATTTAATACCACCCT U251-MG isolate 
 
1560 CACTGGGCTCCATGAGGTCTCGGCCCAAAACCCTACTAACTGTTGGATAT HERV-W env (C7) (#NM_014590) 
 142 CACTGGGCTCCATGAGGTCTCGGCTCAAAACCCTACTAACCGTTGGATAT BeWo isolate 
 139 CACTGGGCTCCATGAGGTCTCGGCCCAAAACCCTACTAACTGTTGGATAT U251-MG isolate 
 
1609 GCCTCCCCCTGAACTT-CAGGCCATATGTTTCAATCCCTGTACCTGAACA HERV-W env (C7) (#NM_014590) 
 192 GCCTCTCTCTGAACTTTCAGGCCATATGTTTCAATCCCCGTACCTGAACA BeWo isolate 
 189 GCCTCCCCCTGAACTT-CAGGCCATATGTTTCAATCCCTGTACCTGAACA U251-MG isolate 
 
1658 ATGGAACAACTTCAGCACAGAATAAACACCACTT-CCGTTTTAGTAGGAA HERV-W env (C7) (#NM_014590) 
 242 ATGGAACAACTTCAGCACAGAAATAAACACCACTTTCCGTTTTAGTAGGA BeWo isolate 
 238 ATGGAACAACTTCAGCACAGAAATAAACACCACTT-CCGTTTTAGTAGGA U251-MG isolate 
 
1707 CCTCTTGTTTCCAATCTGGAAATAACCCATACCTCAAACCTCACCTGTGT HERV-W env (C7) (#NM_014590) 
 292 CCTCTTGTTTCCAATCTGGAAATAACCCATACCTCAAACCTCACCTGTGT BeWo isolate 
 287 CCTCTTGTTTCCAATCTGGAAATAACCCATACCTCAAACCTCACCTGTGT U251-MG isolate 
 
1757 AAAATTTAGCAATACTACATACACAACCAACTCCCAA-TGCATCAGGTGG HERV-W env (C7) (#NM_014590) 
 342 AAAATTTAGCAATACTACATACACAACCA-CCCAAAGGGGCAACA      BeWo isolate 
 337 AAAATTTAGCAATACTACATACACAACCAACTCCAAAATGCATCA      U251-MG isolate 
 
 
PCR products of BeWo and U251-MG isolates were aligned with HERV-W env using the 
ClustalW algorithm. Identical bases are highlighted in blue, gaps are indicated with -, 
insertions with ‘. 
 
 
Figure 4.10 Phylogenetic analysis of PCR product sequences with 
HERV-W env (C7)/syncytin 
 
 
 
 
 
Phylogenetic analysis of PCR products aligned with HERV-W env (C7)/syncytin. Both BeWo 
and U251-MG isolates are highly similar to the reference sequences. Shorter branches, i.e. 
less frequent nucleotide substitutions indicate a closer relationship between the sequences. 
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Figure 4.11 Gels illustrating MSRV gag and histidyl tRNA synthetase PCR 
products in human cancer cell lines  
 
 
MSRV gag (pL=571) transcripts were detected in all cell lines tested, with prominent 
expression, particularly in the BeWo choriocarcinoma cell line. Histidyl tRNA synthetase 
(pL=319) bands were expressed uniformly amongst different cell types. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of replicates = 6; 3 RNA batches used for cDNA synthesis, PCR runs performed in duplicate 
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 Figure 4.12 Alignment of sequence of PCR products with MSRV gag 
 
 
201 GAAGTGCCATATGT''GCAAACTTTCTTTTCATTAAGAGACAACTCACAA MSRVgag (#AF123881) 
  1 -----------ACAATGTCAGGTTTCTT-CTCTTACGAGA-CACTCCAT- BeWo Isolate 
  1 -------CCTACCGATGCAGGGCACTAGATGATTAGGAGA-GAGTCAGCA CHME3 Isolate 
  1 ---------CCTTGGGGAAAGGTGTCTT-TAATGA-GAGA-TCCTCGAT- U251-MG Isolate 
 
251 TTATGTAAAAAGTGTGGTTTATGCCCTACAGGAAGC''CCTCAGAGTCCA MSRVgag (#AF123881) 
 37 TTATGTAAAAAGGGTG-ATTATATGTCCACAGGAGGACCTCCAAG'TCCA BeWo Isolate 
 43 TTATGTAAAAAGTGTGATTTATGCCCTACAGGAAGCCC'-TCAGAGTCTA CHME3 Isolate 
 38 TTATTTAGAAATGGTG-TTTATGTCCTCC---GAGGACCTCCAAGT--C' U251-MG Isolate 
 
301 CCTCCCTACCCCAGCGTCCCCTCCCCGACTCCTTCCTCAACTAAT-AAGG MSRVgag (#AF123881) 
 86 CCCCCCTACCCCGGGGTCCCC---CCCGCTTCCCCCTCTGATAATTAAGG BeWo Isolate 
 92 CCTCCCTACCCCAGCGTCCCC---CCGACTCCTTCCCCAACTAAT-AAGG CHME3 Isolate 
 82 CTCCCCCGTTCTTGGGTCCCC---CCGACTTCCCCCTCTAAGAATAAAGG U251-MG Isolate 
 
350 ACCCCCCTT''TAACCCAAACGGTCCAAAAGGAGATAGACAAAGGGGTAA MSRVgag (#AF123881) 
133 ACTCTCCTTTGG--CCCTAACGGCCCAAAAG'GAACCACACCCGAAGATA BeWo Isolate 
138 ACCCCCCTTTTT--CCCAAA-GGTCCA'AAAAAGAAAAACAAAGGGGTGA CHME3 Isolate 
129 ACCCCCCTTTGG--CCCTGAGGGCCCAAAAGGAAC'CACACCCGGAGATA U251-MG Isolate 
 
400 ACAATGAACCAAAGAGTGCCAATATTCCCCG''ATTATGCCCCCTCCAAG MSRVgag (#AF123881) 
181 GTCAAGTCCCCAAAAGGCCCC-CTTGGCCCTCTATTGTGCCCCCTCCACG BeWo Isolate 
185 AAAAAGAACCCAAATGGGCC--CATTCTCCCCTAATATGCCCCCCCCAAT CHME3 Isolate 
177 CTCTGGTACCCAAAAGGCCCC-AATGGCCCTCTATTGTGCCCCCTCCAAG U251-MG Isolate 
 
450 CAGTGAG---AGGAGGAGAATTCGGCCCAGCCAGAGTGCCTGTACCTTTT MSRVgag (#AF123881) 
230 CCGTGGGAGGAGG'AGGAGACTTTGTTCTGGTGTGAATA-CATGTTCCCT BeWo Isolate 
233 CGGTGGGG--AG'AAAAAAATTGTGCCCTTCTCTAGCGC--ATACTTCTT CHME3 Isolate 
226 CCGTGGGAGGAGGAGGA'GACTTTGGCCTGGTGTGAGT--CATGTTTTCT U251-MG Isolate 
 
497 TCTCTC''TCAGACTTAAAGCAAATTAAAATAGACCTAGGTAAATT-CTC MSRVgag (#AF123881) 
279 TTTCCCTCTCA-ACTTAAAATTAATCAAACTGAACGGATAAAAATT'CTC BeWo Isolate 
279 TTTCTCCCTCACACTTAGGGCAAATTAATAAAAACCCCGGGATTT'TCTT CHME3 Isolate 
274 TTTCCCTCTCAGACTTAAAACAAATCAAACTGAACGGAGAAAAATTCTCA U251-MG Isolate 
 
546 AGATAACCCTGACGGCTATATTGATGTTT''TACAAGGGTTAGGACAATC MSRVgag (#AF123881) 
328 AGATTAACCTGATGG--ATGAATATATGTCTTACTAGGATTAGGACATTC BeWo Isolate 
329 ATAAAACCCTGAGGG--GTATTAGGAATTTTTTTAAGGGTTAAGAGAACC CHME3 Isolate 
324 'GATAATCGGGATGG--ATGCATATTTGTCTTACTAGGATTAGGACTTTC U251-MG Isolate 
 
596 CTTTGATCTGACATGGAGAGATATAATGTT-ACTACTAAATCAGACACTA MSRVgag (#AF123881) 
376 ATTTATTTTGGAAAGAAAAAATATTATGT'TGTTGTTAAGACAAACCTTA BeWo Isolate 
377 TTTTGATTGTATGTGGAAAAATATAATG'TTACTGCTAATTCAAAAAGGA CHME3 Isolate 
372 TTTTAATTTGGAAAGAAAAAATGTTATGTTTTT'GT-----CAGACACTA U251-MG Isolate 
 
645 AC''CCCAAATGAGAGAAGTGCCGCTGTAACTGCAGCCCGAG-AGTTTGG MSRVgag (#AF123881) 
426 --ACTCCCGACAAAAAACGGGCCACCTTACTTGCGACCCTTG-AGTTGGT BeWo Isolate 
427 --CCCCCATAAGAGAAAAGCGGCAGCATAACTGGCTCCCGAATAGTTTGG CHME3 Isolate 
417 --CCCCCAAATGAAAGAAGTGTCGCCCTAACTGCATCCCGAACAGTTTGG U251-MG Isolate 
 
694 CGATCTTTGGTA-TCTCAGTCAGGCC''AACAATAGGATGACAACAGAGG MSRVgag (#AF123881) 
473 CAATGTTTGGTAC'CTAAGCCAGG--TAAAAGATAAACTGACAACAAAAA BeWo Isolate 
475 TGATCTCTGGT'ATCTCGATCAGG--TCGATGATAGGATGACAACAGAGA CHME3 Isolate 
465 TGATCTCTGGTATCTCACTCA'GG--TCAGTGATAGGATGACAACCGAGG U251-MG Isolate 
 
743 AAA--GAACAACTCCCACAGGCCAGCAGGCAGTTCCCAGTGTAGACCCTC MSRVgag (#AF123881) 
521 AAGAGGACCACCTCCCGCCG'                              BeWo Isolate 
523 AAAAAGAACACCTCCCACAGGGCC'                          CHME3 Isolate 
513 AAAGAGAACAACTCCCACCCGCCAGCAGGAAG'                  U251-MG Isolate 
 
 
PCR products of BeWo, CHME3 and U251-MG were aligned with MSRV gag using the 
ClustalW algorithm. Identical bases are highlighted in blue, gaps are indicated with -, 
insertions with ‘. 
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Figure 4.13 Phylogenetic analysis of PCR product sequences with 
MSRV gag 
 
 
 
 
 
Phylogenetic analysis of PCR products aligned with MSRV gag. CHME 3 is closely related to 
the MSRV gag prototype sequence, in comparison to isolates sequenced from BeWo and 
U251-MG cell lines. 
 
 
Figure 4.14 Cell viability of CHME3 cells treated with IFN gamma 
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Cell viability of the CHME3 cell line is significantly reduced by IFN-γ (F=20.52, p=0<0.0005, 
One-way ANOVA) to 89% and 83% at concentrations of 5 ng/ml and 50 ng/ml respectively. 
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4.3.5 Modulation of HERV-W gag expression in the CHME3 foetal 
microglia cell line by IFN-γ 
 
Treatment of cells with 5 ng/ml and 50 ng/ml IFN-γ substantially reduced cell viability to 
83-89% of that of untreated cells (F=20.52, p<0.0005, One-way ANOVA) (Figure 4.14), 
indicated that IFN-γ had biological activity in the cells, through toxic and anti-proliferative 
effects. MSRV gag expression was decreased in CHME3 cells with increased IFN-γ 
concentration (Figures 5.15 and 5.16), though this is not significant (F=2.89, p=0.092, One-
way ANOVA). No bands coded for the MSRV gag sequence in negative controls, and no 
genomic histidyl tRNA synthetase was detected. However, expression of histidyl tRNA 
synthetase increased as a consequence of cytokine stimulation, indicating poor reliability as a 
housekeeping gene when cells have been IFN-γ stimulated. 
 
 
Figure 4.15 Gel illustrating MSRV gag RNA levels in CHME3 cell lines 
treated with IFN-γ 
 
 
 
MSRV gag (pL=571) transcripts were detectable in both treated and untreated CHME 3 cell 
lines. Histidyl tRNA synthetase (pL=319) expression increased with increased 
IFN-γ concentration. No transcripts were detected in the reverse transcriptase negative 
controls. 
 
 
 
 
 
 
 
Number of replicates = 6; 2 RNA batches used for cDNA synthesis, PCR runs performed in triplicate 
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Figure 4.16 Comparison of HERV-W gag mRNA expression in the CHME3 
cell line after treatment with IFN-γ for 48 hours 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 5 50
IFN-γ  ng/ml
M
SA
V 
ga
g 
: H
is
tid
yl
 P
I
 
 
Expression of MSRV gag : histidyl tRNA synthetase is decreased with increasing IFN-γ 
concentration to levels 60% of that of untreated cells at concentrations of 5 and 50 ng/ml. The 
association is not statistically significant (F=2.89, p=0.092, One-way ANOVA). 
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4.4 Discussion 
 
 
HERV-W env mRNA expression is extremely high in the BeWo placental choriocarcinoma 
cell lines, but is present at lower levels in other tissues. There is strong evidence that 
although HERV-W env appears to be present in all the cell lines tested expression levels are 
specific to the tissue that the tumour originates from. HERV-W env is thought to have a role 
in mediating trophoblast cell fusion in the placenta (Mi et al., 2000), and the high expression 
levels in the BeWo cell line are expected. Real time PCR analysis of a panel of HERVs with 
homology to the gammaretroviruses indicates significantly higher levels of HERV-W 
expression in the placenta, and slightly higher levels in the brain, testis and uterus (Forsman 
et al., 2005). Interestingly, the same study shows significant expression of HERV-H and 
HERV-I in the brain. 
 
Genomic contamination can be ruled out, as the samples have been RNase treated to 
eliminate genomic DNA. As primers designed for the histidyl tRNA synthetase housekeeping 
gene are intron spanning, the band at 319 bp can only correspond to mRNA. As HERV-W 
env and MSRV gag are encoded by a single exon, primers could not be designed in this way, 
and consequently reverse transcriptase negative controls were required to eliminate the 
possibility of genomic DNA as a source of the PCR product. 
 
A study by Yi et al. (2004) has indicated that HERV-W env is expressed in both normal brain 
tissue, and in a brain tumour cell line, PFSK-1, though the gag gene product is only 
expressed in normal brain tissue. Sequencing of the products by the authors showed that the 
clone from normal brain tissue was identical to syncytin, whilst a number of the cancer cells 
tested showed sequences with greater similarity HERV-W isolates on chromosomes 12,14, 
17 and X. Sequence analysis of the PCR product for U251-MG indicated a 100% identity with 
that of syncytin. The high degree of homology of the transcripts to syncytin indicates that 
capacity for encoding functional protein is high.  
 
The results show that HERV-W env levels differ between the established glioma cell lines 
and the astrocytoma short term cultures. Comparison of astrocytoma cell lines with mutant 
P53 (U251-MG, U373-MG, IN1528) against those with wild type P53 (IN859 and IN1472) 
indicated that expression of HERV-W env is considerably increased in the former.  
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A recent study by Chang et al. (2007) has indicated that HERV-I LTRs, promoters consisting 
of repeating sequences of nucleotides that flank retroviruses, are negatively regulated by wild 
type P53 in vitro, and that a conformation mutation (V143A) may stimulate transcriptional 
activity. Wild type P53 has multiple roles in DNA repair, cell cycle arrest and the initiation of 
apoptosis, and mutation results in breakdown of cell control. Initiation of HERV-W env 
transcription and the presence of such sequences may represent a breakdown of such 
control. Whether HERV-W env is a cause of gliomas or a consequence is not yet clear. 
Further studies may elucidate whether HERV-W env expression levels could be a marker for 
glioma cell progression. It is of note that HERV-K10 antibodies are raised in patients with 
seminomas compared to that of healthy controls (Sauter et al., 1995).  
 
MSRV gag variants were also detectable in all of the cell lines tested, but as is the case with 
pol (Yi et al., 2004), a large number of frameshifts and point mutations are present, indicating 
that if the protein is translated it is not likely to be functional, as is the case for other MSRV 
gag isolates, which have premature stop codons and frameshift mutations, such as the CL2 
clone which has a stop codon in the capsid region (Komurian-Pradel et al, 1999).  In addition 
to HERV-W, a number of other retroviruses, such as HERV-FRD and ERV-3 do not have 
functional gag regions (Rote et al., 2004). The presence of MSRV gag transcripts is striking, 
as Yi et al. (2002) reported that HERV-W gag has a limited distribution, both in cancerous 
and healthy cells, although the brain tumour line tested was positive for HERV-W gag. 
 
Sequence analysis of the variants indicated that there was a large diversity in sequence 
homology, with CHME3 having the closest homology to that of the GenBank sequence 
(AF123881) for MSAV gag. It would have been worthwhile sequencing the remainder of the 
PCR products, and testing a number of other tissues (cancerous and non-cancerous) to 
investigate whether the sequences present in cancer cell lines are more distinct from foetal or 
benign tissues. 
 
As MSRV pol and the presence of particles has shown to be increased in cell lines derived 
from MS patients by cytokine stimulation, in particular IFN-γ and TNF-α CHME3 cells were 
stimulated by IFN-γ for 48 hours, and the effects on MSRV gag expression.  The CHME3 cell 
line was chosen due to the central role of macrophages and microglia in MS., and that IFN-γ 
is produced in the CNS by microglia (Kawanokucki et al., 2006) as well as Th1 cells. IFN-γ 
has a number of effects on macrophages, including anti-microbial and anti-tumour 
mechanisms (for review, see Schroder et al., 2004). The presence of IFN-γ decreased the 
viability of CHME3 cells considerably. This was expected as cell proliferation is reduced in 
IFN-γ exposed cells, which enter S-phase arrest (Matsuoka et al., 1999), and possibly also 
due to apoptotic effects. 
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A number of retroviral elements, including a number of retrosposons (Long interspersed 
elements (LINEs) and Short interspersed elements (SINES)), HERV-DRB7 (a member of the 
HERV-K family), and ERV-9 (Andersson et al., 1998) are present in MHC regions. Another 
effect of IFN-γ is to upregulate both MHC class I and class II expression and antigen 
presentation. Interestingly, ERV-9 is a retrovirus with a high degree of homology with 
HERV-W, with approximately 75-90% homology in the pol gene (Perron et al., 1997), and has 
IFN-γ responsive elements in its LTRs (Andersson et al., 1998).  If copies of HERV-W gag 
were present in the MHC region, it would be expected that upregulation of MSRV gag mRNA 
expression would occur. 
 
In contrast to pol, where expression is upregulated by IFN-γ (Serra et al., 2003), our results 
indicate that IFN-γ has no significant effect on the expression of MSRV gag. It is also worth 
noting that the expression of the histidyl tRNA synthetase housekeeping gene was increased 
with increasing IFN-γ concentration, affecting the reliability of the results for the IFN-
γ quantitation. The choice of housekeeping genes is important in the reliability of RT-PCR, 
and should be stably expressed in the conditions that are used. The transcription of β actin 
and glyceraldehyde-3-phosphate dehydrogenase, for example, are significantly increased by 
exposure to serum, while beta-2-microglobulin and 18s ribosomal RNA are not (Schmittgen 
et al., 2000). For this reason, applications where enhanced sensitivity is required, such as 
real time PCR, it is recommended that a panel of housekeeping genes are used. 
 
In summary, primers for HERV-W env have been successfully developed, optimised and 
used in a multiplex PCR system to quantify RNA expression in a variety of cell lines. High 
levels of expression were present in the placental cell line, in agreement with other studies. 
Lower levels were detected in astrocytoma cell lines, where the expression of HERV-W env 
showed a correlation with P53 status. No sequences with a high identity to HERV-W gag 
were found, though variants were found in all cell lines tested. Expression of these variants 
was not altered by exposure to IFN-γ. 
 
The primers developed would be useful in analysing levels of RNA expression in pathological 
sections of MS and glioma patients in order to see if the expression correlates with the 
severity of the disease and symptoms. The sequencing data enables the development of 
probes to investigate by in situ hybridisation. The PCR systems, and in particular the 
multiplex system developed for HERV-W env allows investigation in vitro to determine the 
effects of cells cultured in ‘disease conditions’, e.g. by exposure to other cytokines, steroid 
hormones, transactivation by exogenous viruses, irradiation, or demethylating agents. 
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5 Detection of MSRV gag 311 epitope in astrocytoma cell 
lines 
 
 
5.1 Introduction 
 
Bioinformatic analysis identified a potential epitope of HERV-W gag with homology to MBP. 
This was then immunised into a New Zealand White Rabbit in order to produce polyclonal 
antibodies to this peptide. After verifying that the rabbit had an appropriate immune response 
to the peptide, it was necessary to purify the polyclonal IgG using affinity chromatography in 
order to remove other components of the serum that might interfere with any assays carried 
out. These purified fractions were then evaluated in order to ensure that the antibody was not 
denatured during the purification process. Purified antibody was then used in 
immunocytochemical analysis of a number of astrocytoma cell lines, as well as BeWo (a 
placental choriocarcinoma cell line), where a large number of retroviruses are expressed, 
including HERV-E, HERV-R, HERV-H (Forsman et al., 2005 and HERV-W. The aim was to 
identify whether expression of the MSRV gag 311 epitope is present in these cell lines, the 
subcellular localisation, and how the expression differs between cell lines. 
 
PCR analysis indicated that sequences related to HERV-W gag mRNA were detected in 
astrocytoma cell lines, but this does not necessarily mean that this is translated into a 
functional product. HERV-W retroviral particles have been demonstrated in cell lines derived 
from MS patients (Perron et al., 1989; Komurian-Pradel et al., 1999), while retroviral particles 
(notably from the HERV-K family) are commonly found in germline tumours and testicular 
tumours (Lower et al., 2001). The vast majority of HERVs do not produce functional products 
(Kim et al., 2001), with a few notable exceptions, such as syncytin (HERV-W/7q env) 
(Mi et al., 2000). 
 
Functional gag proteins assemble in the cytoplasm and are transported to the plasma 
membrane (types A, B, and D retroviruses) or are assembled at the plasma membrane itself 
(type C retroviruses), and are important in viral assembly. The vast majority of human 
endogenous virus products which form particles form into immature structures, such as 
HERV-K-HTDV (human teratocarcinoma derived virus) which forms non-infective particles 
resembling Type C retroviruses in teratocarcinomas (Boller et al., 1983; Lower et al., 1984). 
MSRV particles are observable at the surface of the cytoplasmic membrane or clustered in 
vacuoles of EBV-immortalised lymphoblast cell lines derived from MS patients during peak 
periods of RT activity (Perron et al., 2001). 
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In order to detect whether the MSAV gag transcripts detected in astrocytoma cell lines in the 
previous chapter were translated into protein, a direct immunofluorescence-based protocol 
was used, involving propagation of cultured cells in culture slides and fixation in 
paraformaldehyde. Dilutions of purified anti-MSRV gag 311 antibody were applied to the fixed 
cells along with anti-alpha tubulin antibody to enable visualisation of cytoskeletal detail upon 
incubation with fluorophore-conjugated anti-species antibodies. Nuclear detail was revealed 
by staining with DAPI.  
 
 
5.2   Methods 
 
5.2.1 Immunisation of rabbits 
 
Antibodies specific for the MSRV gag 311 peptide were raised commercially by Severn 
Biotech, Kidderminster, Worcestershire (home office license number: 40\2154). New Zealand 
White Rabbits were immunised with MSRV gag peptide (LREALRKHTSLSP) (Severn 
Biotech) bound to purified protein derivative according to the schedule outlined in Table 5.1. 
Carrier molecules, such as purified protein derivative (PPD) are necessary in order to elicit a 
sufficient immune response. Test bleeds were taken, and analysed by ELISA at regular 
intervals. 
 
 
Table 5.1 Schedule of immunisation and test bleeds 
 
 
Day  
0 Immunisation with PPD-conjugated peptide + Freund’s complete adjuvant (FCA) 
28 Booster immunisation with PPD-conjugated peptide + Freund’s incomplete 
adjuvant (FIA) 
38 1st test bleed taken 
42 2nd booster immunisation with PPD-conjugated peptide + FIA 
52 2nd test bleed taken 
56 3rd booster immunisation with PPD-conjugated peptide + FIA 
66 3rd test bleed taken 
70 4th booster immunisation with PPD-conjugated peptide + FIA 
80 Terminal bleed taken 
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5.2.1 ELISA for testing antibody reactivity in rabbit sera and purified terminal 
bleeds 
 
50 μl of 50 ng MSRV gag 311 peptide in phosphate buffered saline (PBS), pH 7.2 stock was 
added to the wells of a Nunclon Δ 96 well plate (Nunc), and was left to coat overnight at 37 
ºC. The plates were washed thoroughly four times in PBS (Sigma) with 0.05% Tween-20 
using an automated plate washer (WellWash Mk4), and blotted dry. 
 
The plates were then blocked with 150 μl of blocking buffer (PBS with 1% bovine serum 
albumen (BSA); 0.05% Tween-20) and incubated at room temperature for 1 hour, before 
being washed four times in PBS (Sigma) with 0.05% Tween-20 using the automated plate 
washer, as before. This was done to reduce potential unwanted interactions of antibody with 
the plasticware. For the rabbit sera (Severn Biotech), serial dilutions (either a 2-fold series 
from 1:200 to 1:1600, or a 10-fold series from 1:100 to 1:10,000) of each test bleed were 
added in duplicate. With the purified antibody, fractions were added in triplicate to the wells at 
a concentration of 1:200. Negative controls were included, including peptide-free, primary 
antibody negative, and irrelevant peptide controls (e.g. predicted epitopes for other HERVs 
such as HERV-K10 gag).  
 
After incubation for 1 hour at room temperature the plates were washed 4 times with PBS 
and blotted dry. 50 μl of HRP conjugated polyclonal swine anti-rabbit immunoglobulins (Dako) 
diluted 1:800 in blocking buffer was added to each well in the plate, and incubated at 1 hour 
at room temperature. After washing and blotting 50 μl of TMB solution (Sigma) (for rabbit 
sera) or 0.4 mg/ml OPD (Sigma) (for purified terminal bleed antibody) in phosphate-citrate 
buffer with sodium perborate (Sigma) was added to each well on the plate, and incubation 
took place at 37 ºC in the dark for 10 or 30 minutes (for TMB and OPD respectively). 
Readings were also taken at 620 nm and 450 nm after stopping the reaction by the addition 
of 50 μl 2N hydrochloric acid for TMB, and at 450 nm and 492 nm (stopped) for OPD.  
 
 
5.2.3 Affinity purification of rabbit bleeds 
 
Purification of antibody from serum is often necessary to remove unwanted components, 
such as albumin, transferrin, and α2-macroglobulin, which may interfere with assays that the 
antibodies are used in, e.g. by blocking antibody sites in ELISA, or sticking to cells analysed 
in immunocytochemistry or immunofluorescence. 
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Figure 5.1 Schematic representation of the principle of antibody purification using  
a Protein G column 
 
 
 
 
(a) Antibody binds with high affinity to protein G, and remains covalently bound to the matrix 
while other serum proteins pass through the column. (b) By changing the pH from 7.0 to 2.7, 
the interaction is disrupted and the purified antibody is eluted. 
Protein G-coupled 
Sepharose beads 
Serum protein 
IgG antibody
(a) Binding, pH 7.0 
(b) Elution, pH 2.7 
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Affinity chromatography relies on the separation of biological molecules based on reversible 
interactions with specific ligands bound to a matrix, such as sepharose. The ligands bind 
reversibly to the antibody of interest at pH 7, whilst other, undesired components of the 
sample are not retained by the column (Figure 5.1). Antibody purification can be carried out 
using chromatography with sepharose bound to protein A (derived from Staphylococcus 
aureus) or protein G (derived from Group G Streptococci), or by ion exchange 
chromatography.  
 
Separation using protein A or protein G ligands are rapid, and require little optimisation. Both 
protein A and protein G are suitable for purifying polyclonal rabbit antibody, though protein G 
binds to a wider range of IgGs. To disrupt the binding of the antibody to the ligand, the 
conditions are made more acidic, and the antibody is eluted. Antibodies, as with many 
proteins denature at low pH, so it is important to neutralise the eluent rapidly. 
 
Laboratory protocol 
 
1.25 ml of rabbit serum terminal bleed (Severn Biotech) was diluted 1:1 in 1.25 ml binding 
buffer (20 mM sodium phosphate) (Amersham) and loaded into a syringe. The AKTAprime 
system (GE Healthcare) was washed and prepared as per the User Manual, and a HiTrap 
Protein G HP column (Amersham) and 500 μl sample loop was connected to the system. The 
inlet tubing for buffer A was placed in binding buffer, and the tubing for buffer B placed in 
elution buffer (0.1 M glycine-HCl, pH 2.7) (Amersham), and the waste outlets placed in an 
empty conical flask. Collection tubes were filled with 100 μl neutralisation buffer (Amersham) 
(1M Tris, pH 9.0). The neutralisation buffer is necessary to reduce potential protein 
denaturation in the acidic elution conditions used. 
 
The sample loop was filled by adding 2.5 ml of 1:1 rabbit serum in binding buffer and the 
recorder was connected to the system, powered on, and pens connected. The chart speed 
and voltages were set to appropriate values (e.g.  10 mm/min, 0.5 V). The MAbTrap step 
elution program was selected on the AKTAprime system, and the purification started. 
Fractions collected were analysed for activity using ELISA, and stored at -20 ºC. 
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5.2.4 Culture of cells grown as monolayers 
 
Cells were grown to ≥70% confluency in T75 tissue culture flasks (Sarstedt) under the 
appropriate conditions shown in Table 5.2 at 37 ºC. To passage the cells further, the 
supplemented media was aspirated, and cells were washed twice with 2ml HBSS (Sigma) 
and detached by the addition of 2 ml of Trypsin-EDTA solution (Sigma), followed by 
incubation for 2 minutes at 37 ºC (for complete detachment of cells). Trypsinisation of the 
cells was ended by the addition of 8 ml of supplemented media, and an appropriate dilution of 
cells (between 1:2 and 1:10) was set up in fresh flasks containing 25 ml of fresh 
supplemented media. 
 
 
 
Table 5.2 Cell lines used and culture conditions 
 
A list of the cell lines used for immunoflourescence, and the culture conditions used. All the 
cell lines, except the IN series are established cell lines, which are short term cell cultures 
derived from patient biopsies.  
 
Cell Line Description Conditions Source 
BeWo Choriocarcinoma F12 Ham’s (Sigma) 
   w/ 10% FCS (PAA) 
    [5% CO2] 
ECACC 
IN859 Grade IV astrocytoma F10 Ham’s w/ (HEPES) (Sigma) w/ 
   10% FCS (PAA) 
Institute of 
Neurology 
IN1472 Grade IV astrocytoma F10 Ham’s w/ HEPES (Sigma) w/ 
   10% FCS (PAA) 
Institute of 
Neurology 
IN1528 Grade IV astrocytoma F10 Ham’s w/ HEPES (Sigma) w/  
   10% FCS (PAA) 
Institute of 
Neurology 
IN1612 Grade IV astrocytoma F10 Ham’s w/ HEPES (Sigma) w/  
   10% FCS (PAA) 
Institute of 
Neurology 
U87-MG Grade III Glioblastoma  MEM (Sigma) w/ 
   10% FCS (PAA) 
   1% NEAA (Sigma) 
   1% L-Glutamine (Sigma) 
   1% Sodium pyruvate (Sigma) 
Prof. Nicola 
Woodroofe, 
Sheffield-
Hallam 
University 
U251-MG Grade IV : Glioblastoma 
Multiforme 
F10 Ham’s w/ HEPES (Sigma) w/  
   10% FCS (PAA) 
Institute of 
Neurology 
U373 Grade III Glioblastoma DMEM (PAA) w/ 
   10% FCS [5% CO2] 
ECACC 
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5.2.5 Indirect immunofluorescence of cell lines 
 
Immunofluorescence is a procedure that uses fluorescently tagged antibodies in order to 
directly detect antigens within a cell or tissue. Cells are first attached to a slide, using a 
fixative such as methanol or paraformaldehyde. Paraformaldehyde fixation cross-links 
proteins and DNA (hence is also used as a fixative in in-situ hybridisation), and causes 
minimal loss of the native structures in the cell. If paraformaldehyde is used as a fixative, it is 
also necessary to permeabilise the cell membrane to allow entry of antibodies, and other 
large molecules such as blocking agents. 
 
As with other protocols involving the use of antibodies, a blocking step is employed in order 
to block unwanted antigenic sites, and decrease background fluorescence. BSA is a 
commonly used blocking buffer, but powdered milk and normal serum (from the species that 
the secondary antibody is raised in) are other alternates. The primary antibody is applied, and 
these bind to the epitopes present in the target protein. It is also useful to have a positive 
control antibody, which is known to be expressed in the cells in order to avoid false 
negatives, such as anti-tubulin or against a specific marker (e.g. glial fibrillary acidic protein 
for astrocytes, or MHC-II for macrophages). Negative controls, either from non-immune 
serum from the same species as the primary antibody, or antibody raised against a protein 
not expressed in the cell type under investigation are required to eliminate false positives. 
 
 In direct immunofluorescence, the primary antibody is already attached to the fluorophore, 
and this can be detected under a fluorescent or a confocal microscope. Where indirect 
immunofluorescence is used, it is necessary to bind a labelled secondary antibody directed 
against the species in which the primary antibody is raised. While indirect 
immunofluorescence requires this step, which makes the procedure slower, it is more 
sensitive as multiple secondary antibodies can bind to the primary antibody, acting as an 
amplification step.  
 
It is also necessary to counterstain the slides, so that all cells can be identified. Commonly 
used counterstains in immunofluorescence include 4’-6’-diamidino-2-phenylindole (DAPI) 
which binds to double stranded DNA (highlighting cell nuclei) and fluorophore-conjugated 
phalloidin, an F-actin-binding toxin from the death cap mushroom (Amanita phalloides) which 
reveals cytoskeletal detail. 
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Laboratory protocol 
 
Cells were cultured at a seeding density of 320 cells/well in a BD Falcon CultureSlide (BD 
Biosciences), and incubated at 37 ºC for 24 hours. The media was removed, and adherent 
cells were washed twice in 300 μl of PBS (Sigma) per well, followed by fixation in 200 μl 4% 
paraformaldehyde (Sigma) solution (in PBS) per well for 15 minutes. The fixation reaction 
was quenched by removing the paraformaldehyde solution, and adding 200 μl 0.1 M glycine. 
The fixed cells were then permeabilised using 0.1% Triton X-100 (Sigma) in PBS for 90 
seconds, followed by washing twice in 300 μl of PBS. 
 
The CultureSlide chambers were blocked with 200 μl 4% BSA in PBS at 37 ºC for 1 hours, 
followed by washing twice in 300 μl of PBS. Purified antibody (diluted at 1:25 or 1:50) or 
control (pre-immune bleeds or antibody negative) were prepared in 1:800 mouse anti-tubulin 
antibody (Sigma) in 1% BSA/0.1% Tween-20 in PBS. 150 μl amounts of the antibody mixture 
were added to the appropriate chambers of the CultureSlide and incubated at 4 ºC overnight. 
After incubation, the CultureSlide was washed 3 times in 300 μl of PBS, and secondary 
antibodies (Alexa-Fluor ® 594 donkey anti-rabbit (Invitrogen) and Alexa Fluor ® 488 goat 
anti-mouse (Invitrogen)), diluted 1: 400 in 1% BSA/0.1% Tween-20 in PBS) added to the 
CultureSlide chambers, and incubated at 37 ºC for 1 hour in the dark. The CultureSlides were 
then washed twice in 300 μl of PBS, before being counterstained with 50 μl of 1 μg/ml DAPI 
in ethanol for 90 seconds. These were then washed twice in 300 μl of PBS, left to dry for 5 
minutes, and the chambers were removed. The slides were then mounted in fluorescent 
mounting medium (Dako). The slides were then visualised and scanned at a 40x resolution 
under a Olympus BX61 fluorescence microscope and images captured using CytoVision 
software (Applied Imaging). 
 
 
5.3 Results 
 
5.3.1 ELISA reactivity of MSRV gag 311 antibodies in rabbit test bleeds 
 
The MSRV gag 311 peptide elicited a strong immune response in immunized rabbits (Figures 
5.2 (2 fold series) and 5.3 (10 fold series)), with titres detectable at dilutions as low as 
1:10,000, whereas minimal cross-reactivity was found with peptides derived from the gag 
epitope predicted in HERV-K10 (RIGKELKQAGRKGNI). The strongest bleed was the second 
test bleed, though all immune bleeds were deemed suitable for use for further work. The 
terminal bleed was selected for purification as larger quantities were available. 
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5.3.2 Purification of antibodies and response of purified fractions 
 
Antibody purification produced a significant antibody peak during elution between 
approximately 20 and 30 minutes after commencing the run (Figure 5.4), with fractions were 
collected at 60 second intervals. Testing of the fractions eluted in ELISA indicated that 
fraction 3 had the highest absorbance (A492) value (Figure 5.5), and therefore the greatest 
amount of antibody reactivity. The ELISA results also confirmed that the purified antibody still 
had affinity for the MSRV gag 311 peptide, and was considered suitable for use for further 
experimentation. 
 
 
5.3.3 Detection of MSRV gag 311 epitope in astrocytoma cell lines 
 
All of the cell lines tested had positive staining (in red) for the MSRV gag 311 epitope (Figures 
5.6-5.13, summarised in Table 5.3). Prominent nuclear staining in red, with prominent foci 
were present in all the cell lines tested at a 1:25 antibody dilution (of fraction 3), and were 
prominent at a 1:50 dilution in BeWo, IN1528, IN1612, and U251-MG cell lines. This staining 
pattern was only observed where MSRV gag 311 antibody was used, and not in controls using 
a dilution of serum from the same rabbit prior to immunisation, or where no primary antibody 
was applied. Whilst it would have been more appropriate to use purified pre-immune bleeds 
as negative controls, this was not practical as each purification run (repeated 3 times) 
requires 1.25 ml of sample, whereas only approximately 4.5 ml was provided by the 
manufacturer for each bleed, with the exception of the terminal bleed (approximately 20 ml). 
No reactivity against the epitope was identified in the cytoplasm or at the plasma membrane 
in any test or control, where it might be expected that gag or gag-pol polyproteins accumulate 
in the cells. 
 
The staining was strongest in the BeWo cell line and the P53 mutant grade IV astrocytoma 
cultures, namely the IN1528 and IN1612 short-term cultures, and the established grade IV 
glioblastoma multiforme cell line U251-MG. The grade III glioblastoma cell lines, U373-MG 
and U87-MG (with mutant and wild type P53 respectively) showed less reactivity against the 
anti-MSRV gag 311 antibody, as did the P53 wild type short-term cultures IN859 and IN1472. 
This data suggests that while not directly linked with P53 status, expression of the epitope 
appears to be stronger where the cells are derived from higher grade tumours, and the gross 
abnormalities that can result from P53 mutation, such as aneuploidy and loss of 
heterozygosity in a number of chromosomes. 
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Figure 5.2  2-fold serial dilution for MSRV gag 311 protein and rabbit test 
sera 
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In a 2-fold serial dilution series, antibody titres remain high, even at 1:1600 (ANOVA: p<0.001 
for all dilutions; p=0.729 for nil). The 2nd test bleed is the strongest bleed, though all post-
immunisation bleeds would be suitable for antibody purification. The secondary antibody 
used, HRP conjugated polyclonal swine anti-rabbit immunoglobulins (Dako) is specific 
against all immunoglobulin subtypes, including both IgM and IgG, so no inferences can be 
made whether the response is IgM or IgG-predominant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of replicates = 6; 3 plates run with duplicate wells on each plate 
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Figure 5.3  10-fold serial dilution for MSRV gag 311 protein and rabbit test 
sera 
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In a 10-fold serial dilution series, antibody titres are diluted out at >1:100,000 (ANOVA: 
p<0.001 for all dilutions; p=0.781 for nil).  As with the 2-fold series, the 2nd bleed (14 days) 
gives the highest antibody titre.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of replicates = 6; 3 plates run with duplicate wells on each plate 
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Figure 5.4 Output of recorder for antibody purification for SEV 3 
(anti-MSRV gag 311) terminal bleed (run 2)* 
 
 
 
Peaks in absorbance, or protein detected (red trace) were seen at 12 minutes and 22 
minutes. The first peak is the flow-through the column consisting of unwanted components of 
the serum, such as albumen, while the second peak represents the eluted antibody. The blue 
trace measures the conductivity in the system, and rises during the flow-through peak (due to 
ions present in the serum) and during the elution step (due to the acidic buffer used to break 
antibody-antigen interactions).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Run was performed 3 times 
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Figure 5.5  Reactivity of purified SEV 3 (anti-MSRV gag 311) terminal bleed 
(run 2) antibody fractions 
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All fractions of purified antibody retain activity against the MSRV gag 311 peptide. A peak of 
antibody reactivity (measured at 492 nm) is present in the 3rd fraction (22-23 minutes after 
commencing the run). 
 
 
 
 
 
 
 
 
 
 
 
 
Number of replicates = 6; 2 plates run with triplicate wells on each plate 
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Table 5.3 Summary of anti-MSRV gag 311 nuclear staining in cell lines 
tested  
 
MSRV gag 311 antibody dilution  
Cell Line 
 
Type 1:25 1:50 preimmune 
serum 
PBS 
 
Figure 
       
BeWo Placental 
choriocarcinoma 
+++ +++ - - Fig. 5.6 
IN859 Grade IV 
astrocytoma 
++ + - - Fig. 5.7 
IN1472 Grade IV 
astrocytoma 
++ + - - Fig. 5.8 
IN1528 Grade IV 
astrocytoma 
+++ +++ - - Fig. 5.9 
IN1612 Grade IV 
astrocytoma 
+++ ++ - - Fig. 5.10 
U87-MG Grade III 
glioblastoma 
++ + - - Fig. 5.11 
U251-MG Grade IV 
glioblastoma 
multiforme 
++ ++ - - Fig. 5.12 
U373-MG Grade III 
glioblastoma 
++ +/- - - Fig. 5.13 
       
 
Legend  +++ strong staining, punctate distribution 
  ++ moderate staining, punctate distribution 
  + weak staining, punctate distribution 
  +/- very weak staining, diffuse distribution 
  - no staining detected 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of replicates = 2; fixing and staining performed on 2 different passages of cell lines 
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Figure 5.6 Immunofluorescent microscopy of BeWo cells stained for 
MSRV gag 311  
 
 
 
BeWo cells were fixed in 4% paraformaldehyde, permeabilised with 0.1% Triton X-100 in PBS and incubated with 
1:400 monoclonal mouse anti-tubulin antibody with (A) 1:50 polyclonal rabbit anti-MSRV gag 311 antibody; (B) 1:25 
polyclonal rabbit anti-MSRV gag 311; (C) 1:200 pre-immune rabbit serum; and (D) PBS. Secondary incubation was 
performed using 1:400 Alexa-Fluor ® 594 donkey anti-rabbit and Alexa-Fluor ® 488 goat anti-mouse antibodies and 
counterstained with 1 μg/ml DAP in ethanol. Slides were scanned at 40x magnification using Cytovision software.  
 
 
Punctate staining (red) within the nucleus can be seen in both the 1:50 and 1:100 dilutions of 
anti-MSRV gag 311, which is absent in both the pre-immune and PBS negative controls. 
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Figure 5.7 Immunofluorescent microscopy of IN859 cells stained for 
MSRV gag 311 
 
 
 
IN859 cells were fixed in 4% paraformaldehyde, permeabilised with 0.1% Triton X-100 in PBS and incubated with 
1:400 monoclonal mouse anti-tubulin antibody with (A) 1:50 polyclonal rabbit anti-MSRV gag 311 antibody; (B) 1:25 
polyclonal rabbit anti-MSRV gag 311; (C) 1:200 pre-immune rabbit serum; and (D) PBS. Secondary incubation was 
performed using 1:400 Alexa-Fluor ® 594 donkey anti-rabbit and Alexa-Fluor ® 488 goat anti-mouse antibodies and 
counterstained with 1 μg/ml DAP in ethanol. Slides were scanned at 40x magnification using Cytovision software.  
 
 
Punctate staining (red) within the nucleus can be seen in both the 1:25 and 1:50 (weak 
staining) dilutions of anti-MSRV gag 311, which is absent in both the pre-immune and PBS 
negative controls. 
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Figure 5.8 Immunofluorescent microscopy of IN1472 cells stained for 
MSRV gag 311 
 
 
 
IN1472 cells were fixed in 4% paraformaldehyde, permeabilised with 0.1% Triton X-100 in PBS and incubated with 
1:400 monoclonal mouse anti-tubulin antibody with (A) 1:50 polyclonal rabbit anti-MSRV gag 311 antibody; (B) 1:25 
polyclonal rabbit anti-MSRV gag 311; (C) 1:200 pre-immune rabbit serum; and (D) PBS. Secondary incubation was 
performed using 1:400 Alexa-Fluor ® 594 donkey anti-rabbit and Alexa-Fluor ® 488 goat anti-mouse antibodies and 
counterstained with 1 μg/ml DAP in ethanol. Slides were scanned at 40x magnification using Cytovision software.  
 
 
Punctate staining (red) within the nucleus can be seen in both the 1:25 and 1:50 (weak 
staining) dilutions of anti-MSRV gag 311, which is absent in both the pre-immune and PBS 
negative controls. 
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Figure 5.9 Immunofluorescent microscopy of IN1528 cells stained for 
MSRV gag 311 
 
 
 
IN1528 cells were fixed in 4% paraformaldehyde, permeabilised with 0.1% Triton X-100 in PBS and incubated with 
1:400 monoclonal mouse anti-tubulin antibody with (A) 1:50 polyclonal rabbit anti-MSRV gag 311 antibody; (B) 1:25 
polyclonal rabbit anti-MSRV gag 311; (C) 1:200 pre-immune rabbit serum; and (D) PBS. Secondary incubation was 
performed using 1:400 Alexa-Fluor ® 594 donkey anti-rabbit and Alexa-Fluor ® 488 goat anti-mouse antibodies and 
counterstained with 1 μg/ml DAP in ethanol. Slides were scanned at 40x magnification using Cytovision software.  
 
 
Strong punctate staining (red) within the nucleus can be seen in both the 1:25 and 1:50 
dilutions of anti-MSRV gag 311, which is absent in both the pre-immune and PBS negative 
controls. 
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Figure 5.10 Immunofluorescent microscopy of IN1612 cells stained for 
MSRV gag 311 
 
 
 
IN1612 cells were fixed in 4% paraformaldehyde, permeabilised with 0.1% Triton X-100 in PBS and incubated with 
1:400 monoclonal mouse anti-tubulin antibody with (A) 1:50 polyclonal rabbit anti-MSRV gag 311 antibody; (B) 1:25 
polyclonal rabbit anti-MSRV gag 311; (C) 1:200 pre-immune rabbit serum; and (D) PBS. Secondary incubation was 
performed using 1:400 Alexa-Fluor ® 594 donkey anti-rabbit and Alexa-Fluor ® 488 goat anti-mouse antibodies and 
counterstained with 1 μg/ml DAP in ethanol. Slides were scanned at 40x magnification using Cytovision software.  
 
 
Punctate staining (red) within the nucleus can be seen in both the 1:50 and 1:100 dilutions of 
anti-MSRV gag 311, which is absent in both the pre-immune and PBS negative controls. 
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Figure 5.11 Immunofluorescent microscopy of U87-MG cells stained for 
MSRV gag 311 
 
 
 
U87-MG cells were fixed in 4% paraformaldehyde, permeabilised with 0.1% Triton X-100 in PBS and incubated with 
1:400 monoclonal mouse anti-tubulin antibody with (A) 1:50 polyclonal rabbit anti-MSRV gag 311 antibody; (B) 1:25 
polyclonal rabbit anti-MSRV gag 311; (C) 1:200 pre-immune rabbit serum; and (D) PBS. Secondary incubation was 
performed using 1:400 Alexa-Fluor ® 594 donkey anti-rabbit and Alexa-Fluor ® 488 goat anti-mouse antibodies and 
counterstained with 1 μg/ml DAP in ethanol. Slides were scanned at 40x magnification using Cytovision software.  
 
 
Punctate staining (red) within the nucleus can be seen in both the 1:50 and 1:100 dilutions of 
anti-MSRV gag 311, which is absent in both the pre-immune and PBS negative controls. 
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Figure 5.12 Immunofluorescent microscopy of U251-MG cells stained for 
MSRV gag 311 
 
 
 
U251-MG cells were fixed in 4% paraformaldehyde, permeabilised with 0.1% Triton X-100 in PBS and incubated with 
1:400 monoclonal mouse anti-tubulin antibody with (A) 1:50 polyclonal rabbit anti-MSRV gag 311 antibody; (B) 1:25 
polyclonal rabbit anti-MSRV gag 311; (C) 1:200 pre-immune rabbit serum; and (D) PBS. Secondary incubation was 
performed using 1:400 Alexa-Fluor ® 594 donkey anti-rabbit and Alexa-Fluor ® 488 goat anti-mouse antibodies and 
counterstained with 1 μg/ml DAP in ethanol. Slides were scanned at 40x magnification using Cytovision software.  
 
 
Punctate staining (red) within the nucleus can be seen in both the 1:50 and 1:100 dilutions of 
anti-MSRV gag 311, which is absent in both the pre-immune and PBS negative controls. 
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Figure 5.13 Immunofluorescent microscopy of U373-MG cells stained for 
MSRV gag 311 
 
 
 
U373-MG cells were fixed in 4% paraformaldehyde, permeabilised with 0.1% Triton X-100 in PBS and incubated with 
1:400 monoclonal mouse anti-tubulin antibody with (A) 1:50 polyclonal rabbit anti-MSRV gag 311 antibody; (B) 1:25 
polyclonal rabbit anti-MSRV gag 311; (C) 1:200 pre-immune rabbit serum; and (D) PBS. Secondary incubation was 
performed using 1:400 Alexa-Fluor ® 594 donkey anti-rabbit and Alexa-Fluor ® 488 goat anti-mouse antibodies and 
counterstained with 1 μg/ml DAP in ethanol. Slides were scanned at 40x magnification using Cytovision software.  
 
 
Punctate staining (red) within the nucleus can be seen in both the 1:25 and 1:50 (weak 
staining) dilutions of anti-MSRV gag 311, which is absent in both the pre-immune and PBS 
negative controls. 
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 5.4 Discussion 
 
The MSRV gag 311 epitope was detected in all of the cell lines tested, but not in any of the 
negative controls. If retroviral packaging was taking place, we would expect that the gag 
would be detected in the cytoplasm of the cell, or accumulating at the cell membrane. 
Retroviruses with a type B or type D morphology assemble in the cytoplasm where they are 
transported to the plasma membrane for release (Rhee et al., 1990), whilst type C 
retroviruses assemble at the plasma membrane (Henderson, 1983). Type A particles, such 
as IAPs associated murine endogenous retroviruses and a number of HERVs such as 
HERV-K (HTDV) bud into the endoplasmic reticulum. Instead, the epitope was detected in 
the nucleus of the cells, often exhibiting a punctate distribution. Intranuclear localisation has 
been demonstrated in a number of exogenous retroviruses including MoMuLV (Nash et al., 
1993), foamy viruses (Chang et al., 1995), and HIV Tat and Rev (Truant & Cullen, 1999), as 
well as the endogenous retrovirus (Rec) product of HERV-K (HTDV) (Magin-Lachman et al., 
2001), but not HERV-W. 
 
Analysis of the protein sequence of MSRV gag has identified a potential bipartite nuclear 
localisation sequence, located between 269-286 aas (Figure 5.14), with the MSRV gag 311 
epitope lying further upstream. The consensus sequence for such nuclear localisation signals 
is BBX10BXBXB, consisting of two basic residues, followed by an alpha helix of 10 amino 
acids, and with at least 3 of the following 5 bases being basic residues (Figure 5.15). Such 
sequences have been identified in MoMuLV (Nash et al., 1993), as well as established 
nuclear proteins such as nucleoplasmin (a molecular chaperone) (Robbins et al., 1991) and 
P53. Wild type P53 is predominately located in the cytoplasm of cells, but can shuttle to and 
from the nucleus due to the presence of nuclear localisation signals and nuclear export 
sequences (Canman et al., 1997). At least two nuclear localisation sequences are encoded 
by P53, a monopartite sequence with homology to SV40 (Dang et al., 1989), and a 
BBX10BXBXB bipartite sequence (Liang & Clarke, 1999) which associates with importin α, 
and it docks to the nuclear membrane in association with importin β as part of a 
heterodimeric nuclear import complex. Mutations in these sequences cause aberrant 
distribution of P53 in the cell, affecting its normal function as a tumour suppressor gene. 
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Figure 5.14 Protein sequence of MSRV gag (AAD48375) indicating 
locations of potential nuclear localisation sequence and linear 
epitope of antibody. 
 
 
 
        1 lerilenwdq cdtqtlrkkr fiffcstawp qyplqgretw lpegsinyni ilqldlfcrk 
 
       61 egkwsevpyv qtffslrdns qlckkcglcp tgspqspppy psvpsptpss tnkdppltqt 
 
      121 vqkeidkgvn nepksanipr lcplqavrgg efgparvpvp fslsdlkqik idlgkfsdnp 
 
      181 dgyidvlqgl gqsfdltwrd imlllnqtlt pnersaavta arefgdlwyl sqannrmtte 
 
      241 erttptgqqa vpsvdphwdt esehgdwchk hlltcvlegl rktrkkpmny smmstitqgk 
 
 
 
 
      301 eenltafldr lrealrkhts lspdsiegql ilkdkfitqs aadirknfks lp 
Epitope recognised by antibody 
Potential nuclear localisation sequence 
 117
Figure 5.15 Comparison of nuclear localisation sequences of SV40, 
MoMuLV gag, MSRV gag, nucleoplasmin and P53 (adapted from 
Nash et al., 1993) 
 
 
 
 
Nuclear localisation sequences fall into 2 categories, with either homology to SV40, or having 
a bipartite consensus (BBX10BXBXB). The predicted nuclear localisation sequence for MSRV 
gag falls into the latter category, as do MuLV, nucleoplasmin, and the bipartite P53 
sequence. 
 
SV40 consensus PKKKRKV 
Bipartite consensus BB X10 BXBXB 
Key 
 
B – basic amino acid 
e.g.  Lysine (K),  
Arginine (R), 
Histidine (H) 
 
X – any amino acid 
MuLV (alt. 1) RR RTEDEQKEKE RDRRR 
MuLV (alt. 2) R RR TEDEQKEKER DRRR 
MSRV gag (alt. 2) H KH LLTCVLEGLR KTRKK 
MSRV gag (alt. 1) HK HLLTCVLEGL RKTRK K 
P53 (NLS1) PQPKKKD 
P53 KR ALPNNTSSSP QPKKK D 
Nucleoplasmin KR PAATKKAGQA KKKKL 
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In order to determine whether the putative MSRV gag nuclear localisation sequence is 
functional, it may be worthwhile constructing a biotin-labelled peptide (and a number of 
mutants with disruption at key residues) of the putative localisation sequences, and loading 
these onto a carrier protein such as Transportan-10 and carrying out fluorescence 
microscopy to determine the localisation of the construct in the cells, or by assaying nuclear 
extracts for the peptide and mutant constructs. Transportan-10 is a cell penetrating peptide, a 
chimeric molecule derived from the N-terminal of galanin and the complete sequence of the 
wasp venom, mastoparan, and enters the cells by a mechanism involving the transcellular 
pathway rather than endocytosis (Lindgren et al., 2004). Once internalised, the disulphide 
bridge that binds the cargo is disrupted in the cellular environment. 
  
Alternatively it may be possible that the antibodies are not recognising HERV-W gag, and are 
recognising an alternate, unidentified epitope. It is not clear from immunocytochemical 
analysis what protein is being expressed, merely that an antibody recognises a protein target.  
Had time allowed, it would have been useful to perform western blotting on either whole cell 
or nuclear extracts in order to determine whether the protein detected is MSRVgag, and if so 
whether the sequence is truncated as an approximation of molecular weight can be 
determined. If the protein can be isolated, it is possible to determine the amino acid sequence 
by the sequencing utilising the Edman degradation reaction or by cleaving into smaller 
peptides and performing mass spectroscopy (Steen and Mann, 2004). The expected size of a 
HERV-W gag product is highly variable due to large numbers of premature stop codons 
present in the open reading frames of such sequences, though truncated forms of 45 kDa 
have been detected in the placenta (Voisset et al., 2000). Gammaretroviruses, such as 
HERV-W contain PROT and POL genes in the same reading frame and polyproteins are 
produced by translational readthrough of a stop codon at the end of gag (Goff, 1996). 
Consequently a gag-prot-pol polyprotein is also a possibility. 
 
It is worth noting that the PCR data presented in Chapter 4 do not detect MSRVgag mRNA 
transcripts, but a variant with homologies between ~75-85%, and the putative localisation 
sequence is likely to be heavily mutated (and as consequence functionality is likely to be 
altered due to altered protein sequence). The antibodies were designed to have cross-
homology with MBP (see Chapter 2), though the homology was weak (3 amino acids), but 
this is expressed by oligodendrocytes rather than astrocytes (Baumann and Pham-Dinh, 
2001), and is exported out of the cell forming an integral component of the myelin sheath. 
Therefore, astrocytoma cell lines were selected rather than oligodendrioma cell lines, as we 
could be certain that as protein detected would have not been MBP, although it would be 
interesting to test whether MSRV gag 311 antibodies developed are reactive against MBP. 
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Detection of the MSRV gag 311 epitope varied amongst the cell lines tested, with stronger 
expression present in the BeWo cell, the P53 mutant short-term grade IV astrocytoma 
cultures IN1582 and IN1612, and the grade IV glioblastoma multiforme cell line U251-MG. 
Higher expression of MSRV gag 311 would be expected in the BeWo cell line, derived from a 
placental choriocarcinoma, as a wide variety of retroviruses are expressed in the placenta, 
including HERV-W env (7q)/syncytin and a truncated HERV-W gag protein of 363 aas in 
length (Voisset et al., 2000), although no evidence suggests a replication-competent 
HERV-W provirus. 
 
All cell lines tested were positive for MSRV gag transcripts (Chapter 4), and this was also the 
case for MSRV gag 311 expression. As previously stated, the astrocytoma cell lines with the 
most marked expression were grade IV tumours with mutant P53. Such high grade tumours 
have a number of other genetic alterations, including loss of heteozygosity at 9p, 10q, 13q, 
17p and 22q, and a gain of chromosome 7 (Rasheed et al., 1999). These changes become 
more frequent with higher grade of tumour, in particular the loss of chromosome 10 loci, 
whilst the frequency of P53 mutation is constant in tumours categories from grade II upwards. 
 
A variety of genes are amplified on chromosome 7, including CDK 6 (CDK 6) (Costello et al., 
1997), which is located at 7q21 (Johnson et al., 1995).  CDK6 acts by phosphorylating the 
retinoblastoma (Rb) proto-oncogene, and is expressed in the early G1 phase of the cell cycle 
(Harbor et al., 1999). Interestingly, chromosome 7q21-22 is the location of the HERV-W 
provirus encodinging syncytin, and present in tandem with a HERV-H (RGH-2) provirus 
(Perron et al., 2000). Costello et al. (1997) suggested that the amplification was specific to 
CDK6, as the expressed sequence tags (ESTs) nearby were not amplified. 
 
Clearly the molecular pathogenesis of high grade tumours is complex, and a wide variety of 
genes have their expression upregulated or downregulated, and thus their translation into 
functional gene products, Other copies of HERV-W proviruses exist on a number of 
chromosomes, with at least 70 different HERV-W gag sequences present in the human 
chromosome (Voisset et al., 2000). It is more than likely that some of these sequences are 
active in normal tissue, and that regulation of transcription alters in cancerous tissues. 
Exactly which sequences and their importance to the pathogenesis of tumours (and indeed 
MS) is not fully understood, and whether expression is just a consequence of tumourigenesis. 
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6 Summary and conclusions 
 
 
6.1 Prediction and screening of epitopes in MS patient plasma 
 
A novel approach has been applied in order to predict potential epitopes where molecular 
mimicry between HERV proteins and candidate autoantigens in MS.  A number of studies 
have investigated whether antibodies in MS are targeted against molecular mimics. Myelin 
components such as PLP have short stretches of sequence homology to proteins produced 
by a number of viruses (Shaw et al., 1986; Wuchterpfennig & Stromiger, 1995). In the course 
of this project, a number of putative autoantigens were shown to have sequence homology to 
a variety of HERV products. 
 
The first step of the bioinformatics analysis was to identify immunodominant domains in both 
the autoantigens and the HERVs as potential epitopes. By looking at the primary and 
secondary structures of the proteins, a large number of candidate epitopes were predicted. 
Primary sequence analysis looked for groups of residues that are likely to be found on the 
surface of a protein, based on hydrophilicity (hydrophobic residues form the core of most 
globular proteins), polarity (polar residues are important in interactions with other molecules), 
and accessibility and flexibility. Secondary structure analysis utilised web servers ‘trained’ to 
compare protein structures to that of known sequences to look for alpha helices and beta 
turns. These “neural networks” learn the relationships between input and output patterns and 
evolve. The process can only determine linear epitopes, as no analysis of tertiary structure 
was carried out. 
 
The next stage of the process involved investigating whether there was any homology 
between identified HERV epitopes and their autoantigen counterparts, by aligning the large 
number of sequences obtained using the BLOSUM substitution matrix. Sequences with 
identity with at least 4 amino acids out of a stretch of 5 were taken to be significant.  
 
A large number of epitopes from the candidate viruses were identified. Two were selected to 
be produced as peptides, one a HERV-W env peptide with sequence homology to NoGo A (a 
neurite growth inhibitor) (Chen et al., 2001), and the other a MSRV gag peptide with 
sequence homology to S-arrestin, a retinal antigen important in the pathogenisis of uveitis, 
but also detected in MS patients (Ohguro et al., 1993), and screened in a small scale pilot 
study utilising an ELISA system in order to establish suitability for antibody production and/or 
a full scale study of MS patients and controls. It is important to note that evidence of in silico 
homology is not evidence that molecular mimicry is taking place. 
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Screening of the samples in the ELISA system indicated that there was no difference in IgG 
response to either peptide, HERV-W env412 or MSRV gag274, between MS patients, OND 
controls and NHDs, and additionally the levels of response was low. Other studies have 
indicated that NoGo A is produced as a response to CNS injury, and not just MS, with 
significant IgM responses, but not IgG (Reindl et al., 2003). NoGo A has been reported to be 
upregulated in oligodendrocytes surrounding active MS lesions (Satoh et al., 2005). Antibody 
titres to S-arrestin had been shown to be raised in MS patients in a number of studies, 
particularly where patients had reduced visual acuity (Ohguro et al., 1993; Gorczyca et al., 
2004). It may be worth testing the MSRV gag274 peptide in a particular subset of patients with 
ocular symptoms. 
 
The results do not prove that antibodies against HERV epitopes do not cross-react with those 
of putative autoantigens, as a large number of potential matches were found, but it is 
extremely unlikely that either of the two peptides produced do. The sensitivity of the assay 
was poor, and optimisation of the assay may have yielded higher titres of antibody, making 
discrimination of the samples more difficult due to the low signal to noise ratio. Lack of 
reactivity could be due to the peptide binding poorly to the plate, or a genuine lack of antibody 
in patient plasma. 
 
Consequently no suitable candidate was identified for antibody production in this study. 
Polyclonal antibodies produced could be used to provide a calibration for the ELISA system, 
enabling effective troubleshooting of the system. They would also provide a tool to investigate 
patterns of expression in different cell types in pathological specimens of MS tissue, and 
matched to patients and controls, and whether the expression is more marked in active 
lesions. It may have been worthwhile producing recombinant proteins of HERV-W to test for 
reactivity in patient plasma (or serum). This method has been successfully used to detect 
HERV K10 Gag polyprotein in the serum of patients with testicular tumours and a number of 
teratocarcinoma-derived cell lines (Sauter et al., 1995). The production of a recombinant 
protein would also provide a useful tool to screen whether the epitopes that were predicted 
were reflected in the protein, or whether they are obscured. 
 
 
6.2 Detection of HERV-W RNA transcripts in glioma cell lines 
 
The main objective of this study was to produce tools to enable detection of HERV products 
in the central nervous system, both at mRNA level and at protein level. A number of primers 
were developed to enable the detection and quantification of mRNA in a number of cancer 
cell lines. 
 122
As HERV-W env expression is ubiquitous in both cancerous and healthy tissues (Yi et al., 
2004), a multiplex PCR system was utilised to investigate the amount of HERV-W env in 
glioma cell lines in relation to histidyl tRNA synthetase, which was used as a housekeeping 
gene. HERV-W gene products have been detected in a variety of tumour types including 
ovarian tumours (Menendez et al., 2004) and endometrial carcinomas (Strick et al., 2007). A 
number of studies have shown than HERV-W retains transcriptional activity in the normal 
brain by a variety of methods including EST analysis (Nakamura et al., 2003), digital 
expression profiling (Stauffer et al., 2004) and real-time PCR (Forsman et al., 2005). A 
number of studies have also detected HERV-W expression in a small sample of brain tumour 
cell lines (Yi et al., 2002; Yi et al, 2004). 
 
A number of glioblastoma and astrocytoma cells were tested in this study to investigate the 
expression of HERV-W env and MSRV gag at RNA level, and were largely representative of 
higher grade tumours (WHO classification III and IV). HERV-W env RNA was detected in 
every cell line tested, including a placental control line and cell lines derived from 
teratocarcinomas, breast and bowel cancer. Semi-quantitation of HERV-W env expression 
was determined, with levels in the BeWo line significantly higher than that other cell lines, as 
in the placenta HERV-W env is known to play a key role in syncytialisation and trophoblast 
development (Mi et al, 2000). PCR products had a high sequence homology (>94%) to the 
reference HERV-W env sequence that encodes syncytin. The high degree of sequence 
homology to syncytin indicates that translation of the transcript is likely to produce a 
functional protein.  
 
In the astrocytoma cell lines, expression was significantly higher in the cell lines with mutant 
P53 than those with wild type protein. Wild type P53 has multiple roles in DNA repair, cell 
cycle arrest and the initiation of apoptosis, and mutation results in breakdown of cell control. 
Initiation of HERV-W env transcription and the presence of such sequences may represent a 
breakdown of such control. P53 negatively regulates LTRs of another gammaretrovirus, 
HERV-I (Chang et al., 2007), and conformational mutation of the protein stimulates 
transcriptional activity. LTRs are responsible for mediating intergration of the exogenous 
retrovirus into the chromosome.  
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Whether HERV-W env is a cause or a consequence of the genomic instablility associated 
with glioblastomas has yet to be established. Further studies may elucidate whether HERV-W 
env expression is correlated with glioma cell progression. By looking at expression levels in 
lower grade tumours (anaplastic astrocytomas) and normal astrocytes, a clearer picture of 
the involvement of HERV-W env in the disease may be ascertained. In situ PCR or in situ 
hybridisation (using probes developed from the sequence) of pathological specimens of 
astrocytomas (and also MS) will further indicate the role of MSRV env in the disease by 
giving information about the localisation of the sequences in the central nervous system. 
 
MSRV gag variants were also detected in all of the cell lines tested, but as in the case of pol 
(Yi et al., 2004), a large number of frameshifts and point mutations are present, indicating a 
probable lack of any functional protein. The presence of these transcripts is interesting, as 
HERV-W gag appears to have a limited distribution in cancer cells and healthy tissues (Yi et 
al., 2002), in contrast to HERV-W env which is widely expressed. Sequences of the products 
had only moderate homology to the prototype MSRV gag and to each other, with the sample 
from the CHME3 foetal microglia cell showing the highest degree of similarity. Analysis of the 
sequences of the PCR products in a wide variety of tissues and further cell lines could be 
utilised in order to determine whether particular isolates are associated with particular tissues 
and tumours. 
 
The effects of IFN-γ on MSRV gag transcription levels in the foetal microglial cell line, 
CHME3, was also determined in vitro, as IFN-γ is one of the central cytokines involved in MS, 
and is involved in a variety of functions including anti-microbial and anti-tumour mechanisms, 
and in the upregulation of MHC class I and II. A number of other retroviruses and 
retrotransposons are located in MHC regions, and it might be expected that these sequences 
are upregulated along with MHC expression. IFN-γ and TNF-α have been shown to 
upregulate pol expression (Serra et al., 2003). No significant evidence of MSRV gag 
upregulation was found, indication that any increase in expression present in MS is due to a 
different mechanism. Such mechanisms may include other cytokines, steroid hormones, 
exogenous viruses (such as members of the herpes family), UV irradiation or demethylating 
agents. The PCR developed in this thesis provides a useful tool for investigating these 
possibilities. 
 
 124
In addition to HERV-W and MSRV, a number of other HERVs have been detected in the 
CNS, and are transcriptionally active, including including HERV-H and HERV-I (Forsman et 
al., 2005). Notably, the RGH-2 subtype of HERV-H has also been linked with MS 
(Christensen et al., 1997), and an RGH variant is present in tandem with the HERV-W 
provirus located at 7q (Perron et al., 2000). It would be interesting to see if HERV-H has a 
similar expression pattern to that of HERV-W by synthesising primers to use in a similar PCR 
system to the one detailed here.  
 
 
6.3 Detection of HERV-W protein products in glioma cell lines 
 
Evidence of mRNA expression does not necessarily mean that functional protein is present. 
The vast majority of HERVs encode defective proteins, with a large amount of frameshift 
mutations and premature stop codons present (De Parseval et al., 2003). HERVs are 
estimated to form 5% of the human genome, and a large amount is untranscribed, and in the 
HERV-W family alone at least 70 GAG, 100 PRO and 30 ENV sequences are present. 
 
A polyclonal antibody was made against an epitope of MSRV gag, predicted within our 
research group by Denise Roden, by immunising a short peptide sequence into a rabbit 
which was then purified using affinity chromatography. The purified antibody was applied to 
astrocytoma cell lines including those investigated in the MSRV gag PCR. The MSRV gag 311 
epitope was identified in all cell lines and was localised as small punctate foci in the nucleus 
of the cells. Strong expression of the epitope was detected in the BeWo choriocarcinoma cell 
line along with three grade IV p53 mutant astrocytoma/glioblastoma cell lines. Expression 
was less marked in the grade III glioblastoma cell lines and the two p53 wild type 
astrocytoma cell lines. Expression is not likely to be purely due to the P53 status of the cell 
lines, but more complex involving a number of other factors. Higher grade tumours have a 
number of genetic alterations, including loss of heterozygosity at a number of chromosomal 
loci, and gains at others. 
 
A number of genes are amplified on chromosome 7, including cyclin-dependant kinase 6 
(CDK 6) (Costello at al., 1997), which as located at 7q21, the location of the HERV-W 
provirus which encodes syncytin, and present in tandem with a HERV-H provirus (Perron et 
al., 2000). CDK 6 is expressed in the G1 phase of the cell cycle and is involved in the 
phosphorylation of the retinoblastoma (Rb) oncogene. 
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It is not clear why MSRV gag should localise in the nucleus, as functional gag is important in 
retroviral assembly, and is usually detected at the cytoplasm or at the cytoplasmic membrane 
of the cell. Intranuclear localisation of a number of retroviruses has been decribed – in 
MoMuLV (Nash et al., 1993), foamy viruses (Chang et al., 1995),  HIV Tat and Rev (Truant & 
Cullen, 1999), and HERV-K (HTDV) (Magin-Lachman et al., 2001), but not as yet in 
HERV-W. 
 
Analysis of the MSRV gag protein sequence identified a putative bipartite nuclear localisation 
sequence similar to that described in MoMuLV (Nash et al., 1993). Similar amino acids exist 
in a number of proteins which are imported into the nucleus including nucleoplasmin and 
P53. To establish that the nuclear localisation sequence is active in vitro it is necessary to 
determine interactions with nuclear import molecules such as importin α, and to determine 
whether the sequence is localised into the nucleus. 
 
Exact identification of the MSRV gag311 epitope is important as it is not clear exactly what the 
product is, whether it is MSRV gag (a variant), MSRV gag polyprotein or a different molecule 
entirely. Western blotting would assist in narrowing down the range of possibilities (and is 
able to distinguish partial, complete or a polyprotein), but gives only a molecular weight.  
 
Immunocytochemistry is not quantitative. In order to quantify the data other studies would 
need to be carried out, such as dot-blotting or western blotting nuclear extracts of the cells, 
and relating the quantity against that present in the cytoplasm or the total cell. This would 
also be useful for investigating how HERV protein expression is altered in response to 
exogenous factors such as cytokines. 
 
 
6.4 Further applications 
 
The primers and antibodies developed can be used in a wide variety of applications where 
HERV-W involvement is expected, such as MS. The system developed in the process of this 
project can provide a rapid way of determining levels of other retroviral products, namely 
HERV-W env and MSRV gag in these tissues. It is also possible to utilise the designed 
primers for use with in situ PCR to determine localisation of sequences (DNA or RNA) within 
pathological sections of MS tissue. Sequencing of the products allows the development of 
probes suitable for use with in situ hydbridisation studies as an alternate method.  
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The system can also be used to look at the modulation of HERV-W/MSRV transcription by 
other factors involved in MS pathogenesis, e.g. cytokines, exogenous agents. The HERV-W 
env (syncytin) promoter has been shown to be regulated by proinflammatory cytokines (TNF-
α, IFN-γ, IL-6, IL-1) and suppressed by IFN-β (Mameli et al, 2007). It would be worthwhile 
investigating the promoter activity of the syncytin promoter in the different cell lines tested, 
and establishing whether promoter activity is suppressed in those cell lines with wild type 
P53. 
 
The epitopes predicted can be used to develop peptides suitable for use in MS patient 
studies, once the target of antibody has been identified, such as an ELISA system to detect 
autoantibodies present in patient plasma or serum, and CSF. Other studies have shown 
cross-reactivity of random phage peptides with cross-homology against MSRV (Jolivet-
Reynaud et al., 1999), but no demonstration of molecular mimicry between HERVs and 
putatative autoantigens has been identified. There is very little evidence produced to support 
the presence of anti HERV-W antibody in the plasma or serum of MS patients, though 
responses against synthetic peptides of HERV-H (RGH-2) have been characterised 
(Christensen et al., 2000). 
 
The presence of HERV-W/MSRV gag products has been demonstrated by Perron et al., 
(2005) in brains of MS patients and controls. In MS patients env antigen was overexpressed 
only in recent demyelinating regions, where gag accumulation was higher in demyelinated 
white matter. In controls env was expressed widely within white matter, whilst gag was 
expressed widely in neurons. It is worth detecting using the antibody developed against 
MSRV gag displays the predicted epitope in a similar expression pattern in MS patients. 
Development of antibodies against HERV epitopes predicted in silico may also prove a useful 
tool in such investigations. 
 
The study also raises questions about the role of HERV-W gene and protein products in 
patients with astrocytic tumours, particularly the link with P53 mutation and HERV-W env 
expression. Further study at protein level will establish whether HERV-W env is a fully 
functional product, though the extremely close homology of the HERV-W env isolates to 
syncytin suggests that it is more than likely. The other major question to be resolved is how 
p53 may affect the expression of the provirus. Genomic instability associated with high grade 
tumours results in a number of alterations in the cell, such as loss and gain at a number of 
chromosomal loci, a number of which contain HERV elements. Investigation of the activity of 
the HERV-W ENV promoter in cell lines with wild type and mutant P53 protein could explain 
how this situation arises. This would help to establish whether HERV-W env products are a 
reliable marker of the disease. 
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6.5 Summary 
 
Tools for the detection of HERVs at mRNA and protein level were successfully developed 
and applied in the investigation of the detection of HERV-W/MSRV gag products a number of 
cell lines, predominately astrocytomas. HERV-W env RNA was shown to be present in all 
lines, but levels were particularly high in the BeWo placental choriocarcinoma cell line, while 
in astrocytoma cell lines a relationship was found with P53 status. Exactly how P53 status 
alters HERV-W activity is unclear, but a number of HERV LTRs are active in the genome, 
including that of HERV-W. MSRV gag variants are also widely expressed in astrocytomas, 
but appear to be heavily mutated and unlikely to code for functional protein. IFN-γ had no 
significant effect on the levels of MSRV gag expressed in the CHME3 microglial cell line. 
 
Immunocytochemical analysis indicated the presence of a protein displaying the 
MSRV gag 311 epitope, though this was located in the nucleus rather than in the cytoplasm or 
the cytoplasmic membrane as expected. Expression of this protein was marked in a number 
of astrocytoma cell lines and short-term cultures derived from high grade tumours. 
 
Attempts to show molecular mimicry between HERV epitopes and those of autoantigens 
yielded little, with no significant differences in antibody reactivity between MS patients, OND 
controls, and NHDs in HERV-W env and MSRV gag peptides constructed on the basis of 
bioinformatics analysis and similarities with epitopes of known autoantigens.  
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Appendix A Physicochemical parameters of amino acids 
 
 
 
Amino acid   Polarity Hydrophilicity Accessibility Flexibility 
   (Grantham, 1974) (Hopp & Woods, 1981) (Janin, 1979) (Bhaskaran & 
Ponnuswamy (1998) 
Alanine Ala A 8.100 -0.500 6.600 0.360 
Arginine Arg R 10.500 3.000 4.500 0.530 
Asparagine Asn N 11.600 0.200 6.700 0.460 
Aspartic acid Asp D 13.000 3.000 7.700 0.510 
Cysteine Cys C 5.500 -1.000 0.900 0.350 
Glutamine Gln Q 10.500 0.200 5.200 0.490 
Glutamic acid Glu E 12.300 3.000 5.700 0.500 
Glycine Gly G 9.000 0.000 6.700 0.540 
Histidine His H 10.400 -0.500 2.500 0.320 
Isoleucine Ile I 5.200 -1.800 2.800 0.460 
Leucine Leu L 4.900 -1.800 4.800 0.370 
Lysine Lys K 11.300 3.000 10.300 0.470 
Methionine Met M 5.700 -1.300 1.000 0.300 
Phenylalanine Phe F 5.200 -2.500 2.400 0.310 
Proline Pro P 8.000 0.000 4.800 0.510 
Serine Ser S 9.200 0.300 9.400 0.510 
Threonine Thr T 8.600 -0.400 7.000 0.440 
Tryptophan Trp W 5.400 -3.400 1.400 0.310 
Tyrosine Tyr Y 6.200 -2.300 5.100 0.420 
Valine Val V 5.900 -1.500 4.500 0.390 
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Appendix B Epitopes identified 
 
 
B.1 Retroviral epitopes 
 
HERV-H (RGH-1) env 
97-111    LDRSSKTSPDISH 
230-244 SPCSSDSPPRPSSRLL  
 
HERV-H gag 
190-204 QFTLKKVAGAKGIVK 
 
HERV-W env (Syncytin) 
117-134 GGVQDQAREKHVKEVIS 
412-437 GIVTEKVKEIRDRIQRRAEEL 
RNTGP 
 
HERV-W gag 
134-148 KEIDKGVNNEPKSAN 
307-322 ITQGKEENPTAFLDRL   
 
HRES-1 p15 
68-86  RALHPPSGRDREEEEEMGY 
96-118  ACARGGRGGAREDFGARRKHV 
RG 
 
HRES-1 p25 
37-53  PRLRPRHRHPQDPRSPG 
56-71  PRHRRPPRPDPRAPPA 
107-131 LGGEGPGAGDRRREGPDRSPR 
QPPV 
 
HTLV-1 gag-pro-pol 
105-120 SSTHDPPDSDPQIPPP 
227-242 LRVQANNPQQQGLRRE 
301-317 SLAYSNANKECQKLLQ 
330-344 RACQAWTPKDKTKVL 
397-413 KPTIPEPEPEEDALLLD 
654-669 IDLSSSSPGPPDLSSL 
854-868 CALQRHTDPRDQIYL 
1252-1270 GAISATQKRKETSSEAISS 
1455-1472 RPVGGPADPKEKDHQHHG 
 
HTLV1 gp46 
87-102  HWIKKPNRNGGGYY 
 
HTLV1 tax 
318-337 SLLFNEKEADDNDHEPQISP 
339-353 GLEPLSEKHFRETEV 
 
MSRV env 
120-135 IQGQAREKQVKEAISQ 
412-428 RIVTEKVKEIRDRIQC 
424-439 RIQCRAEELQNTERWG 
 
 
MSRV gag 
123-138 KEIDKGVNNEPKSANI 
274-289 TCVLEGLRKTRKKPMN 
 
MSRV pol 
1-15  SSSRTEGARGKCQPM 
345-359 CGYKVSKPKARLCSQ 
580-596 TFLPDNEEKIEHNCQQV 
731-765 LHCQGHQEEEEREIEGNRQAD 
IEAKKAARQDSPLEML 
 
Visna env 
1-17  MASKESKPSRTTRRGME 
29-48  QELVKRQQQEEEEQQGLVSG 
57-73  DLLGTEGKDIKKVNIWE 
191-218 RQWMKENEKEYKERTNKTKED 
IDDLVAG 
301-315 LRCQDEGKSPGGCVQ 
328-342 EAMKYLRGKKSRYGG 
338-356 SRYGGIKDKNGELKLPLS 
636-651 SYMEAQGENKRSRRNL 
776-791 QQWEEEIEQHEGNLS 
876-896 EAPVELEEKQKRNGDGTNGCA 
897-911 SLEHERRTSHRSFIQ 
950-975 NGWNGENQHKKKKERVDCQDR 
EQMPT 
 
Visna gag 
1-18  MAKQGSKEKKGYPELKEV 
71-86  KGLTPEETSKREFASL 
112-134 ISMKEGLHENKEAKGEKVEQL 
YP 
212-226 LIQGKLNEEAERWVR 
284-299 MLVKQKNTESYEDFIA 
347-362 TVEEKMQACRDVGSEG 
414-436 HMQKDCRQKKQQGNNRRGPRV 
VP 
 
Visna pol 
14-29  LPAEETAGKQQEEGAT 
173-188 KEIVDRLEKEGKVGRA 
210-226 MLIDFRELNKQTEDLA 
350-367 GFMLPEDKRQEGYPAKW 
453-468 GNYYDEEKDIYGQLDQ 
571-568 TYYTDGGKKNGRGSLGY 
596-610 RIHEEGTNQQLELRA 
668-683 PGHKGIPQNEEIDRYI 
695-709 ILQKRAEDAGYDLIC 
799-816 EPWGETRKTERGEQGFGS 
868-883 MPSTLRGSNKRGIDHW 
1028-1045 QRIQQQSKSKQEKIRFCY 
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B.2 MS autoantigen epitopes 
 
Alpha B Crystallin 
100-116 VHGKHEERQDEHGFISR 
 
Beta Arrestin 1 Isoform A 
149-166 FCAENLEEKIHKRNSVRL 
219-233 HVTNNTNKTVKKIKI 
352-367 MHPKPKEEPPHREVPE 
374-389 TNLIELDTNDDDIVFE 
392-417 ARQRLKGMKDDKEEEEDGTGS 
PQLNN 
 
Beta Arrestin 1 Isoform B 
90-114  APEDKKPLTRLQERL 
149-166 FCAENLEEKIHKRNSVRL 
219-233 HVTNNTNKTVKKIKI 
286-301 GLALDGKLKHEDTNLA 
344-359 MHPKPKEEPPHREVPE 
366-381 TNLIELDTNDDDIVFE 
384-409 ARQRLKGMKDDKEEEEDGTGS 
PQLNN 
 
Claudin 11 (Oligodendrocyte Specific 
Protein) 
39-53  PTCRKLDELGSKGLW 
 
2', 3'-Cyclic Nucleotide 3' 
Phosphodiesterase 
1-15  MSSSGAKDKPELQFP 
33-48  FILRGLPGSGKSTLAR 
48-62  RVIVDKYRDGTKMVS 
74-89  GAFSEEYKRLDEDLAA 
98-116  ILVLDDTNHERERLEQLFE 
146-166 QWQLSADDLKKLKPGLEKDFL 
173-187 FLTKKSSETLRKAGQ 
204-221 RQFVPGDEPREKMDLVTY 
330-348 EILRQEKGGSRGEEVGELS 
382-398 KPVPTQGSRKGGALQS 
 
Heterogenous Nuclear Riboprotein 
A2/B1 Isoform B 
6-25  ETVPLERKKREKEQFRKLFI 
51-66  VVMRDPASKRSRGFGF 
114-133 LFVGGIKEDTEEHHLRDYFE 
142-157 EIITDRQSGKKRGFGF 
158-172 VTFDDHDPVDKIVLQ 
195-209 EVQSSRSGRGGNFGF 
226-240 NFRGGSDGYGSGRGF 
334-353 GNYGPGGSGGSGGYGGRSRY 
 
Heat Shock Protein 60 (Chaperonin) 
78-94  VTVAKSIDLKDKYKNIGA 
122-140 SIAKEGFEKISKGANPVE 
172-187 ATISANGDKEIGNIIS 
186-200 ISDAMKKVGRKGVIT 
199-213 ITVKDGKTLNDELEI 
245-260 LLSEKKISSIQSIVPA 
303-319 PGFGDNRKNQLKDMAI 
357-373 LLKGKGDKAQIEKRIQE 
378-397 LDVTTSEYEKEKLNERLAKL 
406-428 VGGTSDVEVNEKKDRVTDAL 
NAT 
477-491 MTIAKNAGVEGSLIV 
544-562 VVVTEIPKEEKDPGMGAMG 
Heat Shock 70kDa Protein 1A 
67-82  VFDAKRLIGRKFGDPV 
93-107  QVINDGDKPKVQVSY 
148-163 AYFNDSQRQATKDAGV 
183-197 YGLDRTGKGERNVLI 
239-262 NHFVEEFKRKHKKDISQNKRA 
VRR 
319-333 KALRDAKLDKAQIHD 
358-373 DLNKSINPDEAVAYGA 
379-393 ILMGDKSENVQDLLL 
441-457 QVYEGERAMTKDNNLLG 
488-503 VTATDKSTGKANKITI 
502-517 TITNDKGRLSKEEIER 
517-540 RMVQEAEKYKAEDEVQRERVS 
AKN 
552-578 AVEDEGLKGKISEADKKKVLD 
  KCQEVI 
579-598 GGFGAGGPKGGSGSGPTIEE 
 
Heat Shock 70kDa Protein 1B 
93-107  QVINDGDKPKVQVSY 
148-163 AYFNDSQRQATKDAGV 
183-197 YGLDRTGKGERNVLI 
239-262 NHFVEEFKRKHKKDISQNKRA 
VRR 
319-333 KALRDAKLDKAQIHD 
358-373 DLNKSINPDEAVAYGA 
379-393 ILMGDKSENVQDLLL 
441-457 QVYEGERAMTKDNNLLG 
489-503 TATDKSTGKASKITI 
502-517 TITNDKGRLSKEEIER 
517-540 RMVQEAEKYKAEDEVQRERV 
SAKN 
552-578 AVEDEGLKGKISEADKKKVLD 
KCQEVI 
579-605 SWLDANTLAEKDEFEHKRKEL 
EQVCN 
620-639 GGFGAQGPKGGSGSGPTIEE 
  
Heat Shock 70kDa Protein 8 Isoform 1 
67-82  VFDAKRLIGRRFDDA 
148-163 AYFNDSQRQATKDAGT 
182-197 AYGLDKKVGAERNVLI 
240-263 HFIAEFKRKHKKDISENKRA 
VRRL 
318-333 EKALRDAKLDKSQIHD 
358-373 ELNKSINPDEAVAYGA 
378-393 AILSGDKSENVQDLLL 
441-457 QVYEGERAMTKDNNLLG 
488-504 VSAVDKSTGKENKITIT 
502-517 TITNDKGRLSKEDIER 
517-544 RMVQEAEKYKAEDEKQRDKVS 
SKNSLES 
550-576 KATVEDEKLQGKINDEDKQKI 
LDKCNE 
578-604 INWLDKNQTAEKEEFEHQQKE 
LEKVCN 
627-643 GGGAPPSGGASSGPTIE 
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Heat Shock 70kDa Protein 8 Isoform 2 
67-82  VFDAKRLIGRRFDDAV 
148-163 AYFNDSQRQATKDAGT 
182-196 AYGLDKKVGAERNVLI 
240-263 HFIAEFKRKHKKDISENKRAV 
RRL 
318-333 EKALRDAKLDKSQIHD 
358-373 ELNKSINPDEAVAYGA 
378-393 AILSGDKSENVQDLLL 
441-458 QVYEGERAMTKDNNLLG 
474-490 GGGAPPSGGASSGPTIE 
 
Myelin Associated Glycoprotein 
Isoform A Precursor 
184-199 AVLGRLREDEGTWVQ 
533-548 ITQTRRKKNVTESPSF 
564-585 ISGAPEKYESERRLGSERRLL 
G 
598-612 SHSDLGKRPTKDSYT 
 
Myelin Associated Glycoprotein 
Isoform B Precursor 
184-199 AVLGRLREDEGTWVQ 
533-548 ITQTRRKKNVTESPSF 
564-580 ISGAPEKYESKEVSTLE 
 
Myelin Basic Protein 
44-61  RFFGGDRGAPKRGSGKVP 
99-103  LPQKSHGRTQDENPV 
168-185 KIFKLGGRDSRSGSPMAR 
 
NoGo A (Reticulon 4 Isoform A) 
8-22  PLVSSSDSPPRPQPA 
23-57  FKYQFVREPEDEEEEEEEEEE 
DEDEDLEELEVLER 
126-146 AAVSPSKLPEDDEPPARPPPP 
173-190 PAAPKRRGSSGSVDETLF 
263-285 GTLQENVSEASKEVSEKAKTL 
LI 
321-342 EEIIVKNKDEEEKLVSNNIL 
352-376 KLVKEDEVVSSEKAKDSFNEK 
RVAV 
391-409 ERVWEVKDSKEDSDMLAAG 
412-426 IESNLESKVDKKCFA 
427-450 DSLEQTNHEKDSESSNDDTSF 
PST 
481-506 PLLGDPTSENKTDEKKIEEKK 
AQIVT 
503-519 QIVTEKNTSTKTSNPFL 
665-684 VSLKKVSGIKEEIKEPENIN 
732-747 SELVEDSSPDSEPVDL 
750-765 DDSIPDVPQKQDETVM 
778-792 SMIEYENKEKLSALP 
926-947 PKVEEKISFSDDFSKNGSATS 
971-997 KVLVKEAEKKLPSDTEKEDRS 
PSAIFS 
 
Proteolipid Protein 
115-129 ATVTGGQKGRGSRGQ 
 
S Arrestin 
2-17  AASGKTSKSEPNHVIF 
14-29  HVIFKKISRDKSVTIY 
49-63  VLVDPDLVKGKKVYV 
98-112  VGAASTPTKLQESLL 
108-122 QESLLKKLGSNTYPF 
154-176 KAFATDSTDAEEDKIPKKSSV 
RL 
229-243 TVTNNTEKTVKKIKA 
296-311 GIALDGKIKHEDTNLA 
359-379 LMHPQPEDPAKESYQDANLVF 
384-405 RHNLKDAGEAEEGKRDKNDAD 
E 
 
Transaldolase 1 
70-84  RKLGGSQEDQIKNAI 
126-141 IELYKEAGISKDRILI 
198-212 VANTDKKSYEPLEDP 
271-286 VPVLSAKAAQASDLEK 
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